  
 
 
 
 
 
The FARAPULSE ADVENT Trial  
 
A Prospective Randomized Pivotal Trial of the  
FARAPULSE Pulsed Field Ablation System   
Compared with Standard of Care Ablation in  
Patients with Paroxysmal Atrial Fibrillation  
 
 
CLINICAL INVESTIGATION PLAN (CIP)  NUMBER : CS0934  REVISION D 
 
SPONSOR : 
FARAPULSE,  INC. 
3715  HAVEN AVE. SUITE 110 
MENLO PARK, CA 94025 
USA  
 
ISSUE DATE: OCTOBER 13, 2021 
 
 
This study is to be performed in accordance with the U.S. Code of Federal Regulations, Good Clinical Practice (GCP) and ethical principles consistent with the Declaration of Helsinki.  
 
This document contains confidential and proprietary information and may not be copied or reproduced in whole or in part without the express written permission of FARAPULSE,
 INC., 
MENLO PARK, CA. 

  
 
  
P
ROTOCOL AGREEMENT FORM  
   
 Study Title: The FARAPULSE ADVENT Trial , Revision D, October 13, 2021 
 I, the undersigned, have read and understand this clinical study, including the appendices. I will implement and conduct the clinical study in strict compliance with the study protocol and in accordance with good clinical practices (GCP) and all applicable laws and regulations. I will ensure that all persons assisting in this study are adequately informed about the protocol, study product(s) and their clinical study-related duties and functions.  I agree to maintain all study related information supplied by FARAPULSE Inc. in strictest confidence. When information regarding this study is submitted to an I nstitutional R eview 
Board (IRB), it will be forwarded with a requirement that all study related material is to be 
held strictly confidential.  
   _________________________ ___________________________ _____________ 
Principal Investigator    Signature    Date  
 
    
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE ii 
  
TABLE OF REVISIONS  
 
Revision  Date  DCO #  Change Description  
A October 20, 
2020  20-235 Initial Release for IDE submission  
B November 
15, 2020  20-255 Modifications for IDE resubmission  
C March 17, 
2021  21-136 Modifications for IDE resubmission  
Revision approved for trial initiation (April 16, 2021)  
D November 
01, 2021 21-355 Modifications for Study Design Consideration IDE 
submission, m aintenance updates and typographical 
corrections.  
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE iii 
 TABLE OF CONTENTS  
 
TABLE OF CONTENTS  ........................................................................................................ III 
LIST OF TABLES  ............................................................................................................... VIII 
LIST OF FIGURES  ............................................................................................................... IX 
PRIMARY STUDY CONTACTS  ...............................................................................................1  
PROTOCOL SUMMARY  .........................................................................................................2  
ABBREVIATIONS AND ACRONYMS  .....................................................................................16  
1. INTRODUCTION .........................................................................................................18  
1.1 BACKGROUND AND RATIONALE ..................................................................18  
1.2 IRREVERSIBLE ELECTROPORATION  .............................................................18  
1.3 SUMMARY OF FARAPULSE  PRECLINICAL STUDIES  ..................................19  
1.4 SUMMARY OF FARAPULSE  CLINICAL STUDIES FOR PAF .........................20  
1.4.1  THE IMPULSE  STUDY  ...................................................................20  
1.4.2  THE PEFCAT  STUDY  .....................................................................21  
1.4.3  THE PEFCAT  II STUDY  ..................................................................23  
1.4.4  CLINICAL SUB-STUDIES  ..................................................................24  
1.5 RATIONALE FOR CONDUCTING THIS PIVOTAL STUDY  .................................25  
1.6 RISKS, BENEFITS AND MITIGATION  .............................................................26  
1.6.1  POTENTIAL RISKS ...........................................................................26  
1.6.2  POTENTIAL BENEFITS ......................................................................26  
1.6.3  RISK MITIGATION AND SUMMARY  ..................................................27  
2. INVESTIGATIONAL DEVICES  ....................................................................................28  
2.1 NAMES OF INVESTIGATIONAL DEVICES  ......................................................28  
2.2 INTENDED USE ............................................................................................28  
2.3 FARAPULSE  PULSED FIELD ABLATION SYSTEM  ......................................28  
2.3.1  FARAWAVE  PULSED FIELD ABLATION CATHETER  ......................30  
2.3.2  FARASTAR  PULSED FIELD ABLATION GENERATOR  .....................32  
2.3.3  FARADRIVE  STEERABLE SHEATH  ................................................32  
2.4 DEVICE ACCOUNTABILITY  ..........................................................................33  
2.5 RETURN OF DEVICES  ...................................................................................33  
3. STUDY POPULATION  .................................................................................................34  
3.1 SUBJECT RECRUITMENT  ..............................................................................34  
3.2 SUBJECT SCREENING  ...................................................................................34  
3.2.1  SCREENING PROCEDURES  ...............................................................34  
3.2.2  SCREENING LOG .............................................................................34  
3.3 STUDY ELIGIBILITY CRITERIA  .....................................................................34  
3.3.1  INCLUSION CRITERIA  ......................................................................34  
3.3.2  EXCLUSION CRITERIA  .....................................................................35  
3.4 SUBJECT STATUS AND DISPOSITION DEFINITIONS  .......................................37  
3.4.1  GENERAL PRE-SCREENING  .............................................................37  
3.4.2  COVID-19  PRE-SCREENING  ...........................................................38  
3.4.3  SCREENED SUBJECTS  ......................................................................38  
3.4.4  SCREEN FAILURE SUBJECTS  ............................................................38  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE iv 
 3.4.5  ENROLLED SUBJECTS  ......................................................................38  
3.4.6  ROLL-IN SUBJECTS  .........................................................................38  
3.4.7  INTENT -TO-TREAT SUBJECTS  ..........................................................39  
3.4.8  SAFETY SUBJECTS  ...........................................................................39  
3.4.9  MODIFIED INTENT -TO-TREAT SUBJECTS  .........................................39  
3.4.10  COMPLETED SUBJECTS  ....................................................................39  
3.4.11  INCOMPLETE SUBJECTS  ...................................................................39  
3.4.12  PER PROTOCOL SUBJECTS  ...............................................................40  
3.5 SUBJECT DISPOSITION CHART  .....................................................................40  
3.6 SUBJECT INFORMED CONSENT  ....................................................................41  
3.7 SUBJECT ENROLLMENT  ...............................................................................41  
3.8 SUBJECT RANDOMIZATION  .........................................................................42  
3.9 SUBJECT COMPLETION OR EXIT ..................................................................42  
4. STUDY SUMMARY AND SCHEDULE ...........................................................................43  
4.1 STUDY OBJECTIVE AND HYPOTHESIS  ..........................................................43  
4.2 STUDY OVERVIEW  ......................................................................................43  
4.3 SUBJECT CONFIDENTIALITY  ........................................................................43  
4.4 SAMPLE SIZE SUMMARY  .............................................................................43  
4.5 INVESTIGATIONAL SITES .............................................................................44  
4.6 DURATION OF STUDY AND SUBJECT PARTICIPATION  ..................................44  
4.7 SCHEDULE OF EVENTS AND ASSESSMENTS  .................................................44  
4.7.1  BASELINE ASSESSMENT  ..................................................................45  
4.7.2  INDEX PROCEDURE  / RESCHEDULED INDEX PROCEDURE  ................45  
4.7.3  PRE-DISCHARGE ASSESSMENT  ........................................................46  
4.7.4  DAY 7 ASSESSMENT  ........................................................................48  
4.7.5  DAY 30 ASSESSMENT  ......................................................................48  
4.7.6  DAY 60 EM  TRAINING AND AAD  DISCONTINUATION  ....................48  
4.7.7  DAY 90 ASSESSMENT  ......................................................................49  
4.7.8  MONTH 6 ASSESSMENT  ...................................................................50  
4.7.9  MONTH 12 ASSESSMENT  .................................................................50  
4.7.10  RE-ABLATION PROCEDURES  ...........................................................52  
4.7.11  UNSCHEDULED ASSESSMENTS  ........................................................52  
4.7.12  COVID-19-R ELATED DISRUPTION OF STUDY ASSESSMENTS  .........53  
4.8 SCHEDULE OF EVENTS  ................................................................................54  
4.9 SUBJECT FLOW CHART  ...............................................................................56  
4.10  CONTROL OF SYSTEMATIC ERROR AND BIAS ..............................................57  
5. STUDY PROCEDURES  ................................................................................................58  
5.1 ANTICOAGULATION  ....................................................................................58  
5.2 INDEX PROCEDURE  .....................................................................................58  
5.3 RESCHEDULED INDEX PROCEDURE  .............................................................61  
5.4 RE-ABLATION PROCEDURES  .......................................................................61  
5.5 START DATE, BLANKING PERIOD AND INDEX PROCEDURES  .......................62  
5.6 ROLL-IN SUBJECTS  .....................................................................................63  
5.7 BLINDING  ....................................................................................................63  
5.8 NEUROLOGIC ASSESSMENT SUBJECTS  ........................................................64  
5.8.1  NAS  SITES ......................................................................................64  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE v 
 5.8.2  POST-ABLATION BRAIN MRI  SPECIFICATIONS FOR NAS  SUBJECTS 
ONLY ..............................................................................................64  
5.8.3  SCE  AND SCL  ANALYSIS  ...............................................................65  
5.8.4  FOLLOW -UP FOR SUBJECTS WITH SCE  OR SCL  LESIONS  ................65  
5.9 ANTIARRHYTHMIC DRUGS  ..........................................................................65  
6. STUDY DEFINITIONS  .................................................................................................66  
6.1 STUDY OUTCOMES  ......................................................................................66  
6.2 ADVERSE EVENT DEFINITIONS  ....................................................................66  
6.3 OTHER DEFINITIONS  ...................................................................................66  
6.3.1  ACUTE PROCEDURAL SUCCESS  .......................................................66  
6.3.2  ACUTE PROCEDURAL FAILURE  .......................................................66  
6.3.3  ACUTE VEIN SUCCESS  ....................................................................66  
6.3.4  ANTIARRHYTHMIC DRUGS , CLASS I AND III ...................................66  
6.3.5  BLANKING PERIOD  ..........................................................................66  
6.3.6  CHRONIC FAILURE  ..........................................................................67  
6.3.7  CHRONIC SUCCESS  ..........................................................................67  
6.3.8  COVID-19-R ELATED DISRUPTIONS  ...............................................67  
6.3.9  DATES  .............................................................................................67  
6.3.10  DAY (OR STUDY DAY) ....................................................................67  
6.3.11  DETECTABLE AF,  AFL  OR AT ........................................................67  
6.3.12  INVESTIGATIONAL DEVICES AND PROCEDURES  ..............................67  
6.3.13  PRE-ABLATION ADVERSE EVENTS  ..................................................68  
6.3.14  PULMONARY VEIN DIAMETER  ........................................................68  
6.3.15  PULMONARY VEIN ISOLATION  ........................................................68  
6.3.16  PULSED FIELD GROUP  / SUBJECTS  ..................................................68  
6.3.17  SEVERE COVID-19  SUBJECTS  ........................................................68  
6.3.18  STUDY PARTICIPANTS  .....................................................................69  
6.3.19  THERMAL GROUP  / SUBJECTS  .........................................................69  
6.3.20  TREATMENT FAILURE  .....................................................................69  
6.3.21  TREATMENT SUCCESS  .....................................................................69  
7. OUTCOME MEASURES  ..............................................................................................70  
7.1 PRIMARY SAFETY ENDPOINT  ......................................................................70  
7.2 SECONDARY SAFETY ENDPOINT  .................................................................72  
7.3 ADDITIONAL SAFETY ANALYSES  ................................................................72  
7.4 PRIMARY EFFECTIVENESS ENDPOINT  ..........................................................73  
7.5 SECONDARY EFFECTIVENESS ENDPOINT  .....................................................73  
7.6 ADDITIONAL EFFECTIVENESS ANALYSES ....................................................74  
7.7 PROCEDURAL ASSESSMENTS  .......................................................................74  
7.8 QUALITY OF LIFE ASSESSMENTS  .................................................................75  
8. ADVERSE EVENTS , DEVICE EFFECTS , MALFUNCTIONS AND DEFICIENCIES  ..........76  
8.1 ANTICIPATED ADVERSE EVENTS  .................................................................76  
8.2 ADVERSE EVENT REVIEW AND ADJUDICATION  ...........................................77  
8.3 ADVERSE EVENTS  .......................................................................................77  
8.4 SERIOUS ADVERSE EVENTS  ........................................................................78  
8.5 PROCEDURE , DEVICE AND COVID- 19 RELATEDNESS  ................................78  
8.6 DEVICE EFFECTS  .........................................................................................79  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE vi 
 8.6.1  ADVERSE DEVICE EFFECTS  .............................................................79  
8.6.2  SERIOUS ADVERSE DEVICE EFFECTS  ..............................................79  
8.6.3  UNANTICIPATED ADVERSE DEVICE EFFECTS  ..................................79  
8.7 DEVICE DEFICIENCIES  .................................................................................79  
8.8 USE ERRORS  ...............................................................................................79  
8.9 MALFUNCTIONS  ..........................................................................................80  
8.10  EVENT MANAGEMENT AND REPORTING  .....................................................80  
8.10.1  ADVERSE EVENTS  ...........................................................................80  
8.10.2  ADVERSE DEVICE EFFECTS  .............................................................80  
8.10.3  DEVICE DEFICIENCY AND MALFUNCTIONS  .....................................80  
8.10.4  OTHER ASSESSMENT AND REPORTING REQUIREMENTS  ..................81  
8.10.5  REPORTING AES, ADE S AND DEVICE DEFICIENCIES  ......................81  
9. STATISTICAL PROCEDURES AND REPORTING  .........................................................83  
9.1 GENERAL STATISTICAL CONSIDERATIONS  ..................................................83  
9.2 RANDOMIZATION  ........................................................................................83  
9.3 SUBJECT DISPOSITION  .................................................................................84  
9.4 POPULATIONS FOR ANALYSIS  .....................................................................84  
9.5 ASSESSMENT OF THE PRIMARY SAFETY ENDPOINT  .....................................84  
9.6 ASSESSMENT OF THE PRIMARY EFFECTIVENESS ENDPOINT  ........................84  
9.7 SAMPLE SIZE CONSIDERATIONS  ..................................................................85  
9.8 ANALYSIS PLAN ..........................................................................................86  
9.9 ASSESSMENT OF THE SECONDARY SAFETY ENDPOINT  ................................87  
9.10  ASSESSMENT OF THE SECONDARY EFFECTIVENESS ENDPOINT  ...................88  
9.11  ASSESSMENT OF SUBJECT BLINDING  ...........................................................88  
10. CORE LABORATORIES  ..............................................................................................89  
10.1  ARRHYTHMIA CORE LABORATORY  .............................................................89  
10.1.1  PROCEDURES  ..................................................................................89  
10.1.2  EVENT MONITORS  ...........................................................................89  
10.1.3  HOLTER MONITORS  ........................................................................89  
10.1.4  ARRHYTHMIA DATA REVIEW AND TRANSMISSION  .........................90  
10.1.5  CEC  OVER-READS OF POTENTIAL ENDPOINTS  ...............................90  
10.2  CARDIAC IMAGING CORE LABORATORY  .....................................................90  
10.2.1  PROCEDURES  ..................................................................................90  
10.2.2  PULMONARY VEIN DIMENSIONS  .....................................................90  
10.2.3  CARDIAC IMAGING DATA REVIEW AND TRANSMISSION  .................90  
10.2.4  CEC  REVIEW OF PULMONARY VEIN STENOSIS RESULTS  ................90  
10.3  BRAIN IMAGING CORE LABORATORY  .........................................................90  
10.3.1  PROCEDURES  ..................................................................................91  
10.3.2  SCE  AND SCL  ASSESSMENT  ...........................................................91  
10.3.3  BRAIN IMAGING DATA REVIEW AND TRANSMISSION  ......................91  
11. MONITORING  ............................................................................................................92  
11.1  MONITORS  ..................................................................................................92  
11.2  CLINICAL MONITORING ACTIVITIES  ...........................................................92  
11.3  MONITORING RESPONSIBILITY AND DATA VERIFICATION  ..........................92  
11.4  SITE VISITS  .................................................................................................92  
12. STUDY MANAGEMENT  .............................................................................................94  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE vii 
 12.1  ETHICAL CONSIDERATIONS  .........................................................................94  
12.1.1  STUDY CONDUCT  ............................................................................94  
12.1.2  ETHICS REVIEW  ..............................................................................94  
12.1.3  INFORMED CONSENT  .......................................................................94  
12.1.4  CONFIDENTIALITY  ..........................................................................95  
12.2  KEY CONTRIBUTORS  ...................................................................................95  
12.2.1  SPONSOR  .........................................................................................95  
12.2.2  CONTRACT RESEARCH ORGANIZATION ...........................................95  
12.2.3  ARRHYTHMIA CORE LABORATORY  .................................................95  
12.2.4  CLINICAL EVENTS COMMITTEE  .......................................................95  
12.2.5  DATA AND SAFETY MONITORING BOARD  .......................................96  
12.3  SPONSOR RESPONSIBILITIES  ........................................................................96  
12.4  MONITOR RESPONSIBILITIES  .......................................................................97  
12.5  INVESTIGATOR RESPONSIBILITIES  ...............................................................98  
12.6  INVESTIGATOR AND SITE STAFF TRAINING  ...............................................100  
12.7  CONFIDENTIALITY AND PUBLICATION POLICY  ..........................................100  
12.8  DATA MANAGEMENT  ................................................................................100  
12.9  INSURANCE  ...............................................................................................101  
12.10  AUDITS AND INSPECTIONS  ........................................................................101  
12.11  STUDY SUSPENSION OR EARLY TERMINATION  ..........................................101  
12.12  CRITERIA FOR SUSPENDING OR TERMINATING A STUDY SITE ...................101  
12.13  DEVIATIONS FROM THE CLINICAL INVESTIGATION PLAN ..........................102  
12.14  COVID-19  PANDEMIC CONSIDERATIONS  .................................................102  
13. REGULATORY CONSIDERATIONS  ...........................................................................103  
13.1  MAINTAINING RECORDS  ...........................................................................103  
13.2  DATA HANDLING AND RECORD KEEPING  .................................................103  
13.2.1  SOURCE DOCUMENTS  ...................................................................103  
13.2.2  DATA COLLECTION  .......................................................................103  
13.3  INSTITUTIONAL REVIEW BOARD AND FDA  APPROVAL  ............................104  
13.4  PROCEDURE FOR AMENDING THE CIP .......................................................104  
13.5  DEVICE ACCOUNTABILITY  ........................................................................104  
14. BIBLIOGRAPHY  .......................................................................................................105  
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE viii 
 LIST OF TABLES  
 
TABLE 1 IMPACT OF ABLATION ENERGIES ON 3-M ONTH PV DIMENSIONS  .............................. 25 
TABLE 2 FARAPULSE  PULSED FIELD ABLATION SYSTEM COMPONENTS .............................. 28 
TABLE 3 SCHEDULE OF EVENTS – ITT  SUBJECTS  ..................................................................... 54 
TABLE 4 SCHEDULE OF EVENTS – ROLL-IN SUBJECTS  ............................................................. 55 
TABLE 5 COMPOSITE SAFETY ENDPOINT DEFINITIONS  ............................................................ 70 
TABLE 6 REPORTING AES, ADE S AND DEVICE DEFICIENCIES  ................................................. 81 
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE ix 
 LIST OF FIGURES  
 
FIGURE 1 FARAPULSE  PULSED FIELD ABLATION SYSTEM COMPONENTS .............................. 29 
FIGURE 2 FARAWAVE  PULSED FIELD ABLATION CATHETER  ................................................. 30 
FIGURE 3 FARAWAVE  PULSED FIELD ABLATION CATHETER - DEPLOYED STATES  ............... 31 
FIGURE 4 FARADRIVE  STEERABLE SHEATH  ........................................................................... 33 
FIGURE 5 SUBJECT DISPOSITION CHART  .................................................................................... 40 
FIGURE 6 PRE-DISCHARGE STROKE EVALUATION , NON-NAS  SUBJECTS  ................................. 47 
FIGURE 7 PRE-DISCHARGE STROKE EVALUATION , NAS  SUBJECTS  .......................................... 47 
FIGURE 8 SUBJECT FLOW CHART  ............................................................................................... 56 
FIGURE 9 INDEX PROCEDURE BLANKING AND FOLLOW -UP INTERVALS  ................................... 62 
FIGURE 10 RESCHEDULED INDEX PROCEDURE BLANKING AND FOLLOW -UP INTERVALS  .......... 63 
 
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 1 
 PRIMARY STUDY CONTACTS  
 
SPONSOR  John Allison, Vice President  
Clinical Affairs, Regulatory Affairs and Quality 
Assurance  
FARAPULSE , Inc. 
3715 Haven Ave. Suite 110 Menlo Park, CA 94025 USA  
Tel: +1 .650.422.3633 
Email: jallison @farapulse.com  
PRINCIPAL INVESTIGATOR  Vivek Reddy, MD , Principal Investigator  
Mount Sinai Hospital One Gustav  L Levy Place, Box 1030 
New York, NY 10029 USA  
Tel:  +1.212.241.7114 
Email: vivek.reddy@mountsinai.org  
CLINICAL RESEARCH 
ORGANIZATION  Patricia Bobzin, Director, Medical Devices  
Medpace Medical Device  
3787 95th Ave NE  
Suite 100 Blaine, MN 55014 USA  
Tel: +1.612.234.8500 Fax: +1.513.527.0368 
Email: p.bobzin@medpace.com  
ARRHYTHMIA CORE LAB HeartcoR Solutions LLC  
2403 Harnish Drive, Suite 201 Algonquin, IL 60102 
USA  
CARDIAC IMAGING CORE 
LAB Medpace Core Laboratories  
5365 Medpace Way Cincinnati, OH 45227  
USA  
BRAIN IMAGING CORE LAB Medpace Core Laboratories  
5365 Medpace Way Cincinnati, OH 45227  
USA  
 
  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 2 
 PROTOCOL  SUMMARY  
 
SPONSOR NAME FARAPULSE , Inc. 
TITLE OF STUDY  The FARAPULSE ADVENT Trial  
A Prospective Randomized Pivotal Trial of the FARAPULSE Pulsed 
Field Ablation System Compared with Standard of Care Ablation in 
Patients with Paroxysmal Atrial Fibrillation  
CIP  NUMBER  / 
REVISION   CS0934 Revision D  
PRIMARY 
OBJECTIVE  To determine whether there is  valid scientific evidence that endocardial 
ablation using the FARAPULSE Pulsed Field Ablation System  is both 
safe and effective for treating drug -resistant symptomatic PAF.  
PRIMARY CLINICAL 
HYPOTHES IS Pulmonary vein isolation (PVI) created by the FARAPULSE Pulsed Field Ablation System is not inferior in safety and effectiveness to 
treatment with approved catheter ablation technologies – force -sensing 
radiofrequency ablation (RFA) or cryoballoon ablation  (CBA) – in the 
treatment of drug -resistant symptomatic P AF. 
INVESTIGATIONAL 
DEVICES  
SECTION 2 FARAPULSE ™ Pulsed Field Ablation System  
• FARAWAVE ™ Pulsed Field Ablation Catheters and 
FARASTAR ™ Catheter Connection Cable  
• FARASTAR ™ Pulsed Field Ablation Generator, 
FARASTAR ™ Stimulation Module, FARASTAR ™ Recording 
System Module and associated cables 
• FARADRIVE ™ Steerable  Sheath  
INTENDED USE 
SECTION 2.2 The FARAPULSE Pulsed Field Ablation System  is indicated for the 
treatment of drug- resistant , recurrent, symptomatic PAF .  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 3 
 STUDY SUMMARY 
AND SCHEDULE  
SECTION 4 This is a prospective, adaptive, multi -center, randomized safety and 
effectiveness pivotal study comparing the FARAPULSE Pulsed Field 
Ablation System with standard of care ablation with force-sensing RF catheters and cryoballoon catheters indicated for the treatment of PAF .  
Subjects with documented drug- resistant ( Class I to  IV) PAF who have 
had ≥ 2 PAF episodes within 6 months  of enrollment will undergo 
percutaneous endocardial ablation for PVI . Subjects with typical right-
sided (isthmus- dependent) atrial flutter (AFL) may undergo ablative 
interruption of the cavo- tricuspid isthmus (CTI).  
Class I  / III antiarrhythmic  drugs ( AADs ) will be discontinued at Day 
60 ± 10, subject to Investigator discretion. 
Safety:  Subjects will be followed at 7 days, 30 days, 90 days, 6 months 
and 12 months for adverse events (AEs) . A composite device - and 
procedure- related serious adverse event ( SAE ) rate will be compared 
between randomization groups for non- inferiority . 
Effectiveness:  Subjects will be monitored with weekly scheduled plus 
symptom-driven event monitoring, as well as 6 and 12- month  Holter 
monitoring, for freedom from recurrent arrhythmia (atrial fibrillation 
[AF], AFL or atrial tachycardia [ AT]) after the Blanking Period (Days 
0 - 90). The proportion of subjects free of post-blanking recurrent arrhythmia  (AF, AFL or AT ), re- ablation or Class I / III  AAD use  will 
be compared between randomization groups for non- inferiority.  
SAMPLE SIZE 
SUMMARY  
SECTION 4.4 A maximum of 900 subjects may be enrolled in this study.  
Roll-In Subjects : Up to 105 subjects (the first 1 -3 Enrolled S ubjects at 
each site) will be treated with the FARAPULSE devices in a manner 
consistent with the randomized Pulsed Field Group  and will be 
analyzed and reported separately.  
ITT S ubjects:  An estimated 450 MITT Subjects will be required to 
support the proposed non- inferiority outcomes.  Interim sample size re -
estimation may decrease this number to 350 or increase it to a maximum of 750. Up to 45 additional subjects (6%) may be enrolled to 
compensate for those ITT Subjects who do not meet the criteria for the 
MITT Population. 
INVESTIGATIONAL 
SITES 
SECTION 4.5 Up to 35 investigational sites in the United States.  
No site may enroll more than 45 ITT Subjects ( excludes Roll -In 
Subjects and ITT Subjects who do not qualify for the MITT 
population) with an intended minimum of 10 subjects per site. Should interim sample size re-estimation lead to an increase in the number of 
MITT Subjects greater than 450, each site will be limited to 10% of the increased total.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 4 
 DURATION OF 
STUDY AND 
SUBJECT 
PARTICIPATION  
SECTION 4.6 Study start-up, inclusive of s ite initiation and Investigator training , is 
estimated to take 6 months. The enrollment period for the first 600 
subjects (105 Roll-Ins plus 495 ITT Subjects) is estimated to take 1 8 
months and subjects will be followed for up to 13 months. There will 
be a 3 -month period of site close-out visits, for a planned study 
duration of approximately 40 months. Coronavirus Disease 2019 (COVID-19)- related disruptions and interim sample size re -estimation 
may alter this timeframe.  
Subject participation is anticipated to be 13 ± 1 months to allow for 
screening, pre- procedural diagnostic procedures, randomization, 
treatment and 12 ±1 months of study follow-up. If a subject requires a 
Rescheduled Index Procedure, this may prolong participation by up to 2 to 3 months. 
SCHEDULE OF 
EVENTS AND 
ASSESSMENTS  
SECTION 4.7 • Baseline  Assessment  
• Index Procedure / Rescheduled Index Procedure:  cardiac 
ablation (Day 0) 
• Pre-Discharge Assessment  
• Day 7 Assessment:  clinical assessment  
(Window Days 7  to 11) 
• Day 30 Assessment:  clinical assessment  
(Window Day 30 ± 7) 
• Day 60 Event Monitor (EM) Training  and AAD 
Discontinuation : (Window Day 60 ± 10) 
• Day 90 Assessment:  clinical assessment, cardiac magnetic 
resonance imaging ( MRI ) / computed tomography ( CT) scan , 
begin weekly scheduled and symptomatic event monitoring (Window Day 90 ± 14) 
• Month 6  Assessment:  clinical assessment , Holter 
(Window Day 180 ± 30) 
• Month 12  Assessment:  clinical assessment , Holter , QoL and 
cardiac MRI/CT if Day 90 study showed pulmonary vein stenosis (PVS) (Window Day 360 ± 30) 
• Re-Ablation Procedure  
• Unscheduled Assessment  
• COVID -19-Related Disruptions of Study Assessments  
ANTICOAGULATION  
SECTION 5.1 Anticoagulation will be guided by the 2017 Heart Rhythm Society  
Expert Consensus Statement and the 2019 American Heart Association 
/American College of Cardiology  / Heart Rhythm Society Focused 
Update relating to this issue.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 5 
 INDEX PROCEDURE  
SECTION 5.2 Index Procedure  / Rescheduled Index Procedure:  All subjects will 
be screened for completion of a minimum of 3 weeks of systemic 
anticoagulation and the absence of atrial thrombus just prior to or at the 
time of the Index Procedure and will be rescheduled if these conditions 
are not met .  
PVI:  Subjects will undergo an attempt to isolate all PV s or their 
anatomic equivalent with the randomized devices: 
• P ulsed Field Group with the FARAPULSE Pulsed Field 
Ablation System  
• Thermal Group with either a study-approved RFA or CBA 
system . Sites will use either RFA or CBA exclusively to treat 
subjects randomized to the Thermal Group. 
CTI:  Subjects in either the Pulsed Field or Thermal Groups with a past 
history of CTI -mediated (typical) AFL , who manifest typical AFL 
during a procedure or within the Blanking Period, or who have 
inducible typical flutter, may undergo ablation of the CTI at the discretion of the Investigator using any approved RF catheter during the Index / Rescheduled  Index Procedure or any re-ablation procedure.  
Other Ablation : O
 ther ablation is not permitted under this protocol 
except  when the Investigator determines that subject welfare requires 
ablation for an accessory pathway , atrioventricular nodal reentrant 
tachycardia (AVNRT) , treatment -emergent left -sided AFL or incessant 
AT. 
RE-ABLATION 
PROCEDURES  
SECTION 5.4 Re-ablation under this protocol requires documentation of Detectable 
AF, AFL or AT. When performed, r e-ablation will be performed 
utilizing a n approved study ablation catheter (RFA or CBA) at 
Investigator discretion.   
Any re -ablation procedure for AF, AFL or AT during study follow -up 
constitutes a Treatment Failure . 
However, CTI ablation or re-ablation for right-sided typical AFL may 
be performed at any time during study follow- up and does not 
constitute a Treatment Failure . 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 6 
 NEUROLOGIC 
ASSESSMENT 
SUBJECTS  
SECTION 5.8 A subset of study sites  qualified and willing to perform the 
standardized brain MRI post- ablation will be established and 
designated as NAS sites. NAS sites will be selected to generate a 
minimum of 80 NAS Subjects, balanced approximately equally between RFA and CBA control sites .  
All ITT Subjects at NAS sites free of contraindications to MRI will be 
consented for post-procedure MRI until the study enrollment target of 
evaluable scans is met.  
The MRI will be performed using standardized parameters to elicit 
characteristics of silent cerebral  events (SCEs) and silent cerebral 
lesions (SCLs).  If a post -procedural SCE or SCL is confirmed, then the 
NAS subject will undergo a pre- discharge neurological assessment and 
a follow-up brain MRI during the 90 Day Assessment window. 
ANTIARRHYTHMIC 
DRUGS  
SECTION 5.9 Antiarrhythmic drugs ( AADs ), except for amiodarone , may be utilized 
during the Blanking Period at the Investigator’s discretion. On Day 60 ± 10 each subject will be contacted by telephone to stop all AADs. 
Class I  / III AADs should be stopped at the Day 60 Assessment. 
However, at the Investigator’s discretion, Class I / III AADs may be continued up to Day 90 without creating a Treatment Failure . 
The use of amiodarone at any time during the study, except intra -
procedurally to control an arrhythmia, or the use of Class I / III AADs after Day 90, constitute a Treatment Failure.
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 7 
 PRIMARY SAFETY 
ENDPOINT  
SECTION 7.1 The primary safety endpoint  is the Composite Safety Endpoint (CSE) 
defined as the proportion of Intent- to-Treat ( ITT) Subjects with one or 
more of the following device - or procedure- related SAEs  as 
adjudicated by the CEC. 
Early onset:  Any of the following with an Onset Date within 7 days of 
the Index / Rescheduled Index procedure: 
• Death  
• Myocardial infarction  
• Persistent phrenic nerve palsy  
• Stroke 
• Transient ischemic attack  (TIA)  
• Peripheral or organ thromboembolism  
• Cardiac tamponade  / perforation 
• Pericarditis  
• Pulmonary edema  
• Vascular access complications  
• Heart block  
• Gastric motility/pyloric spasm disorders  
Late onset : Either of the following with an Onset Date at any time 
through the completion of 12- month follow -up visit: 
• PVS 
• Atrio -esophageal fistula  
SECONDARY 
SAFETY ENDPOINT  
SECTION 7.2 1. Aggregate PV Cross- Sectional Area  
ADDITIONAL 
SAFETY ANALYSES  
SECTION 7.3 1. Severe Ablation Complications  
2. Nonserious / Serious CSEs  
3. Post-Blanking Direct Current Cardioversions 
4. Post-Blanking Arrhythmia Hospitalizations  
5. Any Related SAE  
6. Any Related Stroke or TIA  
7. Categorized PV Dimensional Changes 
8. Thermal Group RF  Ablation / Cryo ablation Safety Assessment  
9. Learning Curve Safety Assessment  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 8 
 PRIMARY 
EFFECTIVENESS 
ENDPOINT  
SECTION 7.4 The primary effectiveness endpoint is Treatment Success in Modified 
Intent- to-Treat ( MITT ) subjects, defined as: 
1. Acute Procedural Success AND  
2. Chronic Success, defined as freedom from:  
a. At the Index / Rescheduled Index Procedure: U se of a non-
randomized treatment modality for PV I 
b. After the Blanking Period: 
i. Occurrence of any Detectable AF, AFL or AT (excluding 
CTI-dependent flutter confirmed by EP study) 
ii. Any cardioversion for AF, AFL or AT (excluding for CTI-dependent flutter) 
iii. Use of any Type I or Type III anti arrhythmic medication 
for the treatment of AF, AFL or AT  
c. At any time:  
i. Re-ablation  for AF, AFL or AT (other than for CTI -
dependent flutter ) 
ii. Use of amiodarone, , except intra -procedurally to control 
an arrhythmia  
Endpoint status will be assessed through the Month 12 Assessment 
(Day 360 ± 30) . 
SECONDARY 
EFFECTIVENESS 
ENDPOINT  
SECTIONS 7.5 The secondary effectiveness endpoint is the same as the primary effectiveness endpoint but will be tested for superiority  rather than 
non-inferiority.  
ADDITIONAL 
EFFECTIVENESS 
ANALYSES  
SECTION 7.6 
 1. Acute Procedural Success  
2. Acute Vein Success  
3. Chronic Success  
4. Chronic Success Allowing Re -ablation 
5. Chronic Success A llowing AADs  
6. Treatment Success Allowing Re -ablation 
7. Treatment Success A llowing AADs  
8. Treatment Success with PVI/CTI Only  
9. Early Recurrence of AF  
10. Rate of Re -ablation 
11. PVI Durability at Re -ablation 
12. CTI Ablation Failure  
13. Thermal Group RF  Ablation/ Cryo ablation Effectiveness 
Assessment  
14. AF Symptom Assessment  
15. Learning Curve Effectiveness Assessment  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 9 
 PROCEDURAL 
ASSESSMENTS  
SECTION 7.7 
 1. Assessments of procedure durations  
a. Procedure time (initiation of venous access to venous access 
closure) 
b. Left atrial dwell time (total time an ablation catheter is in the left atrium [LA] ) 
c. Total ablation time (first ablation to last ablation)  
d. Total mapping time (total time spent mapping)  
e. Fluoroscopy time (total duration of exposure) 
2. Characterization of lesion sets:  
a. PVI ablations  
b. CTI ablations  
c. For subjects undergoing required L A ablation for an 
accessory pathway , AVNRT,  left-sided AFL or incessant 
AT, description of lesion sets utilized  
QUALITY OF LIFE 
ASSESSMENT  
SECTION 7.8 Quality of Life (QoL) will be assessed at baseline and 12 months  using 
two assessments. These assessment s will be tested for nominal p values 
between Pulsed Field Subject s and Thermal Subjects: 
1. The EuroQol standardized questionnaire of health states (EQ-5D-3 L) 
2. The Atrial Fibrillation Effect on Quality of Life ( AFEQT ) 
instrument for the measurement of health -related quality of life  
RANDOMIZATION  
SECTION 9.2 Subjects who meet the inclusion and exclusion criteria will be 
randomized using a 1:1 allocation ratio.  
Each site will utilize only one control modality – either RFA or CBA – 
and will use that modality for all subjects randomized to the Thermal Group. Site activation and enrollment will be monitored and when necessary controlled to maintain a minimum 40% pro portion of 
Thermal Subjects in either the RFA or CBA modality.  
POPULATIONS FOR 
ANALYSIS  
SECTION 9.4 Several analysis populations are defined for this study , including : 
• Safety Subjects 
• Modified Intent -to-Treat (MITT) Subjects  
• Per Protocol (PP) Subjects  
ASSESSMENT OF 
THE PRIMARY 
SAFETY ENDPOINT  
SECTION 9.5 The primary safety endpoint for this study is the Composite Safety Endpoint (CSE) which will be analyzed as a test of non- inferiority of 
the event rate at 12 months using a non- inferiority margin of 8%. 
Statistical methods are Bayesian.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 10 
 ASSESSMENT OF 
THE PRIMARY 
EFFECTIVENESS 
ENDPOINT  
SECTION 9.6 The primary effectiveness endpoint for this study is Treatment Success 
which will be analyzed as a test of non -inferiority of the event rate at 
12 months using a non- inferiority margin of 15%. Statistical methods 
are Bayesian.  
SAMPLE SIZE 
CONSIDERATIONS  
SECTION 9.7 Although the pre -specified statistical analysis methods are Bayesian, 
standard frequentist considerations are used to guide sample size 
selection . 
Parameter selection:  Published IDE studies with available 
information comparing new devices with approved control devices have all used non- inferiority designs with one -sided alpha of 0.05 and 
15% effectiveness margins and either 8% or 9% safety margins.  
Sample size requirements for safet y: The sample size for primary 
safety  was estimated  for a Farrington -Manning test with PASS 13 
indicates that, for 1:1 randomization, 90% power, alpha=0.05 (one -
sided), CSE rate in both Groups of 0.08 and non- inferiority margin of 
0.08. Assuming a 5% rate of loss -to-follow-up (LTFU), 450 subjects 
are needed. Uncertainty in the CSE rate motivates the use of a design wherein the sample size is adaptively determined, with possible sample sizes ranging from 350 to 750. 
Sample size requirements for effectiveness : The sample size required 
for the primary effectiveness endpoint was estimated  by PASS 13  for 
1:1 randomization, 90% power, alpha=0.05 (one-sided) , success rates 
in each group of 0.65 and non- inferiority margin of 0.15. Assuming a 
10% rate of LTFU, 3 82 subjects are needed. U ncertainty in the 
Treatment Success rate motivates the use of a design wherein the 
sample size is adaptively determined, with possible sample sizes ranging from 200 to 550.   
Number of Enrolled Subjects : The primary population for the 
analysis of effectiveness is the MITT Population. The Safety  
Population should be similar but will not be smaller. Considering the 
joint sample size needs of the primary safety and effectiveness objectives, the primary analysis population may range from a minimum of 350 to a maximum of 750. 
To achieve a sample size of 750 MITT  Subjects , up to 900 subjects 
may be enrolled consisting of 750 MITT  and up to 105 Roll -In 
Subjects and up to 45 ITT  Subjects (6%) who do not meet the criteria 
for the MITT Population. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 11 
 ANALYSIS PLAN 
SECTION 9.8 This trial is designed using Bayesian statistical techniques.  The sample 
size will be  determined adaptively via a Goldilocks design, with 
possible sample sizes of N=350, 450, 550, 650, and 750.   
At each of the four interim sample size assessments, the predictive 
probabilit y that the trial will end in a determination of non- inferiority 
for both safety and effectiveness will be computed and compared to 
pre-specified thresholds.  A determination will be made to stop 
enrollment for predicted success, to stop enrollment for predicted 
futility, or to continue enrollment to the next larger sample size.  
Once subject accrual has stopped, all accrued subjects will be followed 
to 12 months, and then the inferential tests of non- inferiority will occur 
as described in Sections 9.5 and 9.6. 
CORE 
LABORATORIES  
SECTION 10 A qualified Arrhythmia Core Lab  (ACL) will be established to receive, 
review and assess all protocol -stipulated ECGs, EMs and Holter 
monitors.  
A qualified Ca rdiac Imaging Core Lab  (CICL) will be established to 
receive, review and assess all protocol -stipulated cardiac MRIs and 
CTs.  
A qualified Br ain Imaging Core Lab (BICL) will be established to 
receive, review and assess all protocol -stipulated brain MRIs for NAS 
Subjects. 
CLINICAL EVENTS 
COMMITTEE  
SECTION 12.2.4 An independent panel of 3 electrophysiologists will review  AEs, 
adjudicate seriousness and relatedness of potential SAEs and adjudicate primary safety and effectiveness outcomes.  
This group will consist of a panel of 3 experienced, independent physicians who are not Investigators and will be supported by one or more Medical Monitor s and staff as required . 
The CEC will convene regularly during the study to review, classify and/or adjudicate AEs reported in this investigation as well as primary 
and secondary study outcomes. 
DATA AND SAFETY 
MONITORING 
BOARD  
SECTION 12.2.5 An independent panel of physicians, trialists and a statistician will assess 
study progress and key study outcomes. 
This group will include at least 2 experienced, independent physicians who are not Investigators and an independent statistician not involved in 
the routine operation of the study.  
The Data and Safety Monitoring Board ( DSMB) will convene regularly 
during the study to assess overall event rates to ensure the integrity of 
the clinical study and the rights, safety and welfare of study subjects.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 12 
 INCLUSION 
CRITERIA  
SECTION 3.3.1 Patients are required to meet all the following inclusion criteria to 
participate in this study: 
1. Patients with drug -re sistant symptomatic PAF meeting all  the 
following criteria:  
a. Paroxysmal: AF that terminates spontaneously or with 
intervention within 7 days of onset. 
b. Frequency: 
i. Physician documentation of recurrent PAF (two or more 
episodes) within 6 months, AND 
ii. At least one (1) documented episode by a recording such as ECG, EM, Holter monitor or telemetry strip within 12 months of enrollment . 
c. D
rug failed: Failed AAD treatment, meaning therapeutic 
failure of at least one  (1) AAD ( Class I  to IV) for efficacy 
and / or intolerance.  
2. P atients who are ≥ 18 and ≤ 75 years of age on the day of 
enrollment.  
3. Patient who are willing and capable of: 
a. Providing i nformed consent to undergo study procedures 
AND  
b. Participating in all examinations and follow -up visits and 
tests associated with this clinical study.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 13 
 EXCLUSION 
CRITERIA  
SECTION 3.3.2 
 
                                    
 
(
CONTINUED NEXT 
PAGE ) Patients will be excluded from participating in this study if they meet 
any one of the following exclusion criteria:  
1. AF that is any of the following: 
a. Persistent (both early and longstanding) by diagnosis or 
continuous duration > 7 days 
b. Requires four (4) or more direct -current cardioversions in 
the preceding 12 months 
c. Secondary to electrolyte imbalance, thyroid disease, alcohol or other reversible  / non- cardiac causes 
2. Any of the following atrial conditions: 
a. Left atrial anteroposterior diameter ≥ 5.5 cm (by MRI, CT or TTE)  
b. Any prior atrial endocardial or epicardial ablation procedure , other than right sided cavotricuspid isthmus 
ablation or for right sided SVT  
c. Any prior atrial surgery 
d. Intra -atrial septal patch  or interatrial shunt 
e. Atrial myxoma  
f. Current LA thrombus 
g. LA appendage closure, device or occlusion, past or anticipated  
h. Any PV abnormality, stenosis or stenting (common and middle PVs are admissible)  
3. At any time, one (1) or more of the following cardiovascular procedures, implants or conditions:  
a. Sustained ventricular tachycardia or any ventricular fibrillation  
b. Hemodynamically significant valvular disease:  
i. Valvular disease that is symptomatic  
ii. Valvular disease causing or exacerbating congestive heart failure  
iii. Aortic stenosis: if already characterized, valve area < 1.5cm or gradient > 20 mm Hg  
iv. Mitral stenosis: if already characterized, valve area 
< 1.5cm or gradient > 5 mm Hg  
v. Aortic or mitral regurgitation associated with abnormal LV function or hemodynamic measurements  
c. Hypertrophic cardiomyopathy 
d. Any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty 
e. Pacemaker, implantable cardioverter defibrillator or cardiac 
resynchronization therapy devices  
f. Any inferior vena cava ( IVC) filter, known inability to 
obtain vascular access or other contraindication to femoral 
access  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 14 
 EXCLUSION 
CRITERIA  
SECTION 3.3.2 
 
 (C
ONTINUED FROM 
PRIOR PAGE ) 
                                 
(
CONTINUED NEXT 
PAGE ) g. History of rheumatic fever  
h. History of congenital heart disease with any residual 
anatomic or conduction abnormality  
4. Any of the following procedures, implants or conditions: 
a. At baseline:  
i. New York Heart Association (NYHA) Class III /IV 
ii. Left ventricular ejection fraction (LVEF) < 40% 
iii. Symptomatic hypotension 
iv. Uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg on two BP measurements at baseline assessment)  
v. Symptomatic resting bradycardia 
vi. Implantable loop recorder or insertable cardiac monitor,  
b. Within the 3 months preceding the Consent D ate: 
i. Myocardial infarction  
ii. Unstable angina 
iii. Percutaneous coronary intervention  
iv. Heart failure hospitalization  
v. Treatment with amiodarone  
vi. Pericarditis or symptomatic pericardial effusion  
vii. Gastrointestinal bleeding  
c. Within the 6 months preceding the Consent D ate: 
i. Heart surgery  
ii. Stroke, TIA or intracranial bleeding  
iii. Any thromboembolic event 
iv. Carotid stenting or endarterectomy  
5. Diagnosed disorder of blood clotting or bleeding diathesis 
6. Contraindication to, or unwillingness to use, systemic anticoagulation 
7. Patient who is not on anticoagulation therapy for at least 3 weeks prior to the ablation procedure  
8. Contraindication to both CT and MRI  
9. Sensitivity to contrast media not controllable by premedication  
10. Women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period 
11. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to:  
a. Body Mass Index (BMI) > 40.0 
b. Solid organ or hematologic transplant, or currently being 
evaluated for an organ transplant  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 15 
 EXCLUSION 
CRITERIA  
SECTION 3.3.2 
 
 (C
ONTINUED FROM 
PRIOR PAGE ) 
  c. Severe lung disease, pulmonary hypertension, or any lung 
disease involving abnormal blood gases or requiring supplemental oxygen  
d. Renal insufficiency with an estimated glomerular filtration rate ( eGFR) < 30 mL/min/1.73 m
2, or any history of renal 
dialysis or renal transplant 
e. Active malignancy or history of treated malignancy within 24 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma) 
f. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration  
g. Active systemic infection  
h. COVID- 19 disease  
i. Current confirmed, active COVID -19 disease  
ii. Current positive test for SARS -CoV-2 
iii. Confirmed COVID- 19 disease not clinically resolved at 
least 3 months prior to the Consent Date.  
i. Other uncontrolled medical conditions that may modify device effect or increase risk, including uncontrolled diabetes mellitus (HgbA1c >  8.0% if test result already obtained) or 
active alcohol abuse  
j. Sleep apnea and:  
i. An apnea- hypopnea index (AHI) ≥ 15, or  
ii. An AHI of ≥ 5 and ≤14 with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease or history of stroke,  
unless compliant with continuous positive airway pressure (CPAP) treatment.  
k. Predicted life expectancy less than one (1) year  
12. Clinically significant psychological condition that in the Investigator’s opinion would prohibit the subject's ability to meet the protocol requirements  
13. Current or anticipated enrollment in any other randomized, interventional or Food and Drug Administration ( FDA)-regulated 
clinical study (data collection for registries or retrospective 
studies is permitted)  
14. Employees / family members of:  
a. FARAPULSE or any of its affiliates or contractors  
b. The Investigator, sub- Investigators, or their medical office or 
practice, or healthcare organizations at which study 
procedures may be performed  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 16 
 Abbreviations and Acronyms 
AAD  Antiarrhythmic drug  
ACL  Arrhythmia Core Laboratory  
ACT  Activated clotting time  
ADC  Apparent diffusion coefficient  
ADE  Adverse Device Effect  
AE Adverse event  
AF Atrial fibrillation  
AFEQT  Atrial Fibrillation Effect on QualiTy -of-Life Questionnaire  
AFL  Atrial flutter  
AT Atrial tachycardia  
AVNRT  Atrioventricular nodal reentrant tachycardia  
BICL  Brain Imaging Core Laboratory  
BMI  Body Mass Index  
BUN  Blood urea nitrogen  
CBA  Cryoballoon ablation  
CEC  Clinical Events Committee  
CHA 2DS 2-VASc      A clinical prediction rule for stroke  
CHF  Congestive heart failure  
CICL  Cardiac Imaging Core Lab oratory  
CIP Clinical Investigation Plan (synonymous with study protocol)  
COVID -19 COrona VIrus Disease  2019 : an illness caused by SARS -CoV -2 
CPS Chronic Procedural Success  
CRF  Includes CRF (case report form) and eCRF (electronic CRF ) 
CRO  Clinical research organization  
CSE Composite Safety Endpoint  
CT Computed tomography  
CTI Cavo -tricuspid isthmus  
CXR  Chest X -ray 
DSMB  Data and Safety Monitoring Board  
DWI  Diffusion weighted image  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eGFR  Estimated glomerular filtration rate  
EM Event monitor  
EQ-5D-3 L EuroQol standardized questionnaire of health states  
ETW  Early Termination  / Withdrawn  
FDA  Food and Drug Administration  
FLAIR  Fluid -attenuated inversion recovery  
HCT  Hematocrit  
HGB  Hem oglobin  
ICE Intracardiac echocardiography  
ICF Informed consent form 
INR International normalized ratio  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 17 
 IRB Institutional  Review Board  
IRE Irreversible electroporation  
ITT Intent(ion) -to-Treat  
IVC Inferior vena cava  
LA Left atrium or left atrial  
LBBB  Left bundle branch block  
LTFU  Lost-to-follow -up 
MITT  Modified Intent(ion) -to-Treat  
MRI  Magnetic resonance imaging  
NOAC  Novel oral anticoagulant  
NIHSS  National Institutes of Health Stroke Scale  
NYHA  New York Heart Association  
PAF Paroxysmal atrial fibrillation  
PFA Pulsed field ablation  
PP Per Protocol  
PV Pulmonary vein  
PVI  Pulmonary vein isolation  
PVS Pulmonary vein stenosis  
RFA  Radiofrequency ablation  
SADE  Serious Adverse Device Effect 
SAE  Serious adverse event  
SCE Silent cerebral events  
SCL Silent cerebral lesions  
TEE Transesophageal echocardiography  
TIA Transient ischemic attack  
TTE Transthoracic echocardiography  
UADE  Unanticipated Adverse Device Effect 
V Volts  
 
 
 
  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 18 
 1. Introduction  
1.1 Background and Rationale 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 
approximately 2.2 million people in the United States and 4.5 million in the European Union.
1, 2. The incidence increases with advancing age, affecting 6% of the population 
over age 60 and 10% of the population over age 803, 4. Age -adjusted population 
trending projects 16 million people in the United States will have AF by 20505. 
AF remains a significant cause of morbidity and mortality in industrialized societies . 
The annual risk of AF -related  stroke is 5% per year and 1 of every 6 strokes diagnosed 
occurs in the presence of AF.6 Therefore, patients with AF require long -term 
anticoagulation to prevent embolic events. Failure to manage AF may also lead to anatomic and electrical remodeling of the left atrium  (LA) , tachycardia-induced 
cardiomyopathy and reduced left ventricular function (heart failure). AF remains an extremely costly public health burden, with annual per patient cost of care approaching €3000 (approximately $3,200 U.S. )
7  
The Heart Rhythm Society (HRS) 2017 Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation
8 defines several different stages of AF . Paroxysmal AF 
(PAF) is defined as AF that terminates spontaneously or with intervention within 7 days of onset.  
1.2 Irreversible Electroporation  
Al-Sakere 2007
9 described irreversible electroporation  (IRE) as a non -thermal tissue 
ablation technique in which intense short duration electrical fields are used to permanently open pores in cell membranes, thus producing non- thermal tissue ablation . 
Their study, using a mouse model, showed complete regression in 92% of treated tumors . IRE ablation has a tissue- specific mechanism of ablation . The tissue injury 
from IRE ablation occurs at the cellular level with loss of homeostasis leading to necrosis or apoptosis.
10, 11, 12, 13 IRE ablation typically spares the extracellular matrix , 
which facilitates  rapid wound healing.14, 15, 16, 17, 18 
Thomson 201119 reported a case -series study (N=38) assessing the safety of IRE for 
treating liver, kidney or lung cancers in humans. The first four patients showed signs of 
transient ventricular arrhythmia, so subsequent patients were all treated using electrocardiogram (ECG )-synchronized delivery of electroporation pulses. There were 
2 further arrhythmias  and 2 cases of inadvertent damage to neighboring organs . 
Approximately 68% of tumors were completely ablated . The authors concluded that 
IRE is safe for clinical use, provided  ECG-synchronized delivery is used.  
A research group led by FHM Wittkampf in Utrecht investigated  the potential 
effectiveness and safety of epicardial electroporation in AF ablation procedures using porcine models . Wittkampf 2011
20 (N=10) used a circular ablation catheter and showed 
that PVI was achieved in all animals, with no sign of stenosis at 3 -week follow-up. 
Van Driel 201421 (N=6) confirmed this result out to 3-month follow-up. Neven 201422 
(N=5) showed that electroporation lesion depth depended on the level of electrical energy applied, reaching 8 mm at 300 joules. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 19 
 Van Driel 201523 (N=20) showed that electroporation could create deep lesions close to 
the phrenic nerve without damage to the nerve. Neven 201424 similarly showed that 
neighboring coronary arteries were undamaged by electroporation (N= 5). These 
animal studies suggest that IRE can safely create deep lesions in heart tissue without harming adjacent tissues . 
1.3 Summary of FARAPULSE Preclinical Studies  
FARAPULSE Inc. (hereinafter FARAPULSE) has performed multiple preclinical animal studies investigating the safety and efficacy of the FARAPULSE ™ Pulsed 
Field Ablation System . These studies demonstrate that pulsed field ablation (PFA) 
using the FARAPULSE technology reliably produces homogeneous, well- demarcated 
and transmural lesions in porcine atrial tissue. Seven - and 30-day studies show mild to 
moderate inflammatory and healing responses consistent with radiofrequency ablation lesions.  
Areas of critical interest that cannot be directly assessed in the clinical studies perform ed to date include:  
• Esophageal S paring : FARAPULSE performed a preclinical study
25 to assess 
the effect of PFA application on the esophagus in a relevant preclinical porcine model. A cohort of swine underwent ablation of the esophagus, which was mechanically deflected to be in close apposition with the inferior vena cava 
(IVC) which contained the PFA catheter.  A control cohort, which underwent 
clinically representative radiofrequency ablation (RFA) was also assessed.  After 
a high- dose delivery of the PFA and RFA energies, the animal subjects were 
survived to 25 days.  
Pathological analysis demonstrated that no PFA subjects showed any gross or 
histological sign of ablation -related injury  to the esophageal tissues. However, 
all RF control subjects showed ablation- related injury  to the esophagus , ranging 
from mucosal lesions to esophageal fistula.  
• Phrenic Nerve Sparing : FARAPULSE performed a preclinical study
26 to 
assess the safety and efficacy of the PFA waveform  directly adjacent to the 
phrenic nerve. Right superior pulmonary vein ( RSPV ), inferior common 
pulmonary vein (IC PV) and  superior vena cava ( SVC) isolation were performed 
using the FARAWAVE Pulsed Field Ablation C atheter in a relevant preclinical 
porcine model.  
None of eleven porcine subjects showed any diminution of phrenic nerve 
function after treatment at the maximum (2.0  kV) and minimum (1.4  kV) 
voltages under investigation. 
• Pulmonary Vein Effects : FARAPULSE performed a preclinical study27 to 
assess the safety and efficacy of ablation using the F ARAWAVE Pulsed Field 
Ablation C atheter  in a relevant preclinical porcine model.  Six porcine subjects 
underwent ablation of the RSPV and ICPV at 2.0 kV and were then survived for 30 days.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 20 
 Pathological analysis demonstrated that no subjects showed any degree of PV 
narrowing or flow impairment in the treated veins.  This study also investigated 
durability of pulmonary vein isolation (PVI) and histological transmurality  at 30 
days, showing that both assessments were present in 91.6% of the treated PVs. 
These results support the safety and performance of the system.  
1.4 Summary of FARAPULSE Clinical Studies  for PAF  
1.4.1 The IMPULSE  Study  
FARAPULSE, Inc. conducted a safety and feasibility study28 at Na Homolce Hospital 
in Prague, Czech Republic and Hôpital Cardiologique du Haut- Leveque in Pessac, 
France under the “IMPULSE” Protocol, CS0188. This study was conducted using a 
version of the FARAPULSE Pulsed Field Ablation System  which functioned 
similarly to the system which will be used in the IDE investigation  and the results are 
summarized below .  
Clinical investigation population : Adult patients with PAF  who provided informed 
consent to participate in the study.  
Methodology: In this pre -market, multi -center study, subjects who had signed the 
informed consent underwent baseline assessment, received treatment with the 
investigational device and were assessed prior to discharge, and at 30 days, 3 months, 
6 months and  12 months following the  index procedure. A remapping procedure was 
required as part of the 3-month assessment . A core laboratory analyzed ECG data 
from the Event Monitors (EM s) and H olter monitors. Adverse events (AEs) were 
reviewed  and where necessary adjudicated by a Clinical Events Committee (CEC) . 
Results: A total of 40 subjects enrolled and were treated in this study with a mean age of 58.2±9.1 years. A majority of subjects were male, 70% (28/40).  
The primary safety endpoint of the study was the incidence of early- onset (within 7 
days of the PFA ablation procedure) primary adverse events (AEs). One subject had a 
qualifying peri-procedural cardiac tamponade resolving with drainage, for a rate of 2.5% (1/40).  
The primary feasibility endpoint of the study was the proportion of subjects that 
achieved Acute P rocedural S uccess, defined as the percutaneous endocardial creation 
of electrically isolating lesions around the ostia of the PV s using the FARAPULSE 
Pulsed Field Ablation System.  The procedural success rate was 100% (40/40).  
Secondary safety endpoints, included the rate of all serious adverse events ( SAEs ) 
reported at the different follow -up time points, as adjudicated by the CEC, with 7.5% 
(3/40) of subjects reporting an SAE between index procedure and 30 days (2 AF events, 1 cardiac tamponade), 0.0% (0/40) of subjects reporting an SAE between 30 days and 3 months, 7.5% (3/40) of subjects reporting an SAE between 3 months and 6 months (1 a rteriovenous fistula, 2 AT s) and 2.5% (1/40) of subjects reporting an 
SAE between 6 months and 12 months (1 urinary calculus).   
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 21 
 No pulmonary vein stenosis (PVS) , esophageal lesions or phrenic nerve impairment 
was observed in any subject. 
The secondary feasibility endpoint was long- term technical success, defined as 
electrical isolation of the PVs assessed during an electroanatomical mapping 
procedure performed 3-months following the index procedure, with 41.2% (1 4/34) of 
subjects achieving technical success.   
For the 40 enrolled subjects, 156 veins were treated at the index procedure, 100% 
(156/156) were successfully isolated and 70% of ablated PVs remained isolated at the 
3-month remapping procedure . Thirty -one (3 1) of 40 subjects (77.5%) remain ed free 
from post-blanking AF, atrial flutter (AFL ) or atrial tachycardia ( AT) after a mean 
follow -up of 356 days. 
Ten ( 10) device deficiencies were reported in 8 subjects, none of which were deemed 
serious or resulted in any associated AEs in subjects. Of the ten deficiencies, one device deficiency was related to a 3rd party guidewire. All procedures were completed as planned and all subjects were successfully treated.  All deficiencies were 
investigated and most resolved with several others under ongoing investigation. 
Conclusion: These results support the safety and feasibility of the FARAPULSE 
Pulsed Field Ablation  System in the treatment of patients with PAF, with a low rate 
of primary AEs through 7 days, a high rate (100%) of procedural success and a rate of 
arrhythmia recurrence consistent with other technologies.  
1.4.2 The PEFCAT Study  
FARAPULSE, Inc. has completed enrollment in a two -center  single arm open label 
safety and feasibility study
29 of the treatment of PAF at Na Homolce Hospital in 
Prague, Czech Republic and Hôpital Cardiologique du Haut- Leveque in Pessac, 
France under the “PEFCAT” Protocol, CS0267. This study was conducted using the 
FARAPULSE Pulsed Field Ablation System, very similar in function to the system 
which will be used in the IDE investigation. 
Clinical investigation population : Subjects with documented drug- resistant 
(Class I to IV) symptomatic PAF who have had ≥ 2 episodes within 6 months of 
enrollment.   
Methodology: In this pre -market, multi -center study, subjects who had signed the 
informed consent underwent baseline assessment, received treatment with the 
investigational device and were assessed prior to discharge, and at 30 days, 75 days, 
6 months and 12 months following the  index procedure. A remapping procedure was 
required as part of the 75 -day assessment . A core laboratory analyzed ECG data from 
the EMs and H olter monitors. AEs were reviewed  and where necessary adjudicated 
by the CEC. 
Results: A total of 71 subjects enrolled and were treated in this study with a mean 
age of 57.2±10.5 years . A majority of study subjects were male, 78.9% (56/71).  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 22 
 The primary safety endpoint of the study was a composite safety endpoint including 
early -onset and late -onset events. One subject had a prolonged hospitalization for a 
1.5mm AV fistula between the right superficial femoral artery and the right common femoral vein that resolved during 5 days of hospitalization. A second subject had a pericardial effusion following a protocol- specified remap procedure that included 
PFA, which resolved after drainage. The proportion of subjects with one or more 
composite safety events was 2.8% (2/71).  
The primary feasibility endpoint of the study was A cute Procedural Success, defined 
as the percutaneous endocardial creation of a complete, electrically isolating set of lesions around the ostia of the pulmonary veins (PVs ) using the FARAPULSE Pulsed 
Field Ablation  System during the first procedure, as clinically assessed by entrance 
and/or exit block performed ≥ 20 minutes after the last PVI lesion is made. The procedural success rate was 100% (71/71).  
Secondary safety endpoints included the rate of device or procedure- related SAEs at 
30 days, 75, days, 6 months and 12 months, with reported rates between 0.0% and 
4.2%. Additional secondary safety endpoint results at 12 months included: stroke/CVA (0.0% [ 0/71]), transient ischemic attack (TIA) (0.0% [0/71] ), major 
bleeding related to anticoagulation treatment (0.0% [0/71]), cardioversion (5.6% 
[4/71]) and arrhythmia -related hospitalization (7.0% [5/71] ). 
No PVS , esophageal lesions or phrenic nerve impairment was observed in any 
subject. 
Chronic Procedural Success (CPS) was defined as persistent electrical isolation of all 
initially ablated PV s assessed during an electroanatomical mapping procedure 
performed 75 days following the index procedure. The rate of Chronic Procedural Success was found in 74.2% (46/62) of treated and remapped subjects.  
Therapeutic Success was  defined as freedom from post-blanking AF, AFL or AT , or 
post-blanking ablation for AF, AFL or AT  using the study device, or ablation for AF, 
AFL or AT  with a non-study device at any time. The overall rate of Therapeutic 
Success was 67.6% (46/68) ; for subjects taking antiarrhythmic drugs (AADs) the rate 
was 51.9% (14/27) and for subjects not taking AADs 78.0% (32/41). 
Sixty -eight (68) of 71 subjects remained in the study past Day 90 and as of the cut- off 
date for this analysis 5 4/68 (79.4%) were free from recurrent arrythmia through a 
mean follow -up of 325 days.  
For the 71 enrolled subjects, 279 veins were treated at the index procedure and 100% 
(279/279) were successfully isolated. Of subjects that attended the 75-day remapping procedure, 90.9% (221/243) were durably isolated.  
Device performance was generally excellent, with 16 device deficiencies reported in 
12 subjects, none of which were deemed serious or resulted in any associated AE s in 
subjects. All procedures were completed as planned and all subjects were successfully treated. All deficiencies were investigated and most resolved with several others under ongoing investigation.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 23 
 Conclusion: These results support the safety and feasibility of the FARAPULSE 
Pulsed Field Ablation  System in the treatment of patients with PAF, with a low rate 
of acute and long-term primary safety endpoint events and a high rate (100%) of 
procedural success. 
1.4.3 The PEFCAT II Study  
FARAPULSE has completed enrollment in  the multicenter, single arm open label 
PEFCAT II expanded safety and feasibility study30 of the FARAPULSE Pulsed Field 
Ablation System as well as the FARAFLEX Pulsed Field Ablation  Catheter . Subjects 
were enrolled at both the Na Homolce Hospital in Prague, Czech Republic and the ‘University Hospital in Split Croatia under the “PEFCAT II” Protocol, CS0571. This study investigated PVI and cavo -tricuspid isthmus ( CTI) ablation using the 
FARAWAVE  and FARAFLEX  Pulsed Field Ablation C atheters . 
Clinical investigation population : Subjects with documented drug- resistant 
(Class I to IV) symptomatic PAF who have had ≥  2 episodes within 6 months of 
enrollment.  
Methodology: In this pre -market, multi -center study, subjects who had signed the 
informed consent underwent baseline assessment, received treatment with the 
investigational device and were assessed prior to discharge, and at 30 days, 75 days, 
6 months and 12 months following the  index procedure. A remapping procedure was 
required as part of the 75 -day assessment . A core laboratory analyzed ECG data from 
the EMs and H olter monitors. AE s were reviewed  and where necessary adjudicated 
by the CEC. 
Results: A total of 10 subjects enrolled and were treated in this study with a mean 
age of 56.0±14.2 years . There was equal number of males 50.0% (5/10) and females 
50% (5/10).  
The primary safety endpoint of the study was a CSE including early -onset and late-
onset events . No primary events occurred giving a rate of 0.0% (0/10).  
The primary feasibility endpoint of the study was acute procedural success, defined as 
above. The procedural success rate was 100% (10/10).  
Secondary safety endpoints included the rate of device or procedure- related SAEs, 
stroke, cardioversion and arrhythmia- related hospitalizations . The rates of these 
events were 0.0% (0/10). CPS – defined as persistent electrical isolation of all initially ablated PV s – was found 
in 77.8% (7/9) of subjects.  
Acute CTI Success – defined as the creation of bi- directional electrical block across 
the cavotricuspid isthmus – was found in 100% (4/4) of subjects undergoing CTI 
ablation. 
Therapeutic Success – defined as freedom from occurrence of AF, AFL or AT, or 
post-blanking ablation for AF, AFL or AT  using the study device, or  ablation for AF, 
AFL or AT  with a non-study device at any time – was 80.0% (8/10), 0.0% (0/1) in 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 24 
 subjects on AADs  and 88.9% (8/9) in subjects off A ADs, at a mean follow -up of 200 
days. 
For the 10 enrolled subjects, 39 veins were treated at the index procedure and 100% 
(39/39) were successfully isolated . For subjects that underwent the 75-day remapping 
procedure, 94.3% (33/35) of treated PVs were durably isolated. 
There have been no device deficiencies reported for this study through the analysis date.  
Conclusion: These results support the safety and feasibility of the FARAPULSE 
Pulsed Field Ablation System in the treatment of patients with PAF , with a rate of 
0.0% for acute and long- term primary safety endpoint events  and a high rate (100%) 
of procedural success.  
1.4.4 Clinical Sub -Studies  
Several investigator- initiated sub- studies were undertaken during the clinical 
investigations cited above.  
• Esophageal Assessment : Thirty -eight (38) subject s enrolled in the PEFCAT 
study underwent esophagogastroduodenoscopy following ablation using the FARAWAVE Pulsed Field Ablation Catheter to isolate all PVs .
31  
None (0%) of these studies revealed any ablation -related findings.  
In another study of imaged PVs, Cochet et al compare post -procedure lesion 
imaging from subjects receiving FARAPULSE PFA, radiofrequency and cryoballoon ablation for PVI . Consistent with its underlying mechanism, 
FARAPULSE PFA demonstrated no gadolinium enhancement of the esophagus 
suggestive of injury (0/18 subjects). Radiofrequency (6/16 subjects) and cryoballoon (4/7 subjects ) ablation did create signals for esophageal injury on 
magnetic resonance imaging ( MRI ).
32 
Phrenic Nerve Assessment : An analysis of the first 117 PFA subjects with 
PAF who underwent PVI using the FARAWAVE Pulsed Field Ablation Catheter  showed 100% of treated veins were isolated acutely . Pre- and post-
ablation phrenic functional testing was performed either by catheter pacing proximal to the region of ablation or by free inspiration fluoroscopic imaging of 
the diaphragm.  
No subject  (0% , 0/117) showed any diminution of phrenic function.
33 
• Pulmonary Vein Morphology:  Data regarding baseline and 3 -month computed 
tomography ( CT) imaging from IMPULSE and PEFCAT (PFA ablated PVs) 
and TOCCASTAR and HEARTLIGHT ( control subjects with RF ablated PVs) 
was re-analyzed and compared.34 
A total of 303 PVs showed that the average percent change in PV ostial 
diameters was reduced significantly more in RF subjects compared with PFA subjects (p < 0.001). When analyzed in standardized percentile change 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 25 
 categories, the distribution of size changes was significantly worse in RF -
treated PVs compared with PF- treated PVs (p < 0.001). 
Table 1 Impact of Ablation Energies on 3 -Month PV Dimensions  
Ostial % diameter change  RFA PVs  PFA PVs  p-value  
     Long axis  -11.8 ± 16.3  +1.7 ± 9.9  < 0.001  
     Short axis  -12.7 ± 18.8  +3.4 ± 12.7  < 0.001  
Frequency Distribution of PV Dimensional Change  
Energy  Total  Mild  
(30-50%)  Moderate  
(50-70%)  Severe  
(70-100%)  p-value  
RFA (n=166)  14.5% (24)  11.4% (19)  1.8% (3)  1.2% (2)  < 0.001  PFA (n=137)  0.7% (1)  0.7% (1)  0% (0)  0% (0)  
PV = pulmonary vein.  
Kuroki et al, Ostial Dimensional Changes after PVI: PFA vs RFA. E-published Heart Rhythm Journal 2020. 
• Peri-Procedural Brain MRI : Eighteen (18) subjects enrolled in the IMPULSE 
and PEFCAT studies have undergone peri-procedural post- ablation brain MRI 
scans to assess for silent cerebral events ( SCEs) and/or silent cerebral lesions 
(SCLs).  
Two of these subject s (2/18, 11%) showed diffusion-weighted positive lesions 
(SCEs) at approximately one day post procedure. One of these subjects, with a 
prior history of TIA, experienced a possible TIA one day post procedure 
presenting as a complaint of 15 minutes of difficulty speaking that was inapparent to observing medical staff ; this event was captured in the AE  dataset 
as a TIA .
35 
These results support the safety and performance of the system.  
1.5 Rationale for Conducting This Pivotal Study  
Catheter ablation for PAF with a variety of energy sources and catheter configurations 
has been demonstrated to be a safe and effective procedure. The FARAPULSE Pulsed Field Ablation System has undergone preclinical and clinical testing to demonstrate its preliminary safety and effectiveness for isolat ing PVs quickly and with minimal 
complications, using a standard catheter -based endocardial procedure. The System  has 
undergone preclinical testing in representative models to demonstrate that it can isolate PVs and create other cardiac lesions quickly, durably  and with minimal complications, 
using a standard catheter -based endocardial procedure.  Clinical data from 
131 endocardially ablated human subjects demonstrates the creation durable lesions when assessed at 75 -day remapping procedures, freedom from recurrent PAF in greater 
than 80% of subjects and an excellent safety profile.  
This pivotal study constitutes the multicenter randomized study  of FARAPULSE  PFA 
technology compared with existing RFA and CBA technologies for marketing approval 
in the United States  and other countries . 
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 26 
 1.6 Risks, Benefits and Mitigation  
1.6.1 Potential Risks  
As detailed in Section 1.4 , the risk profile associated with the FARAPULSE Pulsed 
Field Ablation System and the ablation procedure is expected to be consistent with 
similar devices currently in clinical use for percutaneous cardiac ablation for treatment of PAF .  
The FARAPULSE Pulsed Field Ablation System  utilizes PFA  to produce continuous 
transmural cardiac lesions to treat AF  using an ablation procedure that is similar to 
other commercially available percutaneous ablation catheters. More specifically:  
• The device system is used during percutaneous endocardial ablation procedures 
like other commercially approved catheter systems.  
• The device system is composed of similar biocompatible materials.  
• The device uses standard percutaneous techniques for ablation procedures.  
• The device utilizes a specialized generator to deliver ablation energy.  
• The device has similar procedural properties as compared to the planned 
commercially approved control devices: 
o The device is similar to CBA devices in that it circumferentially ablate s an 
entire PV  during each delivery  
o The device can be manipulated in the same manner as RF A and CBA 
catheters  
o The device uses metal electrodes for ablation energy delivery (RF 
catheters) and sensing  (RFA and CBA catheters.)  
A difference between the FARAPULSE Pulsed Field Ablation System  and other 
commercially approved thermal AF  ablation systems is that PFA  uses non- thermal IRE 
energy for tissue ablation, delivered through electrodes embedded in the FARAPULSE 
Pulsed Field Ablation Catheter for delivery of such energy in the PV s. 
Based on the available preclinical and clin ical data  and the substantial similarities to 
other approved ablation technologies , the anticipated risks are generally equivalent in 
type, severity and frequency to those associated with commercially released systems being used for percutaneous cardiac ablation procedures.  
1.6.2 Potential Benefits  
There are no guaranteed benefits from participation in this study. European feasibility studies of 131 PAF subjects have shown early valid scientific evidence for safety and 
effectiveness similar to existing approved technologies .  
This study may have the following potential  benefits: 
• To provide treatment to subjects with PAF using an investigational device 
which has demonstrated the ability to isolate PV s endocardially , to reduce the 
subsequent occurrence of symptomatic AF in treated subjects and potentially to 
reduce the risk for severe ablation complications associated with thermal 
ablation such as phrenic nerve palsy or atrio- esophageal fistula. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 27 
 • To provide information gained from the conduct of this study that may benefit 
other persons with the same medical condition.  
• To generate additional data demonstrating that the endocardial creation of 
electrically isolating lesions via PFA  applied using the FARAPULSE Pulsed 
Field Ablation System is a safe and effective treatment for drug -resistant, 
recurrent, symptomatic PAF. 
1.6.3 Risk Mitigation and Summary  
FARAPULSE has conducted bench, in-vivo and clinical testing to optimize safe use of 
the device during clinical investigation and the devices are in compliance with the applicable requirements of the 21 CFR 820 Subpart C, Design Controls of the Quality System Regulation, ISO 13485 and ISO 14971. 
The clinical study is designed to mitigate risk by the selection of skilled Investigator s, 
experienced sites, eligibility criteria to eliminate higher risk subjects and the carefully controlled design of the clinical investigational plan. Careful monitoring and comprehensive oversight by independent monitors and physicians are  also planned. 
The potential therapeutic improvement associated with the FARAPULSE Pulsed Field Ablation System has been recognized by the FDA, which was granted Breakthrough Pathway status to the technology in 2019.  
To receive this Breakthrough Pathway designation, the FDA was required to find that 
FARAPULSE Pulsed Field Ablation System: 
“… offers significant advantages over existing approved or cleared alternatives, 
including the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’  ability to manage their own care (such as through self-directed 
personal assistance), or establish long -term clinical efficiencies.”  
Based on the Sponsor’s evaluation of the investigational devices and their performance and the design of this pivotal investigation, the Sponsor has conducted an analysis of the benefits and risks of the FARAPULSE Pulsed Field Ablation System  for the 
treatment of PAF. The conclusion of this review is that this investigation is justified 
because the overall potential benefit to the population outweighs the risks and foreseeable risks which have been mitigated  as fully described in this submission . 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 28 
 2. Investigational Device s 
2.1 Name s of Investigational Devices 
The FARAPULSE Pulsed Field Ablation System  is comprised of the following: 
• FARAWAVE Pulsed Field Ablation Catheters and Connection Cables 
• FARASTAR Pulsed Field Ablation Generator, including 
o FARASTAR Stimulation Module  
o FARASTAR Recording System Module 
o Associated cables  
• FARADRIVE Steerable Sheath  
2.2 Intended Use  
The FARAPULSE Pulsed Field Ablation System  is indicated for the treatment of 
drug- resistant , recurrent, symptomatic paroxysmal atrial fibrillation .  
2.3 FARAPULSE Pulsed Field Ablation System  
The FARAPULSE Pulsed Field Ablation System  consists of the FARAWAVE Pulsed 
Field Ablation Catheter, the FARASTAR Pulsed Field Ablation Generator  and the 
FARADRIVE  Steerable Sheath . These components, sub- components and model 
numbers are listed in Table 2 and depicted in Figure 1 
Table 2 FARAPULSE Pulsed Field Ablation System  Components  
Component  Subcomponents  Model  Numbers  
FARAWAVE  
Pulsed Field 
Ablation Catheter   1. FARAWAVE Pulsed Field Ablation Catheter  (fully 
deployed diameters of 31mm and 35mm)  
2. FARASTAR Catheter Connection Cable  41C601 (31mm) 
41C602 (35mm)  
41C604  
FARASTAR  
Pulsed Field 
Ablation Generator and 
related equipment  1. FARASTAR Pulsed Field Ablation  Generator  
2. FARASTAR Stimulation Module  
3. FARASTAR Stimulation Module Cable  
4. FARASTAR EGM Cable  
5. FARASTAR Recording Syst em Module  
6. FARASTAR Stimulation Module Auxiliary Cable  
7. FARASTAR Stimulation Module Male Cable  
8. FARASTAR Stimulation Module Female Cable  
9. FARASTAR Stimulation Module Y -Cable – Long 
10. FARASTAR Stimulation Module Y -Cable – Short  
11. FARASTAR Recording System Module Catheter 
Pin Cable  
12. FARASTAR Accessories Cable Set  61C601 
61C603 61C604 61C605 
61C607 
61C608 61C609 61C610  
61C611  
61C612  
61C613  
 
61C606  
FARADRIVE  
Steerable Sheath   FARADRIVE Steerable Sheath  and Dilator  
 21C602 
 
For Instructions for U se (IFU) documentation please refer to the following: 
• FARAWAVE Pulsed Field Ablation Catheter Instructions for Use  - LBL0 913 
• FARASTAR Pulsed Field Ablation Generator System Use Manual - LBL0 914 
• FARADRIVE Steerable Sheath Instructions for Use  - LBL0771 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 29 
 Figure 1 FARAPULSE Pulsed Field Ablation System  Components  
 
 
AUX = Stimulation Module output signal that is active during energy delivery and is used by the Recording System Module to disconnect the patient ECG and 
Diagnostic catheter electrodes from the EP Lab Recording system during PFA to reduce the risk of interfer ence, CATH  = Generator PFA output to 
FARAWAVE  catheter, ECG = electrocardiogram signal s, EGM  = Generator output of intracardiac signals from the FARAWAVE Electrodes when not delivering 
energy; disconnected from FARAWAVE during energy delivery, EGM s = elect rogram  signals, EP = Electrophysiology , Lab = laboratory, STIM  = Generator output 
of two internal stimulation channels and a trigger output signal active during energy delivery. 

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 30 
 2.3.1 FARAWAVE Pulsed Field Ablation Catheter   
The FARAWAVE Pulsed Field Ablation Catheter  consists of 2 components: The 
FARAWAVE Pulsed Field Ablation Catheter and the FARASTAR Catheter 
Connection Cable , which are used together. Both components are sterile and single 
use only.  
The FARAWAVE Pulsed Field Ablation Catheter  is offered in 2 different sizes 
(31-mm [41C601] and 35- mm [41C602] fully deployed diameters) to accommodate  
varying PV  anatomy. Selection of either catheter will be at the Investigator ’s 
discretion.  The FARAWAVE Pulsed Field Ablation Catheter  is a multi -electrode catheter that 
connects electrically to the FARASTAR Pulsed Field Ablation Generator ( Figure 2 ). 
It consists of a distal section with electrodes arranged on splines , a shaft section  and a 
proximal handle with a manually operated deployment control.   
Figure 2 FARAWAVE Pulsed Field Ablation Catheter  
 
 
    
(Continued next page)  
  

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 31 
 The FARAWAVE Pulsed Field Ablation Catheter  has five (5) variably deployable 
splines. The five splines are undeployed during insertion and removal and  during use 
can deploy continuously from an undeployed state through a basket -shaped 
configuration to a fully deployed flower -shaped configuration with five petals ( See 
Figure 3).  
 
Figure 3 FARAWAVE Pulsed Field Ablation Catheter  - Deployed States  
 
 
 
Each spline has 1 electrode that is separately wired from the others on that spline to 
facilitate connection to a mapping or recording system via a cable supplied with the 
system.  The handle includes a flush port for saline infusion, a deployment control 
knob with a guidewire lumen hub that can be connected to a hemostasis valve and a short cable that terminates in a single connector for attachment to the FARASTAR 
Catheter Connection Cable . The other end of the Connection Cable  attaches to the 
front panel of the FARASTAR Pulsed Field Ablation Generator. The Connection Cable  is packaged sterile and is single-use only. The PFA  energy is delivered from  
the FARASTAR Pulsed Field Ablation Generator  over the set of ablation catheter 
electrodes.  
Additional details are provided in the IFU LBL0 913 for the specific use and 
procedural steps of the FARAWAVE Pulsed Field Ablation Catheter. 

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 32 
 2.3.2 FARASTAR Pulsed Field Ablation Generator   
The FARASTAR Pulsed Field Ablation Generator consists of the following 
components: 
• FARASTAR Pulsed Field Ablation Generator 
• FARASTAR Stimulation Module  
• FARASTAR Stimulation Module Cable  
• FARASTAR EGM Cable  
• FARASTAR Recording System Module 
• FARASTAR Stimulation Module Auxiliary Cable  
• FARASTAR Stimulation Module Male Cable  
• FARASTAR Stimulation Module Female Cable  
• FARASTAR Stimulation Module Y -Cable – Long  
• FARASTAR Stimulation Module Y -Cable – Short  
• FARASTAR Recording System Module Catheter Pin Cable  
The FARASTAR Pulsed Field Ablation Generator is a 1 2-channel output unit that 
generates a pulsed voltage waveform that can be delivered to the FARAWAVE 
Pulsed Field Ablation Catheter. The user selectable voltage options for the FARAWAVE Pulsed Field Ablation Catheter are 1800V, 1900V and 2000V. 
The FARASTAR Pulsed Field Ablation Generator includes a 2 channel Cardiac 
Stimulator that can be connected to user supplied pacing catheters through the FARASTAR Stimulation Module . While the Generator may be synchronized with the 
Cardiac Stimulator outputs , that feature will not be necessary  in this clinical study .  
Details regarding the generator are provided in the FARASTAR Pulsed Field 
Ablation Generator User Manual LBL0 914. 
2.3.3 FARADRIVE Steerable Sheath  
The FARAWAVE Pulsed Field Ablation Catheter  is used exclusively with the 
FARADRIVE Steerable Sheath. 
The FARADRIVE  Steerable Sheath consists of two (2) primary components , the 
Steerable Sheath and the Dilator, which are used together. Both components are 
sterile and single use only . 
The FARADRIVE Steerable Sheath is comprised of a  distal steerable section and a 
shaft section which connect to the handle. The handle includes a knob to control the deflection  of the distal tip  and a flush port for infusion of saline or contrast. The 
Dilator is intended for insertion through the sheath lumen and includes a shaped tip for dilation for vascular or chamber access ( Figure 4). Details regarding the sheath 
are provided in the FARADRIVE Steerable Sheath IFU  LBL0771. 
  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 33 
 Figure 4 FARADRIVE Steerable Sheath  
 
 
2.4 Device Accountability  
The FARAPULSE Pulsed Field Ablation System  will be stored  in a secure location and 
access will be controlled . Records will be maintained to document the physical location 
of inventory from shipment to investigational sites by Sponsor or contract 
manufactur ing facility through use and / or return or disposal. 
The site will be responsible for maintaining a  Device Accountability Log provided by 
the Sponsor or its designated representative. A t a minimum the following will be 
recorded: date of receipt, FARAPULSE Pulsed Field Ablation System  components 
identification number (Generator, Ablation Catheter and Steerable Sheath lot and / or serial number), expiration date, date of use, subject unique identi fication  code and date 
of disposal or return of the device.  
If there is a product Device D eficiency  / Malfunction or other need to return the system 
or system components to the Sponsor or contract manufacturer, the Sponsor or designee will be contacted for safe product disposal and/ or return details. Appropriate case report forms (CRF s) will be completed in the event of a Device Deficiency  / 
Malfunction . 
The Investigator is responsible for ensuring that the investigational devices are used only under the Investigator’s supervision and are only used according to this protocol, training  and any subsequent amendments or updates. The Investigator will not supply 
an investigational device to any person not authorized and trained to participate in the study. The Investigator shall document on the CRFs the lot numbers and / or serial 
numbers of the devices used during each case.  
2.5 Return of Devices  
All unused investigational devices will be returned to the Sponsor or designee upon completion of the clinical study . Any investigational device that does not meet 
performance specifications will also be returned to the Sponsor or designee for analysis  
per Sponsor procedures. The Investigator or designated representative is responsible for 
device accountability and disposition of all used and unused devices. The Sponsor or its designated representative will conduct device reconciliation at the completion of subject enrollment or at the conclusion of the study. 

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 34 
 3. Study Population  
3.1 Subject Recruitment  
Subjects will be recruited from the clinical practice of, or by referral to, the 
Investigators. Modest compensation may be provided to E nrolled S ubjects for their 
participation in the study and travel costs may be reimbursed.  
3.2 Subject Screening  
3.2.1 Screening  Procedures  
Routine clinical evaluations that would be performed as part of the normal clinical care of patients being considered for participation in this study may be performed prior to 
informed consent and the data used as part of the screening assessment. If the subject  is 
subsequently consented and enrolled in the study, the results of such tests may be used as study data and if used will be entered on the appropriate CRF.  
Site personnel will use care in reviewing the patient ’s clinical status in relation to each 
inclusion and exclusion criterion and ensure that appropriately documented results are available prior to concluding that the subject meets study inclusion and exclusion criteria.  
Screening procedures do not have to be completed on a single day. 
Subjects who become Screen Failures at any time may not be enrolled, randomized or 
participate in any further study procedures unless their disqualifying finding(s) becomes fully resolved.  
3.2.2 Screening  Log 
A Screening Log will be maintained for all consented subjects who undergo formal 
screening for possible enrollment, identified by a Subject Screen Number, noting the 
date screening was completed and the reason(s) for rejection (the specific inclusion  / 
exclusion criteria failed), or that the subject was enrolled. The Investigator will 
maintain the information linking the Subject Screen Number to subject identifiers.  
3.3 Study Eligibility Criteria  
3.3.1 Inclusion Criteria  
Patients ar
e required to meet all the following inclusion criteria to participate in this 
study: 
1. Patients with drug -re sistant symptomatic PAF meeting all  the following criteria:  
a. Paroxysmal: AF that terminates spontaneously or with intervention within 
7 days of onset. 
b. Frequency: 
i. Physician  documentation of recurrent PAF (two or more episodes) 
within 6 months , AND  
ii. At least one (1) documented episode by a recording such as ECG, EM, 
Holter monitor or telemetry strip  within 12 months of enrollment. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 35 
 c. D rug failed : Failed AAD treatment, meaning therapeutic failure of at least 
one (1) AAD ( Class I  to IV) for efficacy and  / or intolerance.  
2. P atients who are ≥ 18 and ≤ 75 years of age on the day of enrollment.  
3. Patient s who are willing and capable of: 
a. Providing i nformed consent to undergo study procedures , AND 
b. Participating in all examinations and follow -up visits and tests associated 
with this clinical study.  
3.3.2 Exclusion Criteria  
Patients  will be excluded from participating in this study if they meet any one  of the 
following exclusion criteria:  
1. AF  that is any of the following: 
a. Persistent (both early and longstanding) by diagnosis or continuous 
duration > 7 days 
b. Requires four (4) or more direct -current cardioversions in the preceding 
12 months 
c. Secondary to electrolyte imbalance, thyroid disease, alcohol or other reversible  / non- cardiac causes  
2. Any of the following atrial conditions: 
a. Left atrial anteroposterior diameter ≥ 5.5 cm  (by MRI, CT or TT E) 
b. Any prior atrial endocardial or epicardial ablation procedure , other than 
right sided cavotricuspid isthmus ablation or for right sided SVT   
c. Any prior atrial surgery   
d. Intra -atrial septal patch  or interatrial shunt 
e. Atrial myxoma  
f. Current LA thrombus 
g. LA appendage closure, device or occlusion, past or anticipated  
h. Any PV  abnormality, stenosis or stenting (common and middle PVs are 
admissible)  
3. At any time, one (1) or more of the following cardiovascular procedures, implants or conditions:  
a. Sustained ventricular tachycardia or any ventricular fibrillation  
b. Hemodynamically significant valvular disease:  
i. Valvular disease that is symptomatic  
ii. Valvular disease causing or exacerbating congestive heart failure 
iii. Aortic stenosis: if already characterized, valve area < 1.5cm or gradient >  20 mm Hg  
iv. Mitral stenosis: if already characterized, valve area < 1.5cm or 
gradient >  5 mm Hg  
v. Aortic or mitral regurgitation associated with abnormal LV function or hemodynamic measurements 
c. Hypertrophic cardiomyopathy 
d. Any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 36 
 e. Pacemaker, implantable cardioverter defibrillator or cardiac 
resynchronization therapy devices  
f. Any IVC filter, known inability to obtain vascular access or other 
contraindication to femoral access  
g. History of rheumatic fever 
h. History of congenital heart disease with any residual anatomic or conduction abnormality  
4. Any of the following procedures, implants or conditions: 
a. At baseline:  
i. New York Heart Association (NYHA) Class III or IV  
ii. LVEF < 40%  
iii. Symptomatic hypotension  
iv. Uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg on two (2) BP measurements at baseline assessment)  
v. Symptomatic bradycardia 
vi. Implantable loop recorder or insertable cardiac monitor
*
b. Within the 3 months preceding the Consent D ate: 
i. Myocardial infarction  
ii. Unstable angina 
iii. Percutaneous coronary intervention  
iv. Heart failure hospitalization  
v. Treatment with amiodarone  
vi. Pericarditis or symptomatic pericardial effusion  
vii. Gastrointestinal bleeding  
c. Within the 6 months preceding the Consent D ate: 
i. Heart surgery  
ii. Stroke, TIA or intracranial bleeding  
iii. Any thromboembolic event 
iv. Carotid stenting or endarterectomy  
5. Diagnosed disorder of blood clotting or bleeding diathesis 
6. Contraindication to, or unwillingness to use, systemic anticoagulation  
7. Patient who is not on anticoagulation therapy for at least 3 weeks prior to the ablation procedure 
8. Contraindication to both CT and MRI  
9. Sensitivity to contrast media not controllable by premedication  
10. Women of childbearing potential who are pregnant, lactating, not using medical 
birth control or who are planning to become pregnant during the anticipated study period 
11. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to:  
a. Body Mass Index ( BMI ) > 40.0 
 
* If an implantable loop recorder or insertable cardiac monitor is explanted prior to study enrollment it must not 
be replaced for the duration of the subject’s participation in the study.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 37 
 b. Solid organ or hematologic transplant, or currently being evaluated for an 
organ transplant 
c. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen 
d. Renal insufficiency with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m
2, or any history of renal dialysis or renal transplant  
e. Active malignancy or history of treated malignancy within 24 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma)  
f. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration  
g. Active systemic infection  
h. COVID- 19 disease  
i. Current confirmed, active COVID -19 disease  
ii. Current positive test for SARS -CoV-2 
iii. Confirmed COVID- 19 disease not clinically resolved at least 3 
months prior to the Consent Date 
i. Other uncontrolled medical conditions that may modify device effect or increase risk, including uncontrolled diabetes mellitus (HgbA1c > 8.0% if test result already obtained ) or active alcohol abuse 
j. Sleep apnea and:  
i. An apnea- hypopnea index (AHI) ≥ 15, or  
ii. An AHI of ≥ 5 and ≤14 with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease or history of stroke, 
unless compliant with continuous positive airway pressure (CPAP) treatment.  
k. Predicted life expectancy less than one (1) year  
12. Clinically significant psychological condition that in the Investigator ’s opinion 
would prohibit the subject's ability to meet the protocol requirements.  
13. Current or anticipated enrollment in any other randomized, interventional or FDA- regulated clinical study (data collection for registries or retrospective 
studies is permitted)  
14. Employees / family members of:  
a. FARAPULSE or any of its affiliates or contractors  
b. The Investigator, sub- Investigators, or their medical office or practice, or 
healthcare organizations at which study procedures may be performed  
3.4 Subject Status and Disposition Definitions  
3.4.1 General Pre -Screening  
Potential subjects screened for enrollment prior to signing informed consent who fail one (1) or more study eligibility criteria determined by routine clinical assessments or the medical record need not be documented. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 38 
 3.4.2 COVID- 19 Pre-Screening  
Screening for COVID-19 status will follow each investigational site’s then -current 
requirements.  
Patients may proceed to informed consent and full screening unless any of the 
following conditions exist : 
• They fail the investigational site’s then -current requirements in relation to 
COVID-19 status and study participation. 
• They currently have confirmed, active COVID- 19 disease or a positive test for 
SARS -CoV-2. 
• They have had confirmed COVID- 19 disease not clinically resolved at least 3 
months prior to the Consent Date. 
The results of COVID-19 screening may be used as study data for any consented 
subject. 
3.4.3 Screened Subjects  
A Screened Subject is any subject who has not failed pre- screening  and who has 
signed an informed consent. Each Screened Subject will be recorded in the Screening 
Log with the date of informed consent and the result of the screening process.  
Should an AE occur that is associated with a screening procedure or test and with onset prior to randomization, it will be recorded in a Screening AE CRF. Such AEs are not part of the ADVENT Trial, its data or analyses and will not be entered into the study database. A listing and summary of Screen ed Subjects will be provided  along 
with any screening- associated AEs. 
3.4.4 Screen Failure Subjects  
A Screen Failure Subject is any subject who has signed an informed consent and who is then excluded due to failure of one or more study eligibility criteria  at any time 
before randomization .  
Subjects who become Screen Failures will be recorded in the Screening Log including all eligibility criteria that were the cause of the Screen Failure. Screen 
Failure Subjects will have a Study Exit CRF completed on the date that Screen Failure is determined. No study data on events with an onset date after the Exit D ate 
may be collected or included as part of the study database or analyses. 
3.4.5 Enrolled Subjects  
An Enrolled Subject is any subject who has signed the informed consent document AND
 who has been determined to meet all pre -procedural study eligibility criteria  
prior to randomization .  
3.4.6 Ro ll -In Subjects  
Roll-In Subjects are Enrolled Subjects who are treated with the FARAPULSE Pulsed 
Field Ablation System under the provisions of Section  5.6. Roll-In Subjects are not 
randomized and will be analyzed and reported separately . 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 39 
 3.4.7 Intent -to-Treat  Subjects  
An Intent- to-Treat (ITT) Subject is an Enrolled Subject who is randomized to either 
the Pulsed Field Group or the Thermal (Control) Group . 
3.4.8 Safety  Subjects  
A Safety  Subject is an ITT  Subject who has had a study ablation catheter inserted into 
the body at an Index / Rescheduled Index Procedure. 
3.4.9 Modified Intent -to-Treat Subjects  
A Modified Intent- to-Treat (MITT) Subject is an ITT Subject who receives any 
energy delivery for PVI with the randomized endocardial ablation catheter at an 
Index / Rescheduled Index Procedure. 
3.4.10  Completed Subjects  
A Completed Subject is an ITT Subject who completes the Month 12 Assessment 
either in -person or remotely. The date on which the Month 12 Assessment is 
completed is the Completed Subject’s Exit Date and a Study Exit CRF will be completed. N o study data on events with an onset date after the Exit D ate may be 
collected or included as part of the study database or analyses. 
3.4.11  Incomplete Subjects  
An Incomplete Subject is any ITT Subject who does not become a Completed Subject. Anticipated reasons for failure to become Completed Subjects include withdraw al of consent by a subject, death or incapacity of a subject, l ost-to-follow -up 
(LTFU) status and terminat ion by the Investigator .  
A LTFU Subject is an ITT Subject who ceases to participate in study follow-up 
procedures or who fails to respond to contact attempts. T he Investigator will attempt 
to contact such a subject 2 or more times within 60 days and if there is no return to 
study participation, the subject will be deemed LTFU. The Investigator will document 
that a minimum of two attempts were made to contact the subject, including sending a certified letter if current address is known, prior to terminating the subject from the study.  
The date on which a subject is determined to be an Incomplete Subject is their Exit 
Date, and a Study Exit CRF will be completed including the reason for becoming an Incomplete Subject.  
No study data on events with an onset date after the Exit D ate may be collected or 
included as part of the study database or analyses. However, if an Incomplete 
Subject’s exit is due to an AE , the Investigator should, if subject consent is 
documented, follow the subject until the AE  has resolved  or is considered stable, but 
in any case, not more than 390 days have passed since the Index / Rescheduled Index Procedure. The data related to that AE may be collected and included in the study database and analyses under such consent. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 40 
 3.4.12 Per Protocol Subjects  
A Per Protocol (PP) Subject  is a Safety or ITT Subject without major protocol 
deviations that would affect the completeness, accuracy and reliability of the study 
data.  Major protocol deviations2 that exclude subjects from a PP Population are the 
following:  
• Failure to meet any of the following study entry criteria:  
o Arrhythmia different than PAF (Inclusion Criterion 1) 
o Prior cardiovascular procedures, implants or conditions (Exclusion Criteria 3 and 4) 
o Medical conditions ( Exclusion Criterion 11) 
• Failure to r eceive the randomized ablation treatment for PVI as specified in 
this protocol  (Section  5.2 or Section 5.3) 
• Receipt of a prohibited study drug (amiodarone , except intra -procedurally to 
control an arrhythmia ) 
• In addition, the data of Severe COVID-19 Subjects will be censored beginning on the Onset Date of infection.  
3.5 Subject Disposition Chart  
Figure 5 Subject Disposition Chart  
 
MITT  = modified intent -to-treat, ITT = intent -to-treat  
 
2 Major protocol deviations also include such events as failure of informed consent, confidentiality violations 
and actions that may affect the subject’s rights, safety or well -being. These, while serious, generally do not 
impact the validity of data collec ted and so are not part of the per protocol exclusions for outcome assessment.  

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 41 
 3.6 Subject Informed Consent  
All subjects must provide documented informed consent using the Institutional Review 
Board  (IRB)-approved informed consent form ( ICF) / electronic informed consent form 
(eICF ) before undergoing any study-related procedures. If electronic consent is utilized 
it will conform to the FDA Guidance Document “Use of Electronic Informed Consent, 
Questions and Answers”, dated December 2016 (or subsequent revised versions as applicable). 
Since it may become necessary during this study to access study -specific protected 
healthcare information from remote clinical sites, the ICF  / eICF will include this 
permission in the consent process.  
Subjects cannot be asked to sign the ICF  / eICF until the study has been fully approved 
by the institution’s IRB and the Sponsor or their clinical research organization (CRO) 
representative has received and reviewed the IRB -approved ICF  / eICF . Subjects who 
meet the general eligibility criteria will be asked to sign an ICF  / eICF as approved by 
the relevant regulatory authorities before any study -specific tests or procedures are 
performed.  
The Investigator or a designated member of their staff should communicate with the 
subject to obtain written informed consent. As far as possible, non- technical language 
shall be used that is understandable to the subject. The background of the proposed 
study and the benefits and risks of the procedures and study should be explained. The subject should be provided with ample time to read the ICF  / eICF and discuss it with 
their family and physician. The subject shall be informed that their participation in the clinical investigation is confidential. The ICF  / eICF must be read and understood by 
the subject and the subject’s questions answered. The ICF / eICF must be signed and dated by both the subject and physician / designee overseeing informed consent prior to subject enrollment and before the subject undergoes any study -related procedures. All 
subjects are to receive copies of their signed and dated ICF  / eICF . A copy of the 
approved ICF  / eICF  along with a copy of each subject ’s signed ICF  / eICF  will be  
maintained by the Investigator in a designated clinical study administrative file  or 
electronic record system . Subjects may not be consented after receiving any medication 
that might alter their ability to comprehend the consent form ( e.g., sedatives, narcotics, 
etc.). Study personnel should explain that even if a subject agrees to participate in the study and signs the ICF / eICF , the subject may not be eligible to participate if the 
subject fails to meet the screening criteria.  
Written informed consent must be obtained prior to performing any protocol-driven tests or any procedures that are not standard of care for a percutaneous ablation procedure that the subject is scheduled to undergo. Once written consent has been obtained, the subject will be entered on a Screening Log, which will be maintained at each site. All subjects who provide written informed consent will be entered into  the 
Screening Log regardless of whether they are enrolled in the study. 
3.7 Subject Enrollment  
Subjects that meet all the eligibility criteria and are deemed suitable by the Investigator will be invited to participate in the study.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 42 
 When initial screening indicates that the subject will likely meet the inclusion and 
exclusion requirements and agrees to participate in the study, formal written informed consent using the current IRB-approved ICF will be obtained.  
Provisional subject enrollment occurs when the ICF has been signed. Enrollment is confirmed when all study eligibility requirements are determined to have been met.   
If one or more of the required pre -en
 rollment assessments – including cardiac CT/MRI, 
transthoracic echocardiography ( TTE), laboratory tests and ECG  – have not been 
obtained prior  to signing the ICF, then the enrollment is considered provisional until 
that assessment has been obtained and the criteria met.  
Regardless of the sequence of ICF completion and pre-procedural enrollment assess
ments, if study eligibility  criteria are not met , the subject is  a Screen Failure and 
is not enrolled. 
Study eligibility criteria are determined at the time of study entry. In the instance that 
information received after an Index Procedure / Rescheduled Index Procedure reveals that an inclusion or exclusion criterion – determined prior to the Index Procedure / 
Rescheduled Index Procedure to have been met – is found to have been incorrectly assessed, this does not change the enrolled status of the subject, who remains in the study. 
Each Enrolled Subject will be assigned a unique study identification code to protect 
each subject’s confidential health information. The unique study identification code will not include date of birth or subject’s first and last initials and will be used to link study data and other study information to the subject in lieu of the subject name. The Subject Name Log will be used to link the unique study identity code to the subject and 
will be maintained at the site. This log will remain confidential and will not be provided 
to the Sponsor but only used for reference when monitoring at the study site. 
3.8 Subject Randomization  
Subjects excluding Roll -In Subjects – who are determined by the Investigator at the 
time of assessment to have met all pre -randomization inclusion and exclusion criteria , 
who have sign ed an ICF and who are scheduled for the Index Procedure – will be 
randomized. The study staff will confirm documented inclusion / exclusion success prior to requesting randomization.  
3.9 Subject Completion or Exit  
When a subject completes the study at the Month 12 Assessment , exceeds 390 days of 
follow -up without a Month 12 Assessment , or exits prior to such completion, they will 
return to standard medical care and a study termination/exit CRF will be completed, including the reason for exit.  
Subjects may voluntarily withdraw from the study at any time for any reason. The Investigator may terminate the subject without subject consent at any time to protect the subject’s rights, safety or welfare.  Subjects leaving the study prior to completion 
will continue to receive appropriate medical care without prejudice.  
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 43 
 4. Study Summary  and Schedule  
4.1 Study Objective  and Hypothesis  
The primary  obj ective of this pivotal study is to determine whether there is valid 
scientific evidence that endocardial ablation using the FARAPULSE Pulsed Field 
Ablation System is both safe and effective for treating drug -resistant symptomatic PAF.  
The primary clinical hypotheses o f this pivotal study are that PVI created by the 
FARAPULSE Pulsed Field Ablation System is not inferior in safety and effectiveness to treatment with approved catheter ablation technologies (force -sensing 
radiofrequency or cryoballoon ablation) in the treatment of drug -resistant symptomatic 
PAF.  
4.2 St
udy Overview 
This is a prospective, adaptive, multi -center, randomized  safety and effectiveness 
pivotal study  comparing the FARAPULSE Pulsed Field Ablation System  with standard 
of care ablation with force -sensing RF catheters and cryoballoon catheters indicated for 
the treatment of PAF. Subjects will undergo ablation for PVI with the randomized 
treatment and if indicated CTI ablation using an RF catheter . Subjects will be followed 
at 7 days (telephonic), 30 days, 90 days, 6 months and 12 months for AE s, recurrence 
of arrhythmia after a 90 -day Blanking Period and other relevant outcome measures.   
4.3 Subject Confidentiality  
Enrolled Subjects will be assigned a unique, pseudo-anonymous identifier that will be used to maintain confidentiality of each subject’s medical information . Subject names 
will not be captured on the CRFs . All subject identifiers except the unique 
pseudo-anonymous identifier should be redacted from any images or other data submitted from the participating site to the Sponsor or the Sponsor’s designated reviewers for analysis.  All information concerning subjects or their participation in this 
study will be considered confidential. Only the authorized Sponsor, designated representative personnel, designated consultants and regulatory agencies will have access to these confidential files. 
 
4.4 Sample Size  Summary  
A maximum of 900 subjects may be enrolled in this study. 
Roll-In Subjects : Up to 105 subjects (the first 1  to 3 E nrolled S ubjects at each site ) 
will be treated with the FARAPULSE device s in a manner consistent with the 
randomized Pulsed Field Group and will be analyzed  and reported separately.  
ITT Subjects : An estimated 450 MITT Subjects will be required to support the 
proposed non- inferiority outcomes.  Interim sample size re -estimation may decrease this 
number to 350 or increase it to a maximum of 750. Up to 45 additional subjects (6%) 
may be enrolled to compensate for those ITT Subjects who do not meet the criteria for the MITT Population. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 44 
 4.5 Investigational Sites  
The clinical study will be conducted at up to 35 qualified investigational sites in the 
United States. No site may enroll more than 45 ITT Subjects (excludes Roll -In Subjects 
and ITT Subjects who do not qualify for the MITT population) with an intended minimum of 10 subjects per site. Should interim sample size re -estimation lead to an 
increase in the number of MITT Subjects greater than 450, each site will be limited to 10% of the increased total.  
4.6 Duration of Study and Subject Participation  
Study start-up, inclusive of s ite initiation and Investigator training , is estimated to take 
6 months. The enrollment period for the first 600 subjects (105 Roll-Ins plus 495 ITT Subjects) is estimated to take 1 8 months and subjects will be followed for up to 13 
months. There will be a 3-month period of site close-out visits, for a planned study duration of approximately 40 months. Coronavirus Disease 2019 (COVID-19)- related 
disruptions and interim sample size re -estimation may alter this timeframe.  
Subject participation is anticipated to be 13 ± 1 months to allow for screening, pre-
procedural diagnostic procedures, randomization, treatment and 12±1 months of study follow -up. If a subject requires a Rescheduled Index Procedure, this may prolong 
participation by up to 2 to 3 months. 
4.7 Schedule  of Events and Assessments  
Subjects will complete the following visits and assessments as indicated below and as summarized in Table 3, (ITT Subjects) and Table 4, (Roll- In Subjects).  
Assessments that are stipulated as r emote may also be performed in -person at the 
investigational site at the Investigator’s discretion with subject agreement.  
All protocol -stipulated assessments below will be entered into the appropriate CRF s. 
Assessments are to be performed within the specified assessment windows.  
When COVID-19-related disruptions ( Section  6.3.8) interfere with the performance of 
protocol- stipulated follow -up assessments, study sites and Sponsor personnel will 
adjust procedures to optimize data acquisition while protecting the health, safety and 
welfare of all study participants. Study subjects , sites, IRBs and the FDA  will be 
informed of COVID-19- related changes in the study.  
This protocol does not specify how remote assessments should be performed, but these will be specified in related study documentation and may be modified as necessary during the conduct of the study. The method(s) used during the course of this study to interact with study participants and to acquire data remotely will be consistent with relevant FDA Guidance Documents and will be reported in the Clinical Study Report. 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 45 
 4.7.1 Baseline Assessment  
Type of Assessment: In -person at investigational site  
The completion of the Baseline Assessment requires an in -person visit. Such 
assessments must be deferred if this is not possible.  
The below baseline data will be generated in the window beginning 30 days prior to the 
Consent Date and ending on the date of the Index Procedure, unless otherwise 
specified. This data will include: 
• Demographics including gender, height and weight  
• Pertinent m edical and cardiovascular history  
• AAD and anticoagulation medication history  
• Cardiac physical examination  
• Pregnancy test ( all women of child- bearing potential) 
• Hematocrit, hemoglobin , electrolytes, blood urea nitrogen (BUN), creatinine  
• COVID-19 testing  by site 
o PCR for SARS -CoV-2 virus or equivalent testing , or  
o Confirmation of successful vaccination with an FDA-approved vaccine 
• 12-lead ECG . ECGs with any arrhythmia will include a rhythm strip for ACL 
submission. 
• Imaging (within the window beginning 90 days prior to the Consent Date and 
ending on the date of the Index Procedure) 
o TTE  
o Cardiac CT or MRI  establishing PV  dimensions 
• NYHA Classification  
• National Institutes of Health Stroke Scale (NIHSS ) score by NIHSS -certified site 
personnel 
• CHA 2DS 2-VASc score  
• AF symptom assessment  
• Quality of Life Measures:  
o The EuroQol standardized questionnaire of health states ( EQ-5D-3 L)  
o The Atrial Fibrillation Effect on QualiTy -of-Life Questionnaire ( AFEQT ) 
quality of life assessment s 
Introduction to the EM / Holter Device : At the Baseline Assessment, the subject 
will receive an introduction to EMs, Holters, the hardware  and how it will be utilized 
during the follow-up period. The importance of compliance with these critical 
assessments will be stressed.  
4.7.2 Index Procedure / Rescheduled Index Procedure 
Type of Assessment: In -person at investigational site  
The performance of the Index Procedure  / Rescheduled Index Procedure and 
the Pre -Discharge Assessment both require an in -person visit. The Index 
Procedure / Rescheduled Index Procedure must be deferred if this is not 
possible.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 46 
 The Index Procedure will be performed according to Section  5.2. P rocedural data will 
be collected  including: 
• Transesophageal echocardiography ( TEE) or intracardiac echocardiography (ICE) 
will be utilized prior to transseptal puncture for exclusion of LA thrombus. 
• Pregnancy test (all women of childbearing potential if baseline pregnancy test 
obtained more than 30 days prior to procedure) 
• Post-ablation 3D electroanatomical maps (at Investigator discretion)  
• Post-ablation f luoroscopic examination of diaphragm motion to assess phrenic 
nerve response 
• Adverse events 
• Procedural times  
• Lesion set data  
• Peri-procedural anticoagulation data:  
o For subjects on a novel oral anticoagulant ( NOAC) whether NOAC therapy 
was interrupted for procedure  
o For subjects on warfarin, a pre- treatment international normalized ratio 
(INR) value 
o Heparin administration and timing  
• Device deficiencies and malfunctions  
• For Thermal Subjects: 
o The specific thermal technology used, including manufacturer/model 
o The use of any esophageal monitoring, cooling or manipulation during the 
ablation procedure 
4.7.3 Pre-Discharge Assessment  
Type of Assessment: In -person at investigational site  
Prior to hospital discharge study data will be collected  including: 
• Adverse events 
• Hematocrit, hemoglobin, electrolytes, BUN, creatinine  
• Data regarding the use, changes in or discontinuation of anticoagulation, rate control and/or antiarrhythmic medications . 
• Cardiac rhythm as determined by a 12- lead ECG . ECGs with any arrhythmia will 
include a rhythm strip for ACL submission. 
• Occurrence, date, indication and outcome of any c ardioversion(s)  
• Assessment of subject blinding  
EM Training:  The subject will be reminded regarding the use of the EM  hardware , the 
importance of event monitoring and of the importance of the Day 60 EM Training.  
Pre-Discharge Stroke Evaluation for non- Neurologic Assessment Subjects: 
• NIHSS score by NIHSS -certified site personnel 
• If
  either of the following occurs: 
o The post- procedure NIHSS score has increased by 1 or more points over the 
pre-procedure NIHSS score OR 
o There is a clinical suspicion of stroke or TIA  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 47 
 Then  a consulting neurologist will perform a stroke assessment and include the results 
of a concurrent brain MRI . This assessment will be sufficient to determine with 
reasonable certainty whether a stroke, TIA or neither have occurred , using the 
definitions in  Table 5. If a stroke is diagnosed the subject will be assessed using a 
M
odified Rankin Scale. Please refer to Figure 6. 
Figure 6 Pre-Discharge Stroke Evaluation, Non- NAS Subjects  
 
Pre-Discharge Stroke Evaluation for Neurologic Assessment Subjects:  
• A post-procedure brain MRI as specified in Section 5.8. 
• NIHSS score by NIHSS -certified site personnel 
• If  any of the following occurs: 
o The brain MRI is positive for SCE or SCL findings  
o The post- procedure NIHSS score has increased by 1 or more points over the 
pre-procedure NIHSS score OR 
o There is a clinical suspicion of stroke or TIA  
Then  a  consulting neurologist will perform a stroke assessment and review the NAS -
stipulated brain MRI . This assessment will be sufficient to determine with reasonable 
certainty whether a stroke, TIA or neither have occurred , using the definitions in Table 
5
. If a stroke is diagnosed the subject will be assessed using a Modified Rankin Scale. 
Please refer to  Figure 7. 
Figure 7 Pre-Discharge Stroke Evaluation, NAS Subjects  
 
 

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 48 
 4.7.4 Day 7 Assessment  
Type of Assessment: Remote  
Window: Days 7 – 11 
The Day 7 Assessment is essential to establish the primary safety endpoint and 
every effort must be made to complete this assessment between Day 7 and 
Day 11.  
If the assessment is delayed, the onset date of an AE must be elicited as carefully 
as possible to establish whether it occurred within the interval between the 
ablation procedure and Day 7, or thereafter.  
Subjects will be assessed remotely between Day 7 and 11 post-Index 
Procedure / Rescheduled Index Procedure. Study data will be collected by interview, 
including: 
• A dverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate 
control and/or antiarrhythmic medications.  
• Recurrent arrhythmia, c ardioversions, ablations or hospital admissions since 
discharge  
• The date, time and communication method(s) used to collect the data remotely  
4.7.5 Day 30  Assessmen t 
Type of Assessment: Remote  
Window : 30 ± 7 Days  
Discharged subjects will be assessed remotely 30 days (± 7 days) post-Index 
Procedure / Rescheduled Index Procedure. (Any subject who continues to be 
hospitalized 30 days post- ablation will have their 30 -Day Visit assessment performed 
in-hospital). Study data will be collected by interview including: 
• Adverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate control and/or antiarrhythmic medications.  
• Recurrent arrhythmia, cardioversions, ablations or hospital admissions since 7-
day telephonic assessment  
• The date, time and communication method(s) used to collect the data remotely  
4.7.6 Day 60  EM Training and AAD Discontinuation   
Type of Interaction : Remote  
Window: 60 ± 10 Days  
EM Training:  At Day 60 ± 10 days following the Index Procedure / Rescheduled 
Index Procedure, the subject will receive an EM  and receive remote training regarding 
its use and the importance of event monitoring. The subject will be instructed  to begin 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 49 
 using the EM  at the time of the Day 90 Assessment and weekly thereafter and also for 
any symptomatic episodes throughout the remainder of study follow-up. 
AAD Treatment:  During this same subject interaction, Class I  / III AADs should be 
stopped – if they have not already been discontinued – to allow assessment of off -drug 
freedom from recurrent AF , AFL or AT  (the primary effectiveness endpoint). See 
Section  5.9. 
4.7.7 Day 90  Assessment  
Type of Assessment: In -person at investigational site required ; remote only for 
documented COVID -19 related disruption . 
Window: 90 ± 14 Days  
If a COVID -19-related disruption prevents an in -person visit within the visit 
window:  
• As much data as possible may be collected remotely.  
• A cardiac MRI or CT scan performed at another healthcare site may be utilized , 
preferably with the same modality as the baseline scan , or the imaging 
procedure may be delayed for up to 3 months.  
• If a fluoroscopic examination is required due to prior diminished phrenic nerve 
response, an inspiration/expiration chest X -ray (CXR) performed in -person or 
at another healthcare site may be substituted . 
Subjects will be assessed at Day 90 ± 14 days following the Index Procedure / Rescheduled Index Procedure.  
EM 
Review : During this assessment , the subject will be queried as to their 
understanding and use of the EM . Remedial training will be supplied as required. 
The subject will be instructed to begin weekly scheduled and symptomatic use of the 
EM and the critical importance of full compliance for study success will be stressed.  
Study data will be collected at the 90 -Day Visit  including: 
• Adverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate control and/or antiarrhythmic medications  
• Recurrent arrhythmia, c ardioversions, ablations or hospital admissions since last 
visit 
• Radiologic examination of the diaphragm (fluoroscopic sniff test or 
inspiration/expiration CXR) if the post- Index  / Rescheduled Index Procedure 
fluoroscopy indicated diminished phrenic nerve response and resolution has not been previously demonstrated 
• Cardiac rhythm as determined by a 12- lead ECG at the time of the visit  (in-person 
assessment only). ECGs with any arrhythmia will include a rhythm strip for ACL 
submission. 
• Cardiac CT or MRI scan of the same type as the baseline scan to assess the dimensions of the PV s. For subjects with a CICL -confirmed  70% or greater PV 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 50 
 diameter reduction, a Month 12 follow- up Cardiac CT or MRI scan of the same 
type as baseline will be scheduled to assess PV dimensions.  
• Follow-up brain MRI as specified in Section 5.8.2 (only for NAS Subjects with a 
confirmed post-procedural SCE or SCL on the post-procedural brain MRI) 
• For any subject diagnosed with stroke during the Pre- Discharge Assessment, a 
Modified Rankin Scale assessment . 
• If data is collected remotely, the date, time and communication method(s) used to 
collect the data remotely . 
4.7.8 Month 6  Assessment  
Type of Assessment : Remote  
Window : 180  ± 30 Days  
If a COVID -19-related disruption interferes with the performance of this 
assessment:  
• As much data as possible may be collected remotely , in or out of window.  
 
Subjects will be assessed remotely at 6 months (180 days ± 30 days) following the 
Index Procedure / Rescheduled Index Procedure .  
Holter Monitor:  Within the 180 ± 30 -day window for this visit, the subject will be 
contacted, receive remote training regarding the use of the EM hardware for Holter 
monitoring, and complete a 72- hour monitoring session.  
EM Review : During this remote assessment EM  compliance will be reviewed for 
weekly scheduled and ad hoc symptomatic monitoring and retraining of the subject provided as needed.  
Study data will be collected at the 6-Month Visit including: 
• Adverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate 
control and/or antiarrhythmic medications  
• Recurrent arrhythmia, c ardioversions, ablations or hospital admissions since last 
visit 
• The date, time and communication method(s) used to collect the data remotely  
4.7.9 Month 12  Assessment  
Type of Assessment: In -person at investigational site required ; remote only for 
documented COVID -19 related disruption . 
Window : 360  ± 30 Days  
If a COVID -19-related disruption interferes with the performance of this 
assessment:  
• As much data as possible may be collected remotely , in or out of window . 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 51 
 • The absence of a 12 -lead ECG during a remote assessment is not a protocol 
deviation but the subject should make an EM transmission at the time of the 
assessment .  
• A cardiac MRI or CT scan , if required because of PVS being detected at the 90 
Day Assessment, may be performed at another healthcare site if required , 
utilizing if at all possible the pre-specified CICL imaging protocol. 
• If a fluoroscopic examination is required due to prior diminished phrenic nerve 
response, an inspiration/expiration chest X -ray (CXR) performed in -person or 
at another healthcare site may be substituted . 
Subjects will be assessed at 360 days ± 30 days following the I ndex Procedure / 
Rescheduled Index Procedure. The Month 12 Assessment cannot be completed  prior to 
the performance of the 72 hour Holter monitor procedure. 
Holter Monitor:  W ithin the 360 ± 30 -day window for this visit and prior to the date of 
the Month 12 Assessment , the subject will be contacted, receive remote training 
regarding the use of the EM hardware for Holter monitoring, and complete a 72 -hour 
monitoring session . 
Study data will be collected at the 12 - Month Assessment  including: 
• Adverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate control and/or antiarrhythmic medications  
• Recurrent arrhythmia, c ardioversions, ablations or hospital admissions since last 
visit  
• Radiologic examination of the diaphragm (fluoroscopic sniff test or 
inspiration/expiration CXR) if the post- Index  / Rescheduled Index Procedure 
fluoroscopy indicated diminished phrenic nerve response and resolution has not 
been previously demonstrated (in -person assessment only) 
• Cardiac rhythm as determined by a 12- lead ECG  at the time of the visit  (in-person 
assessment only) . ECGs with any arrhythmia will include a rhythm strip for ACL 
submission. 
• AF Symptom Assessment  
• Quality of Life:  
o EQ-5D- 3 L  
o AFEQT  
• Assessment of subject blinding  
• For subjects with a 3 -month cardiac imaging (MRI or CT) showing a  CICL -
confirmed  70% or greater PV diameter reduction , a repeat cardiac imaging 
procedure of the same type to assess PV dimensions.  
• If data is collected remotely, the date, time and communication method(s) used to collect the data remotely  
At the completion of all components of the Month 12 Assessment a Study Exit CRF will be completed.  
  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 52 
 4.7.10  Re-Ablation Procedure s 
Re-a blation under this protocol requires documentation of Detectable AF, AFL or 
AT.  
Each subject undergoing an anticipated PVI  re-ablation procedure on Day 76 or 
later must have a Cardiac CT or MRI scan of the same type as the baseline scan 
obtained prior  to the procedure to assess the dimensions of the PVs.3 
When performed, PVI re-ablation will be performed utilizing an approved study 
ablation catheter (RFA or CBA) at Investigator discretion  for both Pulsed Field 
and Thermal Subjects . Other energy modalities may not be used.  
Any re -ablation procedure for AF, AFL or AT during study follow -up constitutes a 
Treatment Failure , and therefore during such procedures other sites may be 
ablated at Investigator discretion.  
CTI ablation or re- ablation for right- sided typical AFL may be performed at any 
time during study follow -up and does not constitute a Treatment Failure .  
Other sites may be ablated at Investigator discretion using a commercially 
available ablation system. 
For subjects undergoing a re -ablation procedure the following data will be collected:  
• For subjects with a re -ablation scheduled on Day 76 or later, the Day 90 c ardiac 
CT or MRI scan of the same type as the baseline scan will be performed prior to 
re-ablation to assess the dimensions of the PVs.   
• During any re- ablation procedure in which LA access is performed  a mapping 
procedure will characterize the reconnection status for each originally treated PV 
to characterize lesion durability. 
• For subjects who received ablation of the CTI, the persistence of nonconductivity in targeted tissue will be evaluated with either pacing maneuvers or electroanatomical mapping.  
• Lesion set data  
4.7.11  Unscheduled Assessments 
Type of Assessment :
  Either remote  or in-person at investigational site. 
Any unscheduled follow-up assessments that occur throughout study follow -up will be 
documented. Study data will be collected  including: 
• Adverse events 
• Data regarding the use, changes in or discontinuation of anticoagulation, rate control and/or antiarrhythmic medications  
• Recurrent arrhythmia, c ardioversions, ablations or hospital admissions since last 
visit  
• EM compliance will be reviewed for weekly scheduled and ad hoc symptomatic 
monitoring and retraining of the subject provided as needed. 
 
3 The protocol -specified Day 90 cardiac imaging qualifies for this purpose if obtained prior to a re -ablation.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 53 
 • Cardiac rhythm as determined by a 12- lead ECG  
o At the investigational site: required.  ECGs with any arrhythmia will include a 
rhythm strip for ACL submission. 
o At another health care site: not required but should be obtained if available. 
The absence of a 12- lead ECG is not a protocol deviation. 
o Remote, not at a health care site: not required. An EM submission should be requested.  
• If data is collected remotely, the date, time and communication method(s) used to collect the data remotely  
4.7.12 COVID- 19-Related Disruption of Study Assessments  
To avoid study disruptions or missing data related to COVID -19 impacts, such as 
COVID-19 illness or COVID-19 restrictions on movement, association or access to health care facilities, every effort will be made to gather study data by  all available 
means and from any available sources. This includes use of communications media and 
the acquisition of health- related information from other health care facilities and 
providers. 
Telephonic and telemedicine assessments may be used. Important considerations for  
study visits through video conferencing include: 
• The Investigator or study personnel who will conduct remote visits should be 
trained on how to conduct telemedicine video conferencing visits. 
• Procedures should be put in place to maintain a study subject ’s privacy, as 
would be done for a clinical visit. 
• Both the Investigator and the study subject should confirm their respective 
identities with one another before engaging in a real- time video conference visit 
according to an identity verification plan developed by the Sponsor. 
The date and time of the real -time video interaction, the location of the study subject 
and the location of the Investigator or personnel conducting the remote visit should be documented in the electronic case report form ( eCRF ). 
Every effort will be made to gather all available study data within the visit window, but if that is not possible data will be gathered outside of the visit window.  
Critical assessments to receive priority include:  
• Occurrence and characterization of AE s 
• Symptoms of arrhythmia recurrence  
• Cardiac CT or MRI scans 
• Brain MRIs  
• Follow-up a ssessment s of phrenic nerve function 
• Event monitoring 
• Holter monitoring  
For all such COVID-19- related missed or out of window assessments, specific 
information will be captured that explains the basis of the missing data and its relation to COVID-19 for missing information (e.g., from missed visits or subject discontinuations) 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 54 
 4.8 Schedule of Events  
Table 3 Schedule of Events  – ITT Subjects  
Assessment  Baseline1 
(In-
person)  Index 
Procedure 
(In-person)  Pre- 
Discharge 
(In-
person)  Day 7 
(7-11 days)  
(Remote2) Day 30  
(± 7 days)  
(Remote2) Day 60  
(± 10 days)  
(Remote2) Re-
Ablation 
Procedures  
(In-person)  Day 90 
(90 ± 14 
days)  
(In-person ) Month  6 
(180 ± 30 
days)  
(Remote2) Month  12 
(360 ± 30 
days)  
(In-person ) Unscheduled 
(In-person/ 
Remote2) 
Informed consent, baseline assessments  X3           
AAD and anticoagulant medications  X  X X X D/C AADs  X X X X X 
Recurrent arrhythmia, cardioversions, 
ablations, hospital admissions    X X X  X X X X X 
Pregnancy test  X4 X4     X4     
COVID -19 testing  by site  X           
12-lead ECG  X  X     X  X X 
HCT, HGB , electrolytes, BUN, creatinine  X  X         
Transthoracic echocardiogram (TTE)  X           
Event monitors  Training   Training    Training   Weekly + symptomatic transmissions  X 
72-Hour continuous ECG (Holter)  Training   Training       X X  
Cardiac CT/MRI for PV dimensions  X      X5 X  X6  
TEE/ICE  to exclude LA thrombus   X7     X7     
NIHSS  X  X         
Radiologic  examination of diaphragm   X     X X8  X8  
AF Symptom  Assessment  X         X  
EQ-5D-3 L & AFEQT assessment s X         X  
Non-NAS subjects: Neuro assessment    X9     X9    
NAS subjects: Neuro assessment    X10     X10    
Assessment of subject blinding    X       X  
Adverse events   X X X X  X X X X X 
1   All Baseline Assessments must be generated in the window beginning 30 days (90 days for TTE and cardiac CT/MRI) prior to the Consent D ate and ending on the date of the Index Procedure.  
2   Assessments that are defined as remote may also be performed at the investigational site (non -remote) at Investigator discretion and subject agreement.  
3   Baseline assessments include the inclusion/exclusion criteria and the data stipulated in Section 4.7.1 . 
4   Females of childbearing potential only. The pre -procedural pregnancy test is not required if the Index Procedure / Rescheduled Index Procedure is within 30 days of the baseline pregnancy test.  
5   For re -ablations occurring Day 1 -75, pre-procedural imaging is not required. For re -ablations scheduled for Day 7 6 or later, ensure the Day 90 cardiac MRI/CT is performed before re -ablation. 
6   Month 12 cardiac MRI/CT only if 3-month imaging revealed any PV with ≥ 70% reduction  in PV measured diameter . 
7   Performed at the beginning of the procedure prior to ablation. See Section 5.3 for managing subjects whose procedure is delayed by intracardiac thrombus.  
8   Only if resolution of phrenic nerve palsy has not yet been demonstrated. May be performed either by fluoroscopic sniff test or inspiration/expiration CXR.  
9 Non- NAS subjects: If NIHSS score has increased by 1 or more points or if there is a clinical suspicion of stroke/TIA, then a consulting neurologist will perform a stroke assessment and include the 
results of a concurrent brain MRI. If stroke is diagnosed, a Modified Rankin Scale assessment will be performed prior to discharge and again at 3 months.  
10  NAS subjects: If NIHSS score has increased by 1 or more points, if there is a clinical suspicion of stroke/TIA, or if the post- procedural brain MRI is positive for SCE or SCL findings then a 
consulting neurologist will perform a stroke assessment and include review of  the NAS post- procedural brain MRI. If stroke is diagnosed, a Modified Rankin Scale assessment will be performed prior 
to discharge and again at 3 months.  
 
 FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 55 
 Table 4 Schedule of Events – Roll -In Subjects  
 
Assessment  Baseline1 
(In-
person)  Index 
Procedure 
(In-person)  Pre- 
Discharge 
(In-person)  Day 7 
(7-11 days)  
(Remote2) Day 90 
(90 ± 14 
days)  
(In-person)  Month  6 
(180 ± 30 
days)  
(Remote2) Month  12 
(360 ± 30 days)  
(In-person)  Unscheduled 
(In-person/ 
Remote2) 
Informed consent, baseline assessments  X3        
AAD and anticoagulant medications  X  X X X X X X 
Recurrent arrhythmia, cardioversions, 
ablations, hospital admissions    X X X X X X 
Pregnancy test  X4 X4       
COVID -19 testing by site  X        
12-lead ECG  X  X  X  X X 
HCT, HGB, electrolytes, BUN, creatinine  X  X      
Transthoracic echocardiogram (TTE)  X        
Cardiac CT/MRI for PV dimensions  X        
TEE/ICE to exclude LA thrombus   X5       
NIHSS  X  X      
Radiologic  examination of diaphragm   X   X6  X6  
AF Symptom Assessment  X      X  
Neuro assessment    X7  X7    
Adverse events   X X X X X X X 
1   All Baseline Assessments must be generated in the window beginning 30 days (90 days for TTE and cardiac CT/MRI) prior to the date of enrollment and ending on the date of the Index Procedure.  
2   Assessments that are defined as remote may also be performed at the investigational site (non-remote) at Investigator discretion and subject agreement.  
3   Baseline assessments include the inclusion/exclusion criteria and the data stipulated in Section 4.7.1 .  
4   Females of childbearing potential only. The pre- procedural pregnancy test is not required if the Index Procedure is within 30 days of the baseline pregnancy test.  
5   Performed at the beginning of the procedure prior to ablation. See Section 5.3 for managing subjects whose procedure is delayed by intracardiac thrombus.  
6   Only if resolution of phrenic nerve palsy has not yet been demonstrated . May be performed either by fluoroscopic sniff test or inspiration/expiration CXR.  
7   If NIHSS score has increased by 1 or more points or if there is a clinical suspicion of stroke/TIA, then a consulting neurologist will perform a stroke assessment and include the results of a concurrent 
brain MRI. If stroke is diagnosed, a Modified Rankin Scale assessment will be performed prior to discharge and again at 3 months.  
 
 
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 56 
 4.9 Subject Flow Chart  
 
Figure 8 Subject Flow Chart  
 
 
 
 
Hx = history, PE = physical examination, ECG = electrocardiogram, AAD = antiarrhythmic drug  

FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 57 
 4.10 Control of Systematic Error and Bias 
Subjects will be  randomized in this controlled study and key evaluators (CEC , 
Arrhythmia Core Laboratory [ ACL ] and Cardiac Imaging Core Laboratory [ CICL ]) for 
primary and secondary outcome assessments will be blinded.  
Error and bias are controlled by additional means, including a comprehensive set of 
study procedures as defined in the protocol which  ensure consistent management , site 
and data monitoring and outcome measure assessment. Follow -up Holter monitoring 
and event monitoring data, and all MRI/CT dimensions of PVs, will be assessed objectively and without knowledge of subject treatment status by third parties according to standard protocols. SAEs and the primary effectiveness and safety outcomes will be reviewed by an independent CEC ( Section  12.2.4).  
A complete Clinical Study Report and dataset will allow scientific and clinical reviewers to independently assess potential error and bias.  
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 58 
 5. Study Procedures  
5.1 Anticoagulation 
Anticoagulation will be guided by the 2017 Heart Rhythm Society  Expert Consensus 
Statement8 and the 2019 American Heart Association  / American College of 
Cardiology / Heart Rhythm Society Focused Update36 relating to this issue.  
Adjustments  for subject welfare may be made by Investigator s based on clinical 
judgment and do not constitute protocol deviations. 
Throughout the study:  
• Subjects with a CHA 2DS 2-VASc score ≥ 2 (men) or ≥ 3 (women) should receive 
oral anticoagulants throughout the study.  
• NOACs are recommended over warfarin for eligible subjects.  
• Subjects on warfarin should have at least monthly INR assessment.  
Peri-procedural:  
• Non-anticoagulated s ubjects will  be placed on therapeutic anticoagulation for a 
minimum of 3 weeks prior to an ablation procedure regardless of baseline 
CHA 2DS 2-VASc score. 
• Subjects taking warfarin should continue warfarin through the procedure. 
• Subjects taking a NOAC should have either continued NOAC (rivaroxaban) or a single dose interruption in NOAC with a restart shortly after the procedure , at 
Investigator discretion . 
• A heparin bolus will be delivered prior to or immediately following transseptal 
puncture. Procedural activated clotting times ( ACTs ) will be sampled regularly 
throughout the procedure and maintained at a minimum of 300  seconds. 
Post-ablation: 
• If the subject is not otherwise indicated for anticoagulation, suitable anticoagulation will be maintained for a minimum of 2 months following an y 
ablation procedure. 
Thereafter, decisions regarding anticoagulation should be based on the subject’s stroke risk and bleeding risk profiles.  
 
5.2 Index Procedure 
Subjects will be screened for completion of a minimum of 3 weeks of systemic 
anticoagulation prior to the Index Procedure and if this condition has not been met the 
subject will be rescheduled under the procedure defined in  Section 5.3. 
Subjects will undergo sedation / anesthesia according to institutional protocol. They 
will then be prepared in conventional sterile fashion for a cardiac catheterization procedure.  
Femoral vein access will be obtained via Seldinger technique.   
FARAPULSE  ADVENT  TRIAL  OCTOBER 13, 2021 
CS0934,  REVISION D  PAGE 59 
 Use of ultrasound guidance is recommended, but not required, for femoral venous 
access.  
A heparin bolus will be delivered prior to or immediately after transseptal puncture. 
Procedural ACTs will be regularly monitored and maintained at a minimum of 300 
seconds. 
Commercially approved diagnostic catheters may be placed before or after transseptal 
access is established at the Investigator’s discretion. Transseptal access to the LA will 
be obtained using commercially approved devices, establishing guidewire access to 
the LA . 
TEE within 48 hours of the procedure or ICE during the procedure will be utilized prior 
to transseptal puncture for exclusion of LA thrombus. If the study reveals atrial 
thrombus, the investigational procedure will not begin or will be terminated, no 
ablation will be performed and the subject will be rescheduled under the procedure 
defined in Section 5.3. 
 
Pre-ablation and post-ablation voltage maps are not required.  
Pulsed Field Subject s:  
The use of ICE is required for Pulsed Field Ablation procedures.  
The FARADRIVE Steerable Sheath will be prepared and advanced via guidewire to 
the LA . 
Esophageal temperature monitoring, esophageal cooling and esophageal deviation are 
unnecessary during ablation with the FARAWAVE Pulsed Field Ablation Catheter 
and should not be utilized. 
The FARAWAVE Pulsed Field Ablation Catheter  will then be prepared and 
advanced to the LA through the FARADRIVE Steerable Sheath . After confirming an 
ACT of 300 or greater, ablation of the PVs to achieve isolation will be performed according to the approved IFU  documents and institutional practice.
Ablation will be attempted in every clinically relevant PV, including any vein with an 
active muscular sleeve. Small anomalous PVs that are electrically silent need not be 
attempted.  
PVI ablation may be repeated at the Investigator’s  discretion. Each addressable PV 
will be ablated in turn. The isolating effect of the PVI ablation(s) will be checked periodically and then finally twenty (20) minutes after the last PVI ablation. 
Adenosine may be used for the final assessment but is not required. 
 
 At the conclusion of the PVI ablation procedure, the FARAWAVE Pulsed Field 
Ablation Catheter will  be undeployed and withdrawn from the FARADRIVE 
Steerable Sheath .  
The functional status of both phrenic nerves will be assessed before the study is 
concluded. 
Thermal Subject s:  
All Investigators at a given site must use only 1 of the 2 categories of Thermal Group 
technology for ablation, either a force-sensing irrigated RF A catheter or a CBA 
catheter, indicated for the treatment of PAF. A site’s Thermal Group technology will 
be determined prior to the initiation of enrollment at that site and maintained without 
exception throughout the study. 
A commercial ly approved sheath will be prepared and advanced via guidewire to the 
LA. Commercially approved diagnostic catheters may be placed via conventional 
technique at the Investigator’s discretion. A baseline 3D electroanatomical map may 
also be made at the Investigator ’s discretion.  
Esophageal protection (temperature monitoring, deviation or cooling) us ing the site’s  
customary method is required, unless subject welfare precludes such usage. 
The site’s predetermined technology ablation catheter will be prepared and advanced 
to the LA  through the sheath. Ablation of the PVs to achieve isolation will be 
performed according to the approved IFU  documents and institutional practice.  
Ablation will be attempted in every clinically relevant PV, including any vein with an 
active muscular sleeve. Small anomalous PVs that are electrically silent need not be 
attempted.  
PVI ablation may be repeated at the Investigator’s  discretion. The isolating effect of 
the PVI ablation(s) will be checked periodically and then finally twenty (20) minutes after the last PVI ablation. Adenosine may be used for the final assessment but is not required.  
At the conclusion of the PVI ablation procedure, the ablation catheter should be 
withdrawn from the sheath according to the manufacturer’s instructions.  
The functional status of both phrenic nerves will be assessed before the study is concluded. 
All Subjects:  
CTI ablation : Ablation of the CTI may be performed in both Pulsed Field Subjects and 
Thermal Group S ubjects using any approved catheter in subjects with a past history of 
cavo -tricuspid isthmus -mediated (typical) AFL , subjects who manifest typical AFL  
during a procedure or within the Blanking Period, or subjects who have inducible typical flutter.  Bidirectional block should be demonstrated after the last CTI ablation.  
 
 The CTI ablation data will be documented in the CRF and does not constitute a 
Treatment Failure . 
Other Ablation : O ther ablation is not permitted under this protocol except  when the 
Investigator determines that subject welfare requires ablation for an accessory pathway , 
AVNRT, treatment- emergent left AFL  or incessant AT , using any approved ablation 
catheter . This decision and the associated ablation data will be documented in the CRF 
and does not constitute a Treatment Failure. 
5.3 R escheduled Index Procedure 
Subjects found during the Index Procedure to have LA  thrombus will have their Index 
Procedure rescheduled to allow treatment of the thrombus, including a minimum of 3 weeks of continuous therapeutic anticoagulation consistent with Section 5.1. The 
Reschedule Index Procedure will follow the requirements of Section  5.2. 
This rescheduling is permissible and does not create an Acute Procedural Failure. For adjustment of follow -up assessments please see Section  5.5 below. References to 
“Index Procedure” in this protocol should be assumed when appropriate to include “Rescheduled Index Procedure” as well if not otherwise specified.  
5.4 Re-Ablation Procedure s 
Re-ablation under this protocol requires documentation of Detectable AF, AFL or AT. When performed, re- ablation will be performed utilizing a n FDA-approved study 
ablation catheter (RFA or CBA) at Investigator discretion.  
Any re -
ablation procedure for AF, AFL or AT  any time during study follow-up 
constitutes a Treatment Failure . 
 
However, CTI ablation or re-ablation for right-sided typical AFL  may be performed at 
any time during study follow-up and does not constitute a Treatment Failure .  
 
Cardiac imaging: 
• For anticipated PVI re -ablations occurring Day 1-75, pre-procedural imaging is not 
required.  
• For anticipated PVI re -ablations scheduled for Day 76 or later, ensure the Day 90 
cardiac MRI/CT is performed before re- ablation  to assess the dimensions of the 
PVs. The Cardiac CT or MRI scan must be of the same type as the baseline scan 
obtained prior to the Index / Rescheduled Index Procedure. 
 
TEE within 48 hours of the procedure or ICE during the procedure will be utilized prior 
to transseptal puncture for exclusion of LA thrombus. If the study reveals atrial 
thrombus, the investigational procedure will not begin or will be terminated  and no 
ablation will be performed.  
 
 
 Re-ablation does not reset the Blanking Period or otherwise alter the Schedule of 
Events and Assessments ( Section  4.7). 
Remapping will be performed:  
• During any re- ablation procedure in which LA access is performed : 
o Sufficient mapping to establish the durability of isolation of each previously 
treated PV.  
• During any re-ablation procedure in a subject who underwent CTI: 
o Sufficient mapping to establish the durability of a previously treated CTI.  
5.5 Start Date, Blanking Period and Index Procedures  
The day of the Index Procedure or Rescheduled Index Procedure is the Start Date (Day  0) for follow -up scheduling. The Blanking Period consists of a subject’s Day 0 
through and including Day 90. During the Blanking Period, any oc currence of 
Detectable AF, AFL or AT  will be documented; however, occurrences of AF, AFL or 
AT during this time will not be considered Treatment Failure s.  
For subjects who undergo ablation at the Index Procedure, the follow- up intervals for 
safety and effectiveness are depicted in Figure 9 below: 
Figure 9 Index Procedure Blanking and Follow -Up Intervals  
 
For subjects who undergo ablation at a Rescheduled Index Procedure the follow-up intervals for safety and effectiveness are depicted in Figure 10  below. The follow -up 
intervals for effectiveness and safety are still based on the day of the ablation procedure (Day 0) . Pre-ablation AE s that occur between the Index Procedure and the day before 
the Rescheduled Index Procedure will not be included in the safety analyses, but will be documented and reported separately, with the day of occurrence being enumerated from the day of the Index Procedure that was deferred. 

 
 Figure 10 Rescheduled Index Procedure Blanking and Follow -Up Intervals  
 
5.6 Roll-In Subjects  
Up to 105 subjects – to be treated with the FARAPULSE devices – will be consented 
and treated in a manner consistent with the Pulsed Field Group but will be analyzed and reported separately from the study population.  
At each site, these Roll -In Subjects will be the first 1  to 3 sequentially enrolled but non-
randomized subjects at that site. Sites with more than 1 Investigator will utilize 
available Roll -In Subjects jointly as required. 
With Sponsor and Investigator agreement, the Roll-I n phase at a site will be terminated 
at or before 3 Roll- In Subjects have been treated and  all subsequent subjects at the site 
will be randomized as study subjects according to protocol requirements.  
Roll-In 
 Subjects will : 
• Be consented using a Roll- In-specific ICF.  
• Follow the Index Procedures as specified in Section 5.2. 
• Have all study data gathered as specified in Section 4.7.2 and Section 4.7.3. 
• Be followed for 12 months post- ablation , completing Day 7 and Month 3, Month 
6 and Month 12 A ssessments for clinical ly-detected  arrhythmia s and screening 
for the occurrence of AE s 
• Be managed according to Investigator or referring physician discretion. 
• Have their required study data recorded on a specific and separate CRF set . 
• Be analyzed and reported separately from the ITT  Subjects. 
Roll-In Subjects will not: 
• Undergo Quality of Life assessments  
• Undergo NAS assessment  
• Undergo protocol- specified EM or Holter monitoring  
• Undergo protocol- specified cardiac imaging post -procedure 
5.7 Blinding  
• I nvestigators : The treating physicians and site -based study personnel are 
necessarily exposed to a subject’s treatment assignment and cannot be blinded. 
As much as possible, site based study personnel who perform follow- up 
evaluations will remain blinded to subject treatment assignment.  

 
 • S ubjects: Study personnel will be trained to avoid disclosing treatment status to 
study subjects. Study subjects will sign an informed consent that states that they 
will not be informed of their treatment status until the conclusion of their participation in the s tudy. 
• Core Laboratories: The ACL, CICL and Brain Imaging Core Lab (BICL) will 
remain blinded to treatment assignment throughout the study duration. 
• CEC: The CEC will remain blinded as much as possible consistent with accurate 
adjudication.  
• Data and Safety Monitoring Board ( DS MB) : In general, the DSMB will review 
unblinded results in order to perform their function of protecting the integrity of the study and the rights, safety and welfare of study subjects. 
• Study / CRO staff : M
 onitoring staff will be unblinded to perform their function. 
Other Sponsor and CRO staff will be unblinded on a documented need- to-know 
basis to allow conduct of the study. 
5.8 N eurologic Assessment Subjects  
Neurologic Assessment Subjects (NAS) are a subset of ITT Subjects who will undergo 
a post-procedural brain MRI following the ablation procedure. 
5.8.1 NAS Sites  
A subset of study sites qualified and willing to perform the standardized brain MRI 
post- ablation will be established and designated as NAS sites. NAS sites will be 
selected to generate a minimum of 80 NAS Subjects, balanced approximately equally between RFA and CBA control sites . Total NAS enrollment will be limited to a 
maximum of 40 subjects in the PFA group and 40 subjects in the Thermal Group (RFA/CBA). 
• An approximately equal number of RF-control sites and cryoballoon- control sites 
will be targeted . 
• All ITT Subjects at NAS sites free of contraindications to MRI will be consented 
for post- procedure MRI until the study enrollment target of evaluable scans is 
met. 
• Roll-In Subjects are excluded  from participation in the NAS.  
5.8.2 Post-Ablation Brain MRI Specifications  for NAS Subjects Only  
These specification are for the protocol -r
 equired brain MRIs of NAS Subjects only. 
• Standards and Quality Control: The BICL will establish specific standards for 
brain MRI performance, train participating sites and interact with sites to ensure 
that standards and scan quality remain within specification. 
• Timing :  Post index procedure (between 12 hours to  48 hours post- ablation ) brain 
MRIs will be performed on each NAS subject . 
• Parameters:  The following scan parameters will be used: 
o 1.5-T scanners  
o 5mm slice thicknesses  
o DWI, FLAIR and ADC assessed for each scan  
o SCE = DWI + and ADC reduced  
 
 o SCL = DWI + and ADC reduced and FLAIR + 
5.8.3 SCE and SCL Analysis  
The frequency and type of SCE s and SCL s will be reported by randomization group, 
along with potential predictor variables including CHA 2DS 2-VASc  status, duration of 
PAF, history of stroke/TIA, procedur e time, LA  dwell time and total ablation time, 
anticoagulation regimen and ACT levels, occurrence of cardioversion or air 
introduction, frequency of LA catheter exchanges and maximal sheath size.  
5.8.4 Follow- Up for Subjects with SCE or SCL Lesions  
• Subjects with a site -confirmed post- procedural SCE or SCL will undergo a 
pre-discharge neurologic assessment as specified in Section 4.7.3. 
• Subjects with a site- confirmed or BICL -confirmed post- procedural SCE or 
SCL will undergo a follow -up brain MRI using the parameters specified in 
Section 5.8.2 during the 90 Day Assessment  window. 
5.9 Antiarrhythmic  Drugs  
AADs , except for amiodarone, may be utilized during the Blanking Period at the 
Investigator’s discretion.  
On Day 60 ± 10 each subject will be contacted by telephone to stop all AADs.  
Class I  / III AADs (see Section 6.3.4) should be stopped at the Day 60 Assessment. 
However, a t the Investigator’s discretion, Class I  / III AADs may be continued up to 
Day 90 without creating a Treatment Failure . If AADs are required after Day 90 and 
Class I / III AADs are prescribed, the Investigator should document the reason for 
utilizing the medication in the eCRF.  Notwithstanding the impact on study outcomes, 
the use of Class I / III AADs for subject welfare as determined by the Investigator during and after the Blanking Period do not constitute protocol deviations. 
The use of amiodarone at any time during the study, except intra -
 procedurally to 
control an arrhythmia , or the use of Class I / III AADs after Day 90, constitute a 
Treatment Failure.  
 
 6. Study Definitions  
6.1 Study Outcomes  
The primary and secondary effectiveness endpoints and the primary and secondary 
safety endpoints, along with specified additional analyses , procedural assessments and 
quality of life assessments, are defined in Section  7. 
6.2 Adverse Event Definitions 
Definitions relating to AEs, SAEs , procedure relatedness, device relatedness, device 
effects, malfunctions and deficiencies are defined in Section  8. 
6.3 Other Definitions  
6.3.1 Acute Procedural Success  
Demonstration of Acute Vein Success in all attempted  PVs using the randomized 
treatment during the first ablation procedure (Index or Rescheduled Index Procedure). 
(See Section 6.3.3) 
6.3.2 Acute Procedural Failure  
The absence of Acute Procedural Success, including the use of any non-randomized 
energy modality for PVI. 
6.3.3 Acute Vein  Success  
Proportion of all attempted PVs isolated using the randomized treatment during the first ablation procedure (Index or Rescheduled Index Procedure), as clinically assessed by entrance block demonstrated ≥ 20 minutes after the last PVI lesion is made with or without adenosine testing. 
6.3.4 Antiarrhythmic Drug s, Class I and III 
AADs  are those pharmaceutical agents approved or used in the United States for the 
treatment of cardiac arrhythmia. For the ADVENT Trial, the use of Class I and III  
AADs  after the Blanking Period constitute a primary effectiveness endpoint failure . 
Examples of these agents include but are not limited to : 
• Class I , sodium channel blockers: disopyramide, flecainide, procainamide, 
propafenone quinidine. 
• Class III , potassium channel blockers: amiodarone, dofetilide, dronedarone, 
sotalol.  
Should other Class I or III AADs become approved or used in the United States for the treatment of cardiac arrhythmia during the ADVENT Trial, they will be included in the list of AADs that constitute a Treatment F ailure if used after the Blanking  
Period. 
6.3.5 Blanking Period  
An interval in which recurrent AF , AFL or AT  does not constitute a Treatment 
Failure beginning on Day 0 and running for 90 days thereafter. 
• The Blanking Period has no impact on the assessment of AE s. 
 
 • For subjects with only an Index Procedure, the Blanking Period will be Day 0 to 
Day 90 inclusive. 
• For subjects who require a Rescheduled Index Procedure, the Blanking Period 
will be the Study Day of the Rescheduled Index Procedure plus 90 days 
inclusive. 
6.3.6 Chronic Failure  
The absence of Chronic Success.  
6.3.7 Chronic Success  
Defined in Section 7.4.  
6.3.8 COVID- 19-Related Disruptions  
A disruption to any study procedure resulting directly or indirectly from the COVID-19 pandemic, including but not limited to participant illness, study site restrictions and limitations, shipping  / manufacturing interruptions, significant 
changes in FDA guidance and / or governmental restrictions on travel, association and the prioritization of healthcare resources.  
6.3.9 Dates  
• C
onsent Date : The date a subject signs the ICF . 
• Exit Date :  The date on which study participation ends . 
• Onset Date: The date on which a condition or AE  begins. 
• Start Date : Day 0, the date of the Index or Rescheduled Index Procedure. 
6.3.10  Day (or Study Day) 
A Day is an enumerated day of follow-up that begins on an Enrolled Subject’ s Start 
Date (Day 0) . 
6.3.11  Detectable AF, AFL or AT  
Detectable AF, AFL or AT is an episode of AF, AFL or AT which : 
• Is permanently recorded for review  
• Contains at least 30 seconds of continuous interpretable signal 
o Exception: Continuous AF, AFL or AT for the entirety of a 12 lead ECG 
constitutes Detectable AF , AFL or AT  if the continuous interpretable 
signal is 10 seconds  or longer  
• Includes symptomatic and asymptomatic episodes.  
• Excludes CTI isthmus -dependent AFL when the mechanism is confirmed 
electrophysiologically. 
Such episodes are not AE s under this protocol unless deemed to be caused by an 
ablation procedure. 
6.3.12 Investigational D evices and Procedures 
For the purpose of assessing event and outcome rates in study subjects: 
 
 • Investigational devices include any protocol- specified ablation catheter, 
generator/console or sheath, whether FDA approved (radiofrequency ablation or 
cryoablation systems) or not  (FARAPULSE Pulsed Field Ablation System) . 
• Investigational procedures include any ablation procedure performed by a study 
investigator for the treatment of AF, AFL or AT , and study- directed CT/MRI 
testing . 
6.3.13 Pre-Ablation A dverse E vents  
Defined as those AEs that occur between the date of the deferred Index Procedure and 
the day before the Rescheduled Index Procedure in subjects whose first ablation 
procedure is rescheduled due to intracardiac thrombus. These are not included in study safety analyses but wil l be documented and reported separately. 
6.3.14 Pulmonary V ein Dimensions  
For the purpose of study outcomes: 
• PV dimensions will be measured in two roughly orthogonal diameters approximating the longest and shortest diameters at the plane of measurement.  
• The measured PV diameter is defined as the geometric mean of these 2 measurements.   
• The PV cross- sectional area is computed using the formula for area of an 
ellipse, where the longest and shortest axis measurements of the PV diameter serve as the major and minor axes of the ellipse, using half of each axis diameter as the radii for calculation . 
• Aggregate PV Cross- Section Area is the sum of the calculated PV cross-
sectional area of each PV ablated at the Index / Rescheduled Index Procedure, as detailed in the SAP.  
6.3.15 Pulmonary V ein Isolation 
Complete electrical isolation of a PV confirmed by entrance block, specifically: the 
percutaneous endocardial creation of an electrically isolating set of lesions around the ostia of a PV, as clinically assessed by entrance block demonstrated ≥ 20 minutes after the last PV lesion is made, with or without adenosine testing.  
6.3.16 Pulsed Field Group / Subjects  
Subjects randomized to treatment with the FARAPULSE Pulsed Field Ablation System are Pulsed Field Subjects and collectively comprise the Pulsed Field Group.  
6.3.17 Severe COVID- 19 Subject s 
Any study subject who contracts COVID-19 infection during study participation that: 
• Requires supplemental oxygen, positive pressure ventilation, and/or intubation  
OR  
• Is associated with any medically serious sequelae of COVID-19, including but 
not limited to new onset cardiac arrhythmia, heart failure, myocarditis, neurologic dysfunction or other organ dysfunction or thromboembolic disease. 
 
 Such subjects will be initially defined by the Investigator and confirmed by the CEC. 
The Onset D ate will be the date of symptom onset in a subsequently clinically 
confirmed case of COVID-19 infection. 
6.3.18 Study Participants  
Study participants include patients being screened, Enrolled Subjects, study site 
personnel, study monitors and other CRO personnel as well as Sponsor personnel. 
6.3.19 Thermal Group  / Subjects  
Subjects randomized to treatment with RFA or CBA are Thermal Subjects and 
collectively comprise the Thermal Group.  
6.3.20  Treatment Failure  
The absence of Treatment Success. 
6.3.21  Treatment Success  
Defined in Section 7.4.  
 
 
 
 7. Outcome Measures  
7.1 Primary Safety Endpoint  
The primary safety endpoint  is the Composite Safety Endpoint (CSE) defined as the 
proportion of Safety  Subjects with one or more of the following device- or procedure -
related SAEs as adjudicated by the CEC based on the definitions contained in Table 5. 
Early onset:  Any of the following with an Onset Date within 7 days of the 
Index / Rescheduled Index procedure: 
• Death  
• Myocardial infarction  
• Persistent phrenic nerve palsy  
• Stroke  
• TIA 
• Peripheral or organ thromboembolism  
• Cardiac tamponade  / perforation 
• Pericarditis  
• Pulmonary edema  
• Vascular access complications  
• Heart block  
• Gastric motility/pyloric spasm disorders  
Late onset : Either of the following with an Onset Date any time through the 
completion of 12- month follow -up visit: 
• PVS4 
• Atrio -esophageal fistula  
 
Table 5 Composite Safety Endpoint Definitions  
 
Related SAE  Description/Criteria  
Death  AE resulting in subject death  
Myocardial 
infarction Deﬁned as the presence of any one of the following criteria:  
(1) detection of ECG changes indicative of new ischemia (new ST - T wave 
changes or new LBBB) that persist for more than 1 hour  
(2) development of new pathological Q waves on an ECG  
(3) imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality  
 
4 For subjects ablated with more than one energy modality, the CEC will – to the extent possible – determine 
which modality(ies) are related to any observed PVS.  
 
 Related SAE  Description/Criteria  
Persistent phrenic 
nerve palsy  Defined as absent phrenic nerve function as assessed by  
a change from baseline in the elevation of a hemidiaphragm , persisting 
beyond the end of the procedure  that is: 
• Demonstrated radiographically by either an inspiration / expiration 
chest X-ray or fluoroscopic sniff test  
• Not due to a demonstrable pulmonary process such as atelectasis or 
pleural disease.  
Persistent : not resolved at the time of the last follow -up visit.  
Stroke  Rapid onset of a focal or global neurological deficit with at least one of the 
following:  
• Change in level of consciousness  
• Hemiplegia, hemiparesis, numbness or sensory loss affecting 1 side 
of the body  
• Dysphasia or aphasia  
• Hemianopia, amaurosis fugax, or  
• Other neurological signs or symptoms consistent with stroke  
The diagnosis of stroke requires that there be  no other readily identifiable 
non-stroke cause for the clinical presentation (e.g., brain tumor, trauma, infection, hypoglycemia, peripheral lesion, pharmacological influences).  
The duration of the defined neurological deficit(s) must be:  
• ≥ 24-hour s; OR  
• < 24-hour s if  
o Therapeutic intervention(s) were performed (e.g., thrombolytic therapy or intracranial angioplasty), OR  
o Available neuroimaging documents a new hemorrhage or infarct,  OR  
o The neurological deficit results in death.  
Transient ischemic 
attack  Defined as a new focal neurological deficit with:  
• Symptom resolution within 24 hours 
• No new tissue injury demonstrated (if neuroimaging is obtained)  
Peripheral or organ 
thromboembolism  A cardiac thrombus that occludes a more distal arterial site other than the 
central nervous system (see Stroke). Cutaneous petechiae are excluded from 
this definition.  
Cardiac tamponade  / 
perforation The development of a pericardial effusion post-ablation  that results in 
hemodynamic compromise, requires pericardiocentesis or results in a 1 -cm 
or more pericardial effusion as documented by echocardiography. Cardiac tamponade/perforation should also be classiﬁed as “early” or “late” 
depending on whether it is  diagnosed during or following initial discharge 
from the hospital.  
Pericarditis  The development of pericardial inflammation post-ablation  that results in an 
effusion that leads to hemodynamic compromise or requires 
pericardiocentesis, prolongs hospitalization by more than 48 hours, requires hospitalization, or persists for more than 30 days following the ablation 
procedure.  
 
 Related SAE  Description/Criteria  
Pulmonary edem a Respiratory compromise resulting from cardiac dysfunction or volume 
overload leading to increased interstitial lung fluid requiring intubation or 
parenteral diuretics.  
Vascular access 
complications  Vascular access complication (e.g., groin hematoma, AV fistula, 
pseudoaneurysm) requiring a significant and invasive intervention ( e.g., 
surgical repair, blood transfusion or thrombin injection).  
Heart block  Impairment of AV conduction that is related to a protocol -stipulated  cardiac 
ablation procedure and that requires permanent pacing.  
Gastric 
motility/pyloric 
spasm disorders  Evidence of impaired gastric motility or pyloric spasm that prolongs 
hospitalization, requires hospitalization or persists for more than 30 days.  
Pulmonary vein 
stenosis  >70% reduction of an ablated measured PV diameter * compared to the 
baseline CT/MR I scan, as determined by the CICL . 
Atrio -esophageal 
fistula  Confirmation of a fistulous connection between the atrium and the lumen of 
the esophagus by radiographic, endoscopic or post -mortem examination  
AV = atrioventricular, CICL  = Cardiac Imaging Core Laboratory, CT  = computed tomography, ECG  = 
electrocardiographic, LBBB = left bundle branch block, MRI  = magnetic resonance imaging, PV  = pulmonary 
vein, SAE  = serious adverse event.  
* See Section 6.3.14 for the definition of PV diameter.  
 
7.2 Secondary Safety Endpoint  
The secondary safety endpoint is Aggregate PV Cross-S ectional Area, defined as the 
paired comparison of change in the computed Aggregate PV Cross-S ectional A rea 
(Section  6.3.14) between baseline and 3 months in MITT subjects compared between 
randomization groups (intent- to-treat, regardless of re -ablation with any second energy 
modality). Supplemental analyses will include MITT single -procedure subjects and the 
PP population.  
7.3 Additional  Safety Analyses 
Each of these assessments will be tested for nominal p values between Pulsed Field 
Subjects and Thermal Subjects:  
1. Severe Ablation Complications: The proportion of subjects in each randomization group with one or more of the following CSE components as defined in Table 4 will be compared between treatment groups. 
• PVS 
• Persistent phrenic nerve palsy  
• Atrio -esophageal fistula  
2. Nonserious / Serious CSEs:  The proportion of subjects in each randomization 
group with any device or procedure- related AE  in the CSE definitions table 
without regard for serious or nonserious categorization. 
3. Post-Blanking Cardioversions:  The proportion of subjects in each randomization 
group with 1 or more post-Blanking Period direct- current (electrical) 
cardioversions . 
 
 4. Post-Blanking Arrhythmia Hospitalizations: The proportion of subjects in each 
randomization group with 1 or more post -Blanking Period hospitalizations 
primarily due to arrhythmia or arrhythmia complications.  
5. Any Related SAE:  The proportion of subjects in each randomization group  with 
any device- or procedure- related SAE.  
6. Any Related Stroke or TIA : The proportion of subjects in each randomization 
group with any device- or procedure- related stroke or TIA.  
7. Categorized PV Dimensional Changes:  The distribution of PV dimensional 
changes between baseline and 3- month  MRI/CT scans  
a. Categorized by the % change in the PV diameter s: 0-29.9%, 30-49.9%, 50-
69.9% and ≥  70% between randomization groups.  
b. Categorized by the % change in computed cross- sectional areas: 0 -49.9%, 
50-74.9%, 75 -89.9% and ≥  90% between randomization group s. 
8. Thermal Group RF  Ablation  / Cryo ablation Safety Assessment:  a descriptive 
comparison of safety outcomes between the two Thermal Group technologies. 
9. Learning Curve Safety Assessment:  For Pulsed Field Group only, per site and 
per operator learning curve assessment of the primary safety endpoint  and 
supportive assessment of the secondary safety assessment and  / or components of 
the CSE by enrollment sequence. 
7.4 Primary Effectiveness Endpoint  
Treatment Success:  The primary effectiveness endpoint is Treatment Success in 
MITT Subjects , defined as : 
1. Acute Procedural Success ( Section  6.3.1) AND  
2. Chronic Success, defined as freedom from:  
a. At the Index / Rescheduled  Index Procedure: U se of a non-randomized 
treatment modality for PVI  
b. After the Blanking Period: 
i. Occurrence of any Detectable AF, AFL or AT  (Section  6.3.11) 
(excluding CTI -dependent flutter confirmed by EP study) 
ii. Any cardioversion for AF, AFL or AT (excluding for CTI -dependent 
flutter)  
iii. Use of any Type I or Type III anti arrhythmic medication for the 
treatment of AF, AFL or AT  
c. At any time : 
i. Re-ablation  for AF, AFL or AT  (other than for CTI -dependent flutter)  
ii. Use of amiodarone, except intra-procedurally to control an arrhythmia 
Endpoint status will be assessed through the Month 12 Assessment (Day 360 ± 30). 
7.5 Secondary Effectiveness Endpoint  
The secondary effectiveness endpoint is the same as the primary effectiveness endpoint 
but will be tested for superiority  rather than non- inferiority. T he proportion of Pulsed 
Field Subject s with Treatment Success will be assessed for superiority to the proportion 
of Thermal Subject s with Treatment Success.  
 
 7.6 Additional  Effectiveness Analyses 
Each of these assessments will be tested for nominal p values between Pulsed Field 
Subject s and Thermal Subject s: 
1. Acute Procedural Success:  (Section 6.3.1) A ssessed on a per subject basis.  
2. Acute Vein Success:  (Section  6.3.3 ) Assessed on a per vein basis, for all veins 
and for each category of vein. 
3. Chronic Success ( Section  7.4). 
4. Chronic Success Allowing Re -ablation : Chronic Success ( Section 7.4) 
including as successes those subjects who failed only because they underwent a re-ablation procedure during the Blanking Period. 
5. Chronic Success A llowing AADs : Chronic Success ( Section 7.4) including as 
successes those subjects who failed only because they received post-Blanking Period treatment with a Type I / III AAD.  
6. Treatment Success Allowing Re -ablation:  Treatment Success ( Section 7.4) 
including as successes those subjects who failed only because they underwent a re-ablation procedure during the Blanking Period. 
7. Treatment Success Allowing  AADs : Treatment Success ( Section 7.4) including 
as successes those subjects who failed only because they received post-Blanking Period treatment with a Type I / III  AAD.  
8. Treatment Success with PVI/CTI  only : Treatment Success ( Section 7.4) 
excluding all subjects whose Index / Rescheduled  Index Procedure required atrial 
ablation other than PVI or CTI . 
9. Early Recurrence of AF:  The proportion of subjects with early recurrence of AF  
≤ Day 90 after the initial study ablation. 
10. Rate of Re -ablation:  The p roportion of subjects requiring any re -ablation for 
atrial arrhythmias through 12 months of follow-up. 
11. PVI Durability at Re -Ablation : For those subjects undergoing any re -ablation 
procedure with LA access during study follow-up, a per vein and a per subject assessment of PVI durability . 
12. CTI Ablation Failure: Proportion of subjects who undergo a first CTI ablation at 
the Index Procedure / Rescheduled Index Procedure who have recurrent typical (right-sided) AFL  through 12 months of follow- up. 
13. Thermal Group RF A blation  / Cryoablation Effectiveness Comparison:  A 
descriptive c omparison of effectiveness measures between the two Thermal 
Group technologies. 
14. AF Symptom Assessment:  A descriptive comparison of the change in AF 
symptom frequency from baseline to 12 months. 
15. Learning Curve Effectiveness Assessment:  For the Pulsed Field Group only, 
per site  and per operator learning curve assessment of the primary effectiveness 
endpoint and supportive analyses of related effectiveness and procedural data by enrollment sequence. 
7.7 Procedural Assessments 
Each of these assessments will be tested for nominal p values between Pulsed Field 
S
ubject s and Thermal Subject s: 
1. Assessments of procedure durations 
 
 a. Procedure time (initiation of venous access to venous access closure)  
b. LA dwell time (total time an ablation catheter is in the LA ) 
c. Total ablation time (first ablation to last ablation)  
d. Total mapping time (total time spent mapping)  
e. Fluoroscopy time (total duration of exposure) 
2. Characterization of lesion sets:  
a. PVI ablations 
b. CTI ablations  
c. For subjects undergoing required LA ablations for an accessory pathway , 
AVNRT,  left- sided AFL  or incessant AT, a description of lesion sets 
utilized  
7.8 Quality of Life Assessments 
Quality of Life (QoL) will be assessed at baseline and 12 months using two 
assessments. Th ese assessment s will be tested for nominal p values between Pulsed 
Field Subjects and Thermal Subject s: 
1. The EuroQol standardized questionnaire of health states ( EQ-5D-3 L) at baseline 
and 12 months (The EuroQol Group. EuroQol - a new facility for the 
measurement of health -related quality of life. Health Policy 1990;16:199-209) 
2. Atrial Fibrillation Effect on Quality of Life (AFEQT) at baseline and 12 months (Spertus J, Dorian P, Bubien R, et al. Development and validation of the Atrial Fibrillation Effect on QualiTy -of-LIfe (AFEQT) Questionnaire in patients with 
atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15 -25) 
 
 
 8. Adverse Events, Device Effects, Malfunctions and Deficiencies  
8.1 Anticipated Adverse Events  
The following is a list of AE s that may possibly be caused by or associated with the 
proposed use of the investigational devices and other devices, the failure, misuse or 
malfunction of the investigational devices or other devices, or the related procedures stipulated by this protocol or associated with this clinical study .  
Recurrent AF  for the purposes of this protocol is not an AE , but a continuation of a 
previous condition that is potentially a failure of effectiveness.  
• Access site complications (e.g., hematoma, fistula, pseudo -aneurysm, laceration, 
bleeding) potentially requiring surgical intervention  
• Air embolism 
• Allergic reaction or fever resulting from contact with catheters or drugs  
• Anemia  
• Arrhythmia, potentially requiring cardioversion, defibrillation, or rhythm management device 
• Arteriovenous fistula  
• Back pain  
• Bed sores  
• Bleeding, hematoma, hemorrhage or aneurysm at vascular access sites  
• Blood pressure changes including hypotension or hypertension 
• Cardiac tamponade or perforation 
• Cardiac arrest or cardiac failure  
• Cardiogenic shock 
• Catheter entrapment potentially requiring endovascular or surgical intervention  
• Conduction system injury, either transient or permanent, potentially requiring pacemaker insertion  
• Congestive heart failure  
• Coronary artery or vein injury 
• Death  
• Drug allergic reaction or side effects (e.g., from contrast, steroids, analgesics, 
anesthetics, anticoagulants, sedatives)  
• Embolism with damage to body structures due to presence of thrombus, 
particulate, device fragments or the introduction of air  
• Esophageal injury, ulcer or fistula 
• Gastric motility  / pyloric spasm disorders 
• Hemorrhage  
• Hemodynamic compromise  
• Hemopericardium 
• Hemoperitoneum 
• Hemothorax 
• Local infection, systemic infection  and/or sepsis  
• Muscle contractions due to electric stimulation  
• Myocardial infarction  / ischemia  
 
 • Nerve damage 
• Organ failure 
• Pain 
• Perforation (e.g., of diaphragm, liver, lung and/or vessels).  
• Pericardial irritation with pain  
• Pericardial effusion  
• Pericarditis  
• Peritonitis  
• Phrenic nerve injury with potential paralysis of the diaphragm and breathing 
impairment  
• Pneumomediastinum 
• Pneumopericardium 
• Pneumoperitoneum 
• Pneumothorax 
• PV injury, perforation or stenosis 
• Risk of cancer or birth defect/harm to fetus from x -ray exposure 
• Skin burns/irritation from X-ray exposure  
• Stroke / TIA  
• Surgical procedure to correct any anticipated AE  
• Thrombosis 
• Vessel damage, dissection, or occlusion. 
8.2 Adverse Event Review  and Adjudication  
This study will utilize a CEC for the review and adjudication of AEs. All safety 
analyses will utilize the adjudicated rather than site determination of an AE’s 
characteristics in those instances where the CEC has adjudicated that characteristic to be different than the site’s determination. See Section  12.2.4. 
8.3 Adverse Event s 
An AE is a ny untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device . 
NOTE 1:  This definition includes events related to the investigational medical device or the 
control devices . 
NOTE 2 :  This definition includes events related to the procedures involved.  
NOTE 3 :  For users or other persons, this definition is restricted to events related to investigational medical devices.  
NOTE 4:  T
 his definition excludes medical conditions, findings or abnormalities which are 
determined to have been present at the time of enrollment, which are defined as pre-existing conditions. Pre -existing conditions will not be included in the AE  
dataset. However, a worsening of a pre-existing condition during the study does 
constitute an AE . 
NOTE 5 : This definition excludes otherwise uncomplicated recurrent AF . 
 
 
 8.4 Serious Adverse Event s 
An SAE includes any of the following types AE s whether or not related to the 
investigational device or procedures:  
• Any AE  resulting in death  
• Any AE  which is life -threatening  
• Any AE  resulting in hospitalization, or significant prolongation of an existing 
hospitalization  
• Any AE  resulting in a persistent, significant impairment  
• Any AE  requiring significant medical or surgical intervention to prevent a 
significant impairment  
• Any AE  resulting in a congenital anomaly or birth defect  
NOTE 1:  “Life -threatening” means that the study subject was at a substantial and immediate 
risk of dying due to that AE  as it occurred . “Life threatening” AE s do not include 
an AE  that – had it occurred in a more severe form – might have caused death.  
NOTE 2:  “Hospitalization” is a physician -ordered inpatient hospital stay from one calendar 
day to the next or longer. Hospitalization does not include an outpatient facility 
visit or ER visit. 
NOTE 3:  A “significant” prolongation is related to the AE , excludes delays waiting for 
diagnostic results, is medically necessary and extends the hospital stay by at least one calendar day . 
NOTE 4:  “Persistent” is defined as not resolving by the end of study follow -up. 
NOTE 5:  “Significant impairment” is defined as a substantial disruption of a person’s ability to conduct normal life functions.  
NOTE 6:  A “significant medical or surgical intervention” indicates a procedure or therapy 
with significant novel risk or subject discomfort, that results from the AE . 
A “significant medical or surgical intervention” does not include oral medication, 
noninvasive diagnostic testing or blood testing, routine intravenous fluids, the 
administration of antibiotics, or a pharmacologic or electric cardioversion for AF, 
AFL  or AT.  
 
8.5 Procedure, Device and COVID-19 Relatedness  
The causality of all AE s in relation to 3 types of potential causes – the investigational 
devices , a protocol- stipulated procedure or a confirmed COVID-19 infection – will be 
determined according to four different levels of causality:  
1. Definitely Not Related: An AE  for which sufficient information exists to 
determine that it is unrelated to the potential cause. 
2. Unlikely Related: An AE  that occurs during or after device use , study procedure 
or COVID-19 infection that could also have been produced by other disease state s 
or therapies . The Investigator determines after review of available clinical data 
that the AE is unlikely to have been related to the potential cause. 
3. L ikely Related : An AE  that occurs during or after device use, study procedure or 
COVID-19 infection that could also have been produced by other disease state s or 
therapies.  The Investigator  determines after review of the clinical data that the 
AE is likely to have been related to the potential cause . 
 
 4. Definitely Related: An AE  that occurs during or after device use, study 
procedure or COVID-19 infection , is known to be a complication of device use, 
study procedure or COVID-19 infection  and for which no other reasonable 
explanation can be determined. 
For the determination of device, procedure and COVID-19 relatedness for this study’s 
outcome measures, “Likely related” and “Definitely related” AEs will be deemed 
“related” and “Definitely not related” and “Unlikely related” AEs will be deemed 
“unrelated.” A listing of all AEs including their relatedness and seriousness will be 
included in the final Clinical S tudy Report. 
8.6 Device Effects  
8.6.1 Adverse Device Effect s 
An Adverse Device Effect  (ADE) is an AE related to the use of an investigational 
medical device. 
NOTE 1:  This definition includes AE s resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device. 
NOTE 2:  This definition includes any event resulting from use error or from intentional 
misuse of the investigational medical device. 
NOTE 3:  “Related to the uses of an investigational medical device” shall be defined for 
this protocol as a determination that the effects were likely or definitely related to 
an investigational device. 
8.6.2 Serious Adverse Device Effect s 
A Serious Adverse Device Effect  (SADE) is an ADE that  has resulted in any of the 
consequences characteristic of an SAE.  
8.6.3 U nanticipated Adverse Device Effect s 
An Unanticipated Adverse Device Effect (UADE) is an SADE  which by its nature, 
incidence, severity or outcome has not been identified in the current version of the 
risk analysis report as embodied in Section  8.1. 
NOTE  1: An anticipate d ADE  / SADE is an effect which by its nature, incidence, severity 
or outcome has been identified in the risk analysis report  or included in Section 
8.1. 
NOTE 2:  If an SAE is determined to be likely  or definitely related to the device and has not 
been previously anticipated, the clinical finding would be classified as an 
unanticipated adverse device effect (UADE). 
8.7 Device Deficiencies  
A Device Deficiency is an inadequacy of an investigational medical device related to 
its identity, quality, durability, reliability, safety or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. 
8.8 Use Errors 
A “Use Error ” is an act or omission of an act that results in a different medical device 
response than intended by the manufacturer or expected by the user. 
 
 NOTE 1:  Use error includes slips, lapses and  mistakes.  
NOTE 2:  An unexpected physiological response of the subject does not in itself constitute a 
use error.  
8.9 Malfunction s 
A Malfunction is a f ailure of an investigational medical device to perform in 
accordance with its design specifications and intended purpose when used in 
accordance with the instructions for use or this protocol. 
8.10 Event Management and Reporting  
8.10.1  Adverse Events  
All AEs, including all SAEs, will be monitored from the time of the Index Procedure 
through study exit.  
All AEs and SAEs must be documented in the subject  chart  and recorded in the 
appropriate CRF . A description of the event, including the start date, resolution date, 
action taken, and the outcome shall be provided along with the Investigator’s 
assessment of the seriousness of the event and the relationship between the AE and the 
study devices and/or procedures. 
All AEs should be followed until the event is resolved , judged to be chronically stable 
or 12- month  study follow-up has been completed, whichever occurs first. The 
investigational site will provide relevant follow -up information to the Sponsor or 
designee upon request. Any SAE will be reported to CRO within 24 hours of the site becoming aware of the 
event. 
8.10.2  Adverse Device Effects  
The Investigator shall record an ADE or SADE on the appropriate CRF as an aspect of 
reporting the associated AE . 
An ADE will be reported promptly to the CRO. 
A UADE will be reported to the CRO within 24 hours of the site becoming aware of 
the event.  
8.10.3  Device Deficiency and Malfunction s 
The Investigator shall record a Device Deficiency  / Malfunction on the appropriate 
CRF . 
A Device Deficiency or Malfunction that was associated with an SAE, or that could have contributed to an SAE, will be reported to the CRO within 24 hours of the site becoming aware of the event.  
A Device Deficiency or Malfunction that d id not contribute and would not likely 
contribute to a n SAE , will be reported to the CRO within 7 days of the site becoming 
aware of the event.  
 
 8.10.4  Other Assessment and Reporting Requirements  
The Sponsor’s Quality Assurance function shall ensure an assessment is completed for 
each reported Device Deficiency  / Malfunction. Such information shall be summarized  
in the final Clinical Study Report. Depending on the local requirements or following agreement between both parties, the Sponsor, its designated representative (CRO) or the Principal Investigator will be responsible for performing safety reporting to the IRB according to the relevant local r egulatory requirements. The Sponsor or designated 
representative (CRO) will be responsible for reporting to the FDA according to the 
relevant reporting guidelines.  
8.10.5  Reporting AEs, ADEs  and Device Deficiencies  
The following Table summarizes the various reporting requirements for events defined in this section.  
Table 6 Reporting AEs, ADEs  and Device Deficiencies  
Type of Event  Process  
Unanticipated adverse device 
effect (UADE)  
Submit within 24 hours  after study site personnel 
first learn of the event and to the IRB within the 
IRB required timeframe.  Serious adverse events , Serious 
Adverse Device Effects  
(SAE, SADE)  
Device deficiencies  / malfunctions 
that contributed to or could 
contribute to an SAE  
Device deficiencies  / malfunctions 
that did not contribute to or are 
unlikely to contribute to an SAE  Submit within 7 days  after study site personnel 
first learn of the event and to the IRB (if required) 
within the IRB required timeframe.  
Non-serious adverse device effect  
(ADE)  Submit to the CRO as soon as possible after 
Investigator has become aware of the event  and to 
the IRB (if required) within the IRB required 
timeframe.  
 
Documents should be sent electronically to :  
CRO:   Medpace  
   Email: Medpace -safetynotification@medpace.com   
 Return of Subject Device:  
The device involved in the AE, SAE, Device Deficiency and/or Malfunction as 
described above is to be returned to the Sponsor or Sponsor’s designee for analysis  and 
investigation, as appropriate. The Study Coordinator shall  contact the Sponsor for 
instructions on returning the device. 
 
 9. Statistical Procedures  and Reporting  
A separate Statistical Analysis Plan (SAP) governs the analysis and reporting of the 
data from this investigation. This section summarizes the essential elements of that plan.  
9.1 General Statistical Considerations  
This study is designed using Bayesian statistical methods, with non- informative prior 
distributions for all parameters . The appropriate sample size is determined adaptively 
via a Goldilocks design
36, in which the adequacy of the sample size is assessed at 
several pre -specified enrollment milestones.  All primary and secondary objectives will 
be analyzed using Bayesian methods, though frequentist methods may be used for selected analyses such as baseline comparisons, poolability and sensitivity analyses and a subset of the pre- specified Additional Analyses.  
When descriptive statistics are used, continuous variables will be summarized using standard quantitative statistics: number of available observations, mean, standard deviation, median, quartiles and range (minimum and maximum observed values). The number of missing observations will also be reported. C ategorical variables will be 
summarized using classical frequency statistics: number of available observations and percentages by categories. Percentages will be calculated on the number of available observations. The number of missing observations will also be specified.  
A full data listing will be prepared. Data will be pooled from all study sites.  All related and resulting reports, documents and data will be produced and maintained 
in such a way as to ensure their control and the protection of subject privacy. Data files and analytic reports will be archived according to requisite regulatory standards.  
Data gathered regarding COVID-19 impacts – including missed, late or alternative 
assessments, COVID-19- related complications , subject withdrawals or Severe COVID-
19 status – will be used as required to address potential biases or to perform sensitivity 
analyses related to the impact of COVID-19 on the study integrity or outcomes. A 
tabulation and listing of all subjects impacted by COVID-19 will be included, with a 
description of how that subject’s participation and/or outcome may have been altered. COVID-19-related deviations to the sche dule, type of assessment and assessment 
windows will be aggregated and reported. 
9.2 Randomization 
Subjects meeting all pre -randomization inclusion and exclusion criteria who sign an 
ICF will be randomized. The study staff will confirm documented inclusion  / exclusion 
success prior to requesting randomization.  Randomization will be achieved by an interactive web -based or phone-based system. 
Randomization will be stratified by site  and use a permuted block design with 
randomly varying block sizes.  Subjects who meet the inclusion and exclusion criteria will be randomized using a 1:1 
allocation ratio . 
 
 Each site will utilize only one control modality – either RFA or CBA – and will use 
that modality for all subjects randomized to the Thermal Group. Site activation and 
enrollment will be monitored and when necessary controlled to maintain a minimum 40% proportion of Thermal Subjects in either the RFA or CBA modality. 
9.3 Subject Disposition  
The disposition of all subjects enrolled in the study will be described in tables and diagrams, including numbers screened, randomized, excluded, treated and assessed at each scheduled follow -up interval. Roll -In Subjects will be assessed separately. Severe 
COVID-19 Subjects will be noted and the potential impacts on the study results assessed in sensitivity analyses. Subjects who do not complete the study will be enumerated and the reason(s) for their discontinuation will be described. 
9.4 Populations for Analysis 
Study populations , including those for statistical analysis,  are defined in Section 3.4. 
9.5 Assessment of the Primary Safety Endpoint  
The primary safety endpoint for this study is the CSE defined in Protocol Section 7.1.  
The principal analysis population for the safety endpoints is the Safety Population. Analysis in the PP Population will also be conducted as a sensitivity analysis.  
The analysis of the primary safety endpoint is a test of non- inferiority of the event rate 
at 12 months using a non- inferiority margin of 8%. The null and alternative hypotheses 
are presented below for primary safety : 
 H
0: Q T ≥ Q C + 0.08 versus H A: Q T < Q C + 0.08 
where Q T is the CSE proportion in the Pulsed Field ( Treatment) Group  and QC is the 
CSE proportion in the Thermal (Control) Group. The differences in the proportion of subjects with 1 or more CSE events between the Pulsed Field Group and the Thermal Group will be tested with a Bayesian statistical method  and the prior distributions for 
Q
T and Q C in these calculations are Beta (0.5, 0.5), which is the Jeffreys non-
informative prior. Q T will be deemed  to be non- inferior to Q C if it can be established 
that the posterior probability Pr(H A | data) > Ψ saf, where Ψ saf is a pre- specified threshold 
value that controls the one -sided type I error rate (under simulation) at level 0.05 . In the 
absence of missing data, the posterior distributions for Q T and Q C would be conjugate 
Beta distributions . However, some missing data are expected . Therefore, Bayesian 
multiple imputation of 12 -month outcomes will be employed in the principal analysis. 
The imputation model accounts for primary outcome information up through the time of censoring. D etails on the modeling for this imputation are given in the SAP. 
9.6 Assessment of the Primary Effectiveness Endpoint  
The primary effectiveness endpoint for this study is Treatment Success defined at Section 7.4.  
The principal analysis population for the primary effectiveness endpoint is the MITT 
Population. Analysis in the PP Population will also be conducted as a sensitivity analysis.  
 
 The primary effectiveness endpoint for this study is Treatment Success, which will be 
analyzed as a test of non- inferiority of the event rate at 12 months using a non-
inferiority margin of 15%. The null and alternative hypotheses are: 
 H 0: PT ≤ P C – 0.15 versus H A: PT > P C – 0.15 
where P T is the Treatment Success rate at 12 months in the Pulsed Field Group and P C 
is the Treatment Success rate at 12 months in the Thermal ( Control) Group.  
This study is designed using Bayesian statistical techniques and the prior distributions 
for P T and P C in these calculations are Beta (0.5, 0.5), which is the Jeffreys non-
informative prior. P T will be deemed  to be non- inferior to P C if it can be established that 
the posterior probability Pr(H A | data) > Ψ eff, where Ψ eff is a pre- specified threshold 
value that controls the one -sided type I error rate (under simulation) at level 0.05 . In the 
absence of missing data, the posterior distributions for P T and P C would be conjugate 
Beta distributions . However, some missing data are expected . Therefore, Bayesian 
multiple imputation of 12 -month outcomes will be employed in the principal analysis . 
The imputation model accounts for primary outcome information up through the time 
of censoring. D etails on the modeling for this imputation are given in the SAP. 
9.7 Sample Size Considerations  
Please refer to the SAP for a full treatment of this topic.  
Parameter selection:  IDE pivotal studies for the treatment of drug -resistant 
symptomatic PAF are highly standardized and utilize nearly identical definitions of primary effectiveness and similar definitions of primary safety. Published IDE studies  
with available information comparing new devices with approved control devices have all used non- inferiority designs with one -sided alpha of 0.05 and 15% effectiveness 
margins and either 8% or 9% safety margins.  
Peer-reviewed  studies do not undergo the same scrutiny or utilize the rigor of 
FDA- supervised  studies and  therefore their estimates of effectiveness and safety are 
not entirely comparable to IDE  studies. The consensus regarding high quality 
randomized comparisons between currently approved technologies is that none are superior to another. Perhaps the largest  non- IDE study comparing RFA and CBA 
technologies (Fire and Ice
37) found no difference between the two and also reported 
very similar primary outcomes to IDE  studies. 
Sample Size Requirements for Safety:  
Although the pre- specified statistical analysis methods are Bayesian, standard 
frequentist considerations are used to guide sample size selection . The sample size for 
primary safety computed for a Farrington -Manning test with PASS 13 indicates that, 
for 1:1 randomization, 90% power, alpha=0.05 (one- sided), CSE rate in both Groups of 
0.08 and non- inferiority margin of 0.08, the study requires a completed sample size of 
214 subjects in each Group , for a total of 428. Assuming a 5% rate of loss -to-follow-up 
(LTFU), 450 subjects are needed. 
There is uncertainty in the CSE rate, and this can have dramatic impact on sample size requirements.  If the CSE rate is 0.07 in the Pulsed Field group but 0.08 in the Thermal 
 
 group, 326 subjects are required to achieve 90% power (344 after compensating for 5% 
LTFU).  If the CSE rate is 0.10 in the Pulsed Field group but 0.08 in the Thermal group, 690 subjects are required to achieve 85% power (727 after compensating for 5% LTFU ). 
This uncertainty in the CSE rate motivates the use of a design wherein the sample size is adaptively determined, with possible sample sizes ranging from 350 to 750. 
Sample Size Requirements for Effectiveness:  
Although the pre- specified statistical methods are Bayesian, standard frequentist 
considerations are used to guide sample size selection . The sample size required for the 
primary effectiveness endpoint obtained by PASS 13 for 1:1 randomization, 90% 
power, alpha=0.05 (one-sided), success rates in each group of 0.65 and non- inferiority 
margin δ=0.15 is 172 subjects in each arm , for a total of 344 subjects.  Similar to the 
safety objective, there is uncertainty in the success rates, especially in the Pulsed Fi eld 
group.  If the success rate in the Pulsed Field group is 0.625 but 0.65 in the Thermal 
group, 502 subjects are required to achieve 90% power (558 after compensating for up to 10% missing data).  If the success rate in the Pulsed Field group is 0.70 but 0.65 in the Thermal group, only 186 subjects are required to achieve 90% power (207 after compensating for missing data).   
This uncertainty in the Treatment Success rate motivates the use of a design wherein the sample size is adaptively determined, with possible sample sizes ranging from 200 to 550.   
Number of Enrolled Subjects : 
The primary population for the analysis of effectiveness is the MITT Population. The 
Safety Population should be similar but will not be smaller. Considering the joint 
sample size needs of the primary safety and effectiveness objectives, the primary analysis population may range from a minimum of 350 to a maximum of 750. 
To achieve a sample size of 750 MITT  Subjects , up to 900 subjects may  be enrolled 
consisting of 750 MITT and up to 105 Roll -In Subjects and up to 45 ITT Subjects (6%) 
who do not meet the criteria for the MITT Population . 
9.8 Analysis Plan 
This trial is designed using Bayesian statistical techniques.  The appropriate sample 
size is determined adaptively via a Goldilocks design
38, with possible sample sizes of 
N=350, 450, 550, 650, and 750.   
The sample size determination algorithm is as follows.  At a pre-defined interim 
analysis point (e .g., when N=N i subjects have been accrued  into the MITT population; 
Ni = 350, 450, 550 and 650), four predictive probabilities are calculated:  
PPint,saf   =  Predictive probability that the trial will establish non -inferiority for safety,  
once the current sample (N i) is followed to 12 months. 
PPmax,saf   = Predictive probability that the trial will establish non -inferiority for safety,  
assuming the maximum sample size (750) is attained and followed to 12 
months.   
 
 PPint,eff    = Predictive probability that the trial will establish non -inferiority for 
effectiveness,  once the current sample (N i) is followed to 12 months. 
PPmax,eff   = Predictive probability that the trial will establish non -inferiority for 
effectiveness,  assuming the maximum sample size (750) is attained and 
followed to 12 months.   
If PP int,saf exceeds a suitably high threshold W saf,i, and if PP int,eff exceeds a suitably high 
threshold W eff,i, subject accrual will stop because final success looks probable with the 
current sample .  On the other hand, if PP max,saf  is less than a suitably low threshold F saf,i, 
or if PP max,eff  is less than a suitably low threshold F eff,i, subject accrual will stop 
because final success is unlikely.  In either case, follow -up continues to 12 months for 
all subjects, at which time the final analysis will oc cur. If neither of these conditions 
obtains, enrollment will continue to the next larger sample size (subject to the 
maximum of 750) .  These analyses are termed " Interim Sample Size Looks."  Further 
detail s on the calculation of these predictive probabilities and specification of the 
thresholds {W eff,i, Feff,i, W saf,i, Fsaf,i}are provided in the SAP. 
Once subject accrual has stopped, all accrued subjects will be followed to 12 months, 
and then the inferential tests of non- inferiority will occur as described in Sections 9.5  
and 9.6. This is the only time that non -inferiority is tested.  
9.9 Assessment of the Secondary Safety Endpoint  
One endpoint – Aggregate PV Cross- Sectional Area (Section 7.2) – will be formally 
tested as a secondary safety endpoint.   
The paired comparison of change in the Aggregate PV Cross- Sectional Area between 
baseline and 3 months will be compared between Pulsed Field Subjects and Thermal 
Subjects, testing whether the reduction in Aggregate PV Cross- Sectional Area is 
significantly less in the Pulsed Field Subjects . Within -subject changes in Aggregate PV 
Cross -sectional Area (3 -month minus baseline) will be compared between Pulsed Field 
and Thermal groups via a Bayesian version of a t- test. The null and alternative 
hypotheses are:  
H0: μT – μ C = 0  versus H A: μT – μ C > 0,  
where μ T represents the change (3 months minus baseline) in area in the treatment 
(Pulsed Field) group, and μ C represents the corresponding change in area in the control 
(Thermal) group. The null hypothesis will be rejected if the posterior probability P(H A | 
data) exceeds a threshold value Ψ PV = 0.975, corresponding to a one- sided significance 
level of 0.025.   
The population for analysis will be M ITT Subjects with pre - and post-procedure PV 
dimensional data related to one or more protocol-specified ablation lesions. 
Supplemental analyses will be performed using MITT single procedure subjects and the PP population. 
 
 9.10 Assessment of the Secondary Effectiveness Endpoint  
The secondary effectiveness endpoint is Treatment Superiority, which  is Treatment 
Success ( Section 7.4) tested for s uperiority  between  the Pulsed Field and Thermal 
Groups.  
The principal analysis population for the secondary effectiveness endpoint is the MITT 
P
opulation. Analysis in the PP population will also be conducted as a sensitivity 
analysis.  
The null and alternative hypotheses are provided below. 
H0: PT ≤ P C versus H A: PT > P C 
where P T is the Treatment Success rate at 12 months in the Pulsed Field Group, and P C 
is the Treatment Success rate at 12 months in the Thermal Group . Modeling will be 
identical to the test of non -inferiority, and superiority will be concluded if the posterior 
probability Pr(H A | data) > Ψ eff,sup, where the threshold Ψ eff,sup is a pre -specified 
threshold value that controls the one- sided type I error rate (under simulation) at level 
0.025. In the absence of missing data, the posterior distributions for P T and P C would be 
conjugate Beta distributions. However, some missing data are expected, and especially so at the interim analysis . Therefore, Bayesian multiple imputation of 12 -month 
outcomes will be employed in the principal analysis . The imputation model accounts 
for primary outcome information up through the time of censoring. More detail on this imputation is given in the Statistical Analysis Plan.  
9.11 Assessment of Subject Blinding  
Subjects will complete a survey regarding their opinion as to which study group they were assigned to at the time of Index Procedure / Rescheduled Index Procedure discharge and at the 12 -month follow -up visit. Self- assessment of treatment status will 
be formally assessed according to the procedures defined by Bang 2004
39 and 
James 1996.40 
 
  
 
 
 10. Core Laboratories 
10.1 Arrhythmia Core Laboratory 
A qualified ACL will be established to receive, review and assess all protocol-
stipulated  ECGs, EMs and Holter monitors.  
10.1.1 Procedures  
Documented procedures will be established for the provision of equipment, the 
training of study subjects, the receipt of outputs, the assessment of arrhythmia and the transmission of results for inclusion in the study dataset.  
10.1.2  Event Monitors 
Each subject: 
• Will be  introduced to the use and importance of EMs at the Baseline visit  
• Will be f ully instructed on the use of an  EM at the Day 60 EM  training.  
Either the ACL or the site will provide the subject with an EM not later than the 
Day 60 EM  training to be used beginning at the time of the Day 90 Assessment and 
weekly thereafter  and also for any symptomatic episodes throughout the remainder of 
the 12-month study follow-up. 
Careful monitoring and subject follow -up will be implemented to ensure compliance 
with the required weekly scheduled and ad hoc symptomatic utilization and 
transmission of the EMs . Individual missed weekly transmissions will not be counted 
as protocol deviations, but a subject with less than 80% of weeks covered by at least one transmission at the end of follow-up will be considered a protocol deviation. 
The EM will be returned to the ACL or the site at the time of the subject’s exit from the study. ECG data from the EM will be analyzed by the ACL. 
10.1.3  Holter Monitors  
Each  subject: 
• Will be introduced to the use and importance of the Holter monitoring at the 
Baseline visit and the use of the EM hardware for this purpose. 
• Will be fully instructed on the use of a 72-hour continuous ECG (Holter) 
monitor prior to the 6 -Month and 12-Month Holter monitoring.  
Careful monitoring and subject follow -up will be implemented to ensure that the 
device will be utilized by the subject for the nominal 72-hour period for both the 
Month 6 and Month 12 Assessments .  
The 12- M
onth Holter monitor should be performed prior to the completion of the 
Month 12 Assessment.  
ECG data from the Holter  monitor will be analyzed by the ACL.  
 
 10.1.4  Arrhythmia Data Review and Transmission 
The ACL will analyze all protocol- stipulated  ECG,  EM and Holter data and will 
make available the primary data for review and transmit the rhythm analyses of each 
monitoring study to the CRO for inclusion in the study dataset. 
10.1.5  CEC Over -Reads of Potential Endpoints  
Any ECG,  EM or Holter result that is reported by the ACL to contain a first 
post-Blanking Period occurrence of AF, AFL or AT will be reviewed by the CEC to establish the presence or absence of a primary effectiveness endpoint event. Such adjudications will be repeated to the extent necessary to confirm the date, duration and rhythm of any potential Detectable AF, AFL or AT that will determine a post-Blanking Period Treatment Failure.   
The CEC’s determination regarding Detectable AF, AFL or AT is final.  
10.2 Cardiac Imaging Core Laboratory 
A qualified CICL will be established to receive, review and assess all protocol-
stipulated  cardiac MRIs and CTs.  
10.2.1  Procedures  
Documented procedures will be established for the performance of cardiac imaging, the receipt of outputs, the assessment of images – most importantly changes in PV 
dimensions – and the transmission of results for inclusion in the study dataset. 
10.2.2  Pulmonary Vein Dimensions  
Each treated vein will have pre -ablation and 3-month post-ablation assessments of 
standardized diameters ( Section  6.3.14) . Subjects with documented 3-month PVS 
will have a protocol-mandated 12-month post- ablation  assessment.  
10.2.3  Cardiac Imaging Data Review and Transmission 
The CICL will analyze all PV dimensions, calculate changes in dimensions, make 
available the primary data for review and transmit the PV dimensional analyses of 
each imaging study to the CRO for inclusion in the study dataset. 
10.2.4  CEC Review of Pulmonary Vein Stenosis Results  
Any cardiac imaging report that is determined by the CICL to contain a PV S will be 
reviewed by the CEC to confirm the finding of a primary effectiveness endpoint 
event. The  CEC may request a review of the finding but will not review the images. A 
proposed change in the CICL finding will require consent from the CICL. 
10.3 Brain Imaging Core Laboratory 
A qualified BICL will be established to receive, review and assess all protocol-stipulated  brain MRIs for NAS Subjects . 
  
 
 10.3.1  Procedures  
Documented procedures will be established for the performance of brain imaging in 
NAS Subjects to allow assessment of SCEs and SCLs, the receipt of outputs, the 
assessment of images – most importantly SCEs and SCLs – and the transmission of results for inclusion in the study dataset.  
10.3.2  SCE and SCL Assessment  
Each post-procedural brain MRI in NAS Subjects will be assessed according to standardized parameters for SCE and SCL findings.  
10.3.3  Brain Imaging Data Review and Transmission 
The BICL will analyze all diffusion weighted and FLAIR findings in NAS Subjects, make available the primary data for review and transmit the brain lesion analyses of each imaging study to the CRO for inclusion in the study dataset. 
The CEC will not review brain imaging findings for determination of SCE and SCL 
findings in NAS Subjects . 
 
 
 11. Monitoring  
11.1 Monitors 
Clinical and medical monitors, qualified by training and experience, will be responsible 
for monitoring and overseeing the conduct of the study in accordance with a study 
monitoring plan .  
11.2 Clinical Monitoring Activities  
The monitors will evaluate compliance with the protocol, any specific recommendations made by the site’s IRB and the signed Investigator Agreement. 
Phone contacts and site visits will be conducted to ensure that the protocol is being followed and that any protocol deviations are properly documented. Clinical monitoring will include a verification that the ICF  was properly obtained for all 
enrolled study  participants, a review of clinical records for accuracy and completeness, 
resolution of missing or inconsistent results and a review of source documents. The clinical monitor will verify that the CRFs agree with the source documentation and other records. The I nvestigator will make available  to the monitor for review as 
requested ICFs , completed CRFs, source documentation and other relevant records for 
enrolled study subjects.  
If a deficiency is noted during an on- site monitoring visit or at any other time during 
the study, the monitor is required to discuss the situation with the I nvestigator and the 
Sponsor to ensure compliance. 
11.3 Monitoring Responsibility and Data Verification 
The Sponsor or its designated representative, qualified by training and experience, will 
be responsible for monitoring and overseeing the conduct of the study. The accuracy of all (100%) collected data will be verified for:  
• Eligibility criteria  
• Baseline characteristics  
• Primary safety and effectiveness endpoints 
• Secondary endpoints 
• AEs (including SAEs) and Device Deficiencies / Malfunction Reporting  
Verification will utilize source documents including, but not limited to, medical 
records, office/ clinic notes, procedure reports, laboratory results, and physician and nursing progress notes. Verification and quality of data, monitoring of clinical study 
progress and Investigator compliance with the approved protocol will be conducted by the Sponsor or its designated representative. 
11.4 Site Visits  
The Sponsor or its designated representative must be allowed to visit the clinical site and have direct access to all study records throughout the duration of the study. Where this is not possible due to COVID- 19-related disruption, every effort will be made by 
Sponsor and site personnel to achieve monitoring goals remotely. Study procedures for remote monitoring will be consistent with FDA Guidance Documents.  
 
 Specific monitoring requirements are detailed in the study -specific Monitoring Plan 
maintained in the FARAPULSE and CRO clinical study project files. The Investigator 
and / or institution will provide direct access to source data  / documents for study-
related monitoring, audits  and regulatory review and inspection. 
It is important that the Investigator and other relevant site personnel, including the research study coordinator, are available for consultation with the monitors during the monitoring visits and that sufficient time is devoted at the site for the monitor ing 
process.  
Additionally, telephone, email contact, and onsite visits will be conducted on a regular 
basis with the Investigator and the site staff to ensure that the protocol is being followed and to address any issues that may occur during the study. 
If a deficiency is noted during the study , the monitor is required to discuss the situation 
with the site and the Sponsor (if required) to secure compliance . A Monitoring Site 
Visit Report will be issued to the Sponsor.  
 
 12. Study Management 
The Sponsor has overall responsibility for the conduct of the study according to Good 
Clinical Practice Guidelines (ICH E6 Consolidated Guidance to Good Clinical Practice) as well as any conditions imposed by local and national regulatory authorities. 
For th is investigation, the  Sponsor may have certain direct responsibilities and will 
otherwise delegate in writing responsibilities to appropriate and qualified consultants, 
contractors and / or CROs . Together, the Sponsor, consultants and CRO will ensure that 
the study is conducted according to the approved Clinical Investigation Plan (CIP ), 
IRB-approved ICF and all applicable governing regulations. All personnel participating  
in the conduct of this clinical study will be qualified by education and/or experience to 
perform their tasks.  
12.1 Ethical Considerations  
It is expected that all parties will share in the responsibility for ethical conduct in accordance with their respective roles in the investigation. The Sponsor and the Investigator shall avoid improper influence or inducement of the subject, monitor, other Investigator or other parties participating in or contributing to the clinical 
investigation. 
12.1.1 Study Conduct  
The study will be performed in accordance with the relevant parts of the Code of Federal Regulations, ICH Guidelines for Good Clinical Practices  and ethical 
principles consistent with the Declaration of Helsinki. The clinical investigation shall 
not begin until the required approval has been obtained from the FDA and the local IRB. Any additional requirements imposed by the regulatory authority or IRB shall 
be followed. These principles shall be understood, observed and applied at every step in this clinica l investigation.  
12.1.2 Ethics Review  
Before any subject can be enrolled in this study, the local , central  or national IRB and 
the FDA must review and approve the CIP and the ICF to be used. A subject cannot be asked to sign the ICF until the study has been fully approved by the institution’s IRB and by the FDA. The Sponsor or their designated CRO will require a copy of any IRB correspondence, as well as the final IRB approval letter and the final IRB-
approved ICF and approvals for the CIP and ICF revisions on amendments from the IRB. The Sponsor or their designated CRO will keep all the FDA correspondence as well as the FDA approval letter.  
12.1.3 Informed Consent  
Subjects will not sign the ICF until the study has been fully approved by the institution’s IRB and the Sponsor or their designated CRO has received and reviewed 
the specific IRB-approved ICF. When the Investigator has determined the eligibility 
of a specific subject to enter the study, the ICF must be completed. The ICF must be read and understood by the subject, the subject’s questions answered,  and the form 
 
 signed by the subject before any study- related procedures can be performed. All 
subjects are to receive copies of their signed ICF.  
12.1.4 Confidentiality  
Confidentiality of subjects will be maintained throughout the study. A unique 
identification code will be assigned to each subject participating in this study. Any data that may be published in abstracts, scientific journals or presented at medical meetings will reference a unique subject code and will not reveal the subject’s identity. The Sponsor, CRO, Investigators and site personnel will make every 
reasonable effort to protect the confidentiality of all subjects participating in the 
study. 
12.2 Key Contributors  
12.2.1  Sponsor  
Clinical Affairs, Regulatory Affairs and Quality Assurance  
FARAPULSE, Inc.  
3715 Haven Ave. Suite 110 Menlo Park, CA 94025 USA  
John Allison, Vice President Tel: +1 .650.422.3633 
Email: jallison@farapulse.com  
12.2.2 Contract Research Organization  
Medpace Medical Device 3787 95th Ave NE Suite 100 Blaine, MN 55014 USA  
Patricia Bobzin, Director, Medical Devices  
Tel: +1.612.234.8500 Fax: +1.513.527.0368 Email: p.bobzin@medpace.com   
12.2.3 Arrhythmia Core Laboratory 
HeartcoR Solutions LLC 
2403 Harnish Drive, Suite 201 Algonquin, IL 60102 USA  
12.2.4 Clinical Events Committee  
The Sponsor or CRO will establish an external group of expert physicians to serve as the CEC. This group will consist of a panel of 3 experienced, independent physicians 
 
 who are not Investigators and will be supported by one or more Medical Monitor s and 
staff as required . The CEC will develop a Charter, which will establish committee 
procedures. 
The CEC will convene regularly during the study to review, classify and /or adjudicate 
AEs reported in this investigation as well as primary and secondary study outcomes. 
The CEC will be provided with case summaries, relevant source documents and any other information required to evaluate and adjudicate the AE s and study outcomes.  
12.2.5 Data and Safety Monitoring Board 
The Sponsor will establish an external group of physicians and an independent 
statistician to serve as the DSMB. This group will include at least 2 experienced, independent physicians who are not Investigators and an independent statistician not involved in the routine operation of the study. The DSMB will  develop a Charter, 
which will establish committee procedures.  
The DSMB will convene regularly during the study to assess overall event rates to ensure the integrity of the clinical study and the rights, safety and welfare of study subjects. The DSMB will also review the results of the interim analys es. 
Should any protocol changes be necessitated by the findings of the DSMB during its deliberations, or by the impact of externalities such as the COVID-19 pandemic, the DSMB may propose such changes to the Sponsor. The Sponsor will review these changes with the DSMB and upon consensus submit such changes to the FDA.  
12.3 Sponsor Responsibilities  
Sponsor has the overall responsibility for the  study and will perform the following, 
either directly or by documented delegation to qualified contractors: 
• Select qualified Investigators and study site s. 
• Select qualified monitors . 
• Provide the CIP and any subsequent amendments. 
• Provide appropriate information and inves tigational s ystem training to the 
Investigator and study site staff . 
• Ensure that all deviations from the CIP are reviewed with the appropriate Investigator(s) and reported on the CRF s and the final clinical report and that any 
necessary preventative or corrective action is taken . 
• Ensure that all AEs and all ADEs are reported and reviewed with the 
Investigator(s)  and where appropriate, that all SAEs and all SADEs are 
appropriately reported. 
• Ensure that all Device Deficiencies / Malfunctions are reviewed by the Sponsor, and properly assessed and investigated, as appropriate.  
• Promptly inform the Investigator and where applicable, any regulatory authorities, 
if the study is prematurely terminated or suspended and the reason for the 
termination or suspension. 
• Ensure proper device usage, uniform data collection and protocol compliance. 
• Provide comprehensive initial and remedial training throughout the study, including site initiation training regarding the FARAPULSE Pulsed Field 
 
 Ablation System, the  IFU, the CIP, CRF instructions , CRFs , AE/SAE/Device 
Deficiency reporting and requirements for obtaining informed consent. 
• Provide the FARAPULSE Pulsed Field Ablation System to the participating study 
site, in quantities adequate to support study activities. 
• Coordinate ongoing communication with CROs, consultants and study site to 
resolve any problems concerning the protocol or data collection.  
• Ensure compliance with the protocol. Where repeated efforts have failed to 
correct serious compliance issues, the Sponsor may pause or terminate a site’s further enrollment in the study; s ee Section  12.12 . 
• Retain ownership of all clinical data generated in this study and control the use of the data for purposes of regulatory submissions. 
• Protect subject confidentiality.  
12.4 Monitor Responsibilities  
Clinical monitors, qualified by training and experience, supervised and coordinated by 
qualified managers , and supplied with appropriate data and instructions, will be 
responsible for monitoring and overseeing the conduct of the study. 
Site Initiation Visit: Sponsor personnel and / or c linical monitors will conduct site 
initiation visits at the investigational site  – or if required via effective remote 
communication –  to ensure that the I nvestigator and other investigational site 
personnel involved in the conduct of this investigation have received and understood 
the requirements and contents of this CIP, the Investigator’s Brochure, the subject ICF , 
the CRFs, CRF Instructions, AE/SAE/Device Deficiency reporting  requirements  and 
the IFU  and the Institution and / or I nvestigator A greement.  
Site Monitoring: The clinical monitors will conduct routine on -site monitoring visits  
in-person or when this cannot be achieved by effective remote communications in 
accordance with a study monitoring plan to evaluate compliance with the CIP , any 
specific recommendations made by the site’s IRB and the signed Institution and/or Investigator Agreement and to ensure that the CIP is being followed and that any 
protocol deviations are properly documented on the respective CRF . Clinical 
monitoring will include a verification that informed consent was properly obtained and 
documented for all enrolled study participants, a review of clinical records and CRFs 
for accuracy and completeness, resolution of missing or inconsistent results and a review of source documents.  
Clinical monitoring will include a review of all AEs, SAEs  and D evice 
Deficiencies  / Malfunctions to ensure that all information has been reported to the 
Sponsor, IRB and regulatory authorities as required by the Clinical Investigational P lan 
and applicable standards and laws.  
The clinical monitor will verify that the CRFs are complete and in agreement with the source documentation and other records. The clinical monitor will ensure that all CRFs have been signed and dated by the I nvestigator.  
The I nvestigator will make available to the clinical monitor for review upon request 
ICFs, CRFs, source documentation and other relevant records for Enrolled S ubjects at 
the site. It is important that the Investigator and other relevant site personnel are 
 
 available for consultation with the clinical monitors during the monitoring visits and 
that sufficient time is devoted at the site for the monitoring process.  
If a deficiency is noted during an on- site visit or at any other time during the course of 
the study, the clinical monitor is required to discuss the situation with the Investigator and the Sponsor and to subsequently monitor the implementation of corrective actions that are required to address the situation.  
All monitoring activities will be documented by the clinical monitor in a monitoring report and will include, at a minimum, the date, investigational site visited, names of all 
personnel involved in the visit and a summary of all findings, facts, deviations , 
conclusions and recommended actions to be taken. Key findings will be reviewed with the Investigator.  
Upon completion of the study, a study closeout visit will be conducted to ensure that all 
data collection and study requirements are complete.  
Medical monitors qualified by training and experience will support clinical monitors and other study personnel by providing study-related medical judgment regarding such subjects as interpretation of eligibility criteria, reviewing  and assessment of AEs and 
the review of monitoring and study reports. 
12.5 Investigator Responsibilities  
At a minimum, the following documents will be provided by the investigational site to the Sponsor prior to study start (consent of the first subject): 
• Signed Clinical Trial Agreements  
• Signed Financial Disclosure Form 
• Signed CIP s ignature page  
• Investigator and Sub-Investigator’s current curriculum vitae  
• Investigator and site personnel protocol and device training records 
• Any other additional documents as required by the Sponsor 
The Investigator is responsible for ensuring that the investigation is conducted according to all signed agreements, the CIP , governing regulations, data protection 
regulations, medical device laws, the Declaration of Helsinki and any other conditions imposed by the relevant regulatory authorities. The Investigator is responsible for maintaining medical and study records for every subject participating in the clinical study (including information maintained electronically such as digital imaging). The 
Inves tigator will also maintain original source documents from which study -related 
data are derived.  
The Investigator(s) shall be responsible for the day -to-day conduct of the investigation 
as well as for the safety and well -being of the human subjects involved in the clinical 
investigation. 
The Investigator(s) shall:  
• Have the qualified and trained resources to conduct the investigation properly. 
• Obtain from the Sponsor the information that  the Investigator(s) judges essential 
about the device and be familiar with this information . 
 
 • Be well acquainted with the CIP before signing the signature page. 
• Support the monitor  and auditor, if applicable, in their activities to verify 
compliance with the CIP, to perform source data verification and to correct the 
CRF where inconsistencies or missing values are identified . 
• Discuss with the Sponsor management any question of modification of the CIP. 
• Make sure that the CIP is followed by all responsible for the conduct of the study at his/ her institution . Any deviation shall be documented and reported to the 
study Sponsor and CRO.  
• Make the necessary arrangements to ensure the proper conduct and completion of 
the investigation . 
• Make the necessary arrangements for emergency treatment, as needed, to protect 
the health and welfare of the subject . 
• Ensure that appropriate  IRB and FDA approvals are obtained prior to the start of 
the investigation . 
• Inform Sponsor about AE s and D evice D eficiencies  / Malfunctions in a timely 
manner; document on applicable CRFs. 
• Endeavor to ensure an adequate recruitment of subjects. 
• Ensure that the subject has adequate information and time to provide informed 
consent. 
• Ensure that informed consent is obtained and documented on the  IRB-approved 
ICF. 
• Ensure that clinical records are clearly marked to indicate that the subject is enrolled in this study. 
• Provide subjects with well-defined procedures for any emergency situation and safeguard the subject’s interest . Under these circumstances, deviations from the 
CIP shall not require the prior approval of the Sponsor or the national and local regulatory authorities . Such deviations shall not be considered as a breach of 
agreement but shall be documented and reported to Sponsor. 
• Ensure that information which becomes available as a result of the clinical investigation which may be of importance to the health of a subject and the continuation of the investigation shall be made known to the Sponsor and, if pertinent to the safety or well-being of the subject and the private clinician . 
• Inform the subject and/ or the subject’s physician about any premature 
termination or suspension of the investigation with a rationale for study 
termination . 
• Have primary responsibility for the accuracy, legibility and security of all investigation data, documents and subject records both during and after the investigation. 
• Sign each subject’s CRF, as applicable. 
• Be responsible for the supervision and assignment of duties at his/ her clinical 
center.  The Investigator must maintain a Delegation of Authority Form of 
appropriately qualified persons to whom the Investigator has delegated significant 
study related duties.   
 
 • Ensure that all investigational devices are kept in a secure location and that all 
Systems are accounted for on the Device Accountability  Form (number of devices 
used, discarded and returned to Sponsor). 
12.6 Investigator and Site Staff Training  
The participating Investigator and the relevant staff members at each investigational 
site will be trained in the use of the FARAPULSE Pulsed Field Ablation System prior to participating in the study . Device training will be conducted by the Sponsor or its 
representatives. All device training will be documented in a training log that will be maintained in the Regulatory Site Binder. 
12.7 Confidentiality and Publication Policy  
This clinical study, its associated documentation and the study data are all confidential and should not be discussed or shared with persons outside of the study. Additionally, the information in this document and regarding this study contains trade secrets and commercially sensitive information that are  confidential and may not be disclosed 
unless such disclosure is required by law or regulations. Subject to the foregoing, this information may be disclosed only to those persons involved in the study who ha ve a 
need to know, but all such persons must be instructed not to further disseminate this information to others. These restrictions of disclosure will apply equally to all future information that is indicated as confidential.  
The data generated by this clinical study are the property of the Sponsor and may not be disclosed without the prior written permission of FARAPULSE, Inc. These data may be used by FARAPULSE, Inc. now and in the future for presentation or publication at FARAPULSE, Inc.’s discretion or for submission to governmental regulatory agencies. FARAPULSE, Inc. reserves the right of prior review of any publication or presentation of data from the subject investigation.  
A final comprehensive Clinical Study Report including these analyses will be prepared at the conclusion of the study or at such time as the study may be prematurely terminated , regardless of outcome. P ublication in the appropriate peer-reviewed 
medical literature of the pre-specified study results will be attempted, based on the 
Clinical Study Report. Copies of the final report will be provided to the Investigator and their IRB and to the FDA as applicable. Neither Investigators nor their staff will publicize any study results without written permission of the Sponsor. 
12.8 Data Management 
Data management procedures will be included in a data m anagement plan.  
eCRFs  will be made available to the participating site . Investigators are responsible for 
the accurate completion of subject e CRFs  during the study. The Investigator will ensure 
that complete, accurate and timely data in eCRFs are completed, that protocol requirements are followed  and that complications, AE s and ADEs are correctly 
reported and investigated, as appropriate. The Investigator is expected to maintain all source documents as required by the CIP, including laboratory results, supporting 
medical records  and sig ned ICF s. The source documents will be used during the regular 
monitoring visits to verify information against data contained in the completed e CRFs . 
 
 eCRF data will be reviewed to identify any inconsistent or missing data and any AE s. 
Any data issues are to be promptly addressed with the Investigator by the CRO. 
After e CRF monitoring has been complete and deficiencies / discrepancies resolved, 
study data in the central database will be updated to reflect any changes.  
12.9 Insurance 
The Sponsor will maintain the appropriate and necessary insurance coverage for the 
duration of the study. 
12.10 Audits and Inspections  
The Investigator will allow representatives of the governing IRB  and FDA , with 
appropriate notice, to inspect all study records, CRFs and corresponding portions of the subject’s office and  / or hospital medical records at intervals throughout the study. 
These inspections are for the purpose of verifying adherence to the CIP, completeness and exactness of the data being entered onto the CRFs and compliance with regulatory agency regulations. 
The Investigator will inform the Sponsor or the Sponsor’s designee immediately upon 
notice that they are to be audited or inspected by any regulatory agencies. The Sponsor or the Sponsor’s designee will also inform the site if they are made aware of a pending audit or inspection by a regulatory agency. 
12.11 Study Suspension or Early Termination 
The study can be discontinued at the discretion of the Sponsor for reasons including, but not limited to, the following: 
• Occurrence of AEs unexpected as to their nature, severity, or duration, or the 
unexpected incidence of known AEs 
• Obtaining new scientific knowledge that shows that the study is no longer valid or necessary  
• Data demonstrates a benefit to subjects who undergo percutaneous ablation with 
the FARAPULSE Pulsed Field Ablation System  making treatment without the 
FARAPULSE Pulsed Field Ablation System unethical 
• Insufficient recruitment of subjects  
• UADE s presenting an unreasonable risk to subjects (Sponsor may terminate the 
study immediately)  
If the study is discontinued or suspended prematurely, the Sponsor shall promptly 
inform the Investigators of the termination or suspension and the reason(s) for discontinuation / suspension . Regulatory authorities shall also be informed promptly 
and provided with the reason(s) for the termination or suspension by the Sponsor. Subject s enrolled up to the date of suspension / termination will continue to be followed 
for safety through the 12- month timepoint .  
12.12  Criteria for Suspending  or Terminating a Study Site  
Sponsor reserves the right to stop the screening of subjects at an individual study site at 
any time after the study initiation visit for reasons including the following: 
 
 • Absent or insufficient enrollment of study subjects  
• Persistent non -compliance with the CIP or regulatory requirements 
• Repeated failure to complete CRFs prior to scheduled monitoring visits  
• Failure to obtain written informed consent using the  IRB-approved ICF 
• Failure to report SAEs/ UADEs to Sponsor within 24-hours of knowledge 
• Loss of (or unaccounted for) investigational product inventory or repeated failure 
of device accountability. 
12.13 Deviations from the Clinical Investigation Plan 
Under emergency circumstances, deviations from the CIP to protect the rights, safety , 
and well -being of human subjects may proceed without prior approval of the Sponsor 
or IRB, including but not limited to those required to minimize or eliminate immediate hazards or to protect the life and well-being of research participants especially in 
relation to limiting exposure to COVID-19. 
The Investigator must notify the Sponsor and the CRO of any deviation from the CIP 
and document the reason for the deviation in the eCRF . 
The Investigator shall notify the Sponsor and the reviewing IRB of any deviation from 
the CIP  to protect the life or physical well-being of a subject in an emergency. Such 
notice shall be given as soon as possible, but in no event later than five (5) working days after the emergency occurred .  
12.14 COVID-19 Pandemic Considerations  
This clinical investigation has been designed with consideration given to the impact of COVID-19 on the safety of study participants, maintaining compliance with Good Clinical Practice (GCP) requirements and minimizing risks to  study integrity. The 
design includes input from the HRS/ACC/AHA COVID-19 Task Force 
recommendations
41 and the relevant FDA Guidelines.42, 43 
Specific areas of concern include availability of electrophysiology resources for non-urgent procedures, governmental limitations on travel or hospital utilization, hospital restrictions on procedures and personnel access, illness among study or site staff, provision of clinical, rhythm and/ or imaging assessment at locations other than the treating center, handling and reporting of protocol deviations, availability of investigational devices and analysis and reporting of COVID -19-related deviations and 
missing data. 
Should unforeseen circumstances occur,  study- related decision making will prioritize in 
the following order: the safety of study  participants, maintaining compliance with GCP 
requirements and minimizing risks to  study integrity.  
 
 
 
 13. Regulatory Considerations  
13.1 Maintaining Records 
The Sponsor and CRO will maintain copies of critical correspondence, regulatory 
approvals, Trial Master Files, clinical data, shipment of devices, AE s, SAE s, SADEs, 
UADEs and other records related to the clinical study.  
Trial records will be maintained for a minimum of 3 years following the completion of 
research activities and closure of the study with IRB s, whichever is longer. 
13.2  Data Handling and Record Keeping  
13.2.1  Source Documents  
The I nvestigator must maintain detailed source documents on all subjects who are 
enrolled or who undergo screening in the study. Source documents include but are not 
limited to, subject medical records, hospital charts, clinic charts, Investigator subject 
study files, as well as the results of diagnostic tests (e.g., laboratory tests, hemodynamic studies). 
The following minimum information should be entered into the subject’s medical 
record:  
• The date the subject entered the study  and the subject number. 
• The CIP number and the name of the Sponsor. 
• The date that informed consent  was obtained  and signed by the subject  and 
Investigator.  
• Evidence that the subject meets  the study eligibility requirements (e.g., medical 
history, study procedures and/or evaluations). 
• The dates of all study related subject visits. 
• Evidence that required procedures and/or evaluations were completed . 
• Use of any concurrent medications. 
• Documentation of specific device used. 
• Occurrence and status of any AE s or SAEs  
• The date the subject exited the study and a notation as to whether the subject completed the study or was discontinued, including the reason for discontinuation. 
13.2.2 Data Collection  
The Investigator must maintain detailed records on all subjects who sign the ICF  and 
begin the pre- procedure evaluation. Data for Enrolled Subjects are transcribed onto 
eCRFs provided by the Sponsor or designee. All data should be transcribed completely  and promptly .  
Study exit eCRF will be completed for all Enrolled S ubjects, regardless of whether 
they did or did not complete the study (e.g., subject discontinuation, study termination) . The Sponsor and investigational site  will maintain all records pertaining 
to this study in accordance with local and national regulations . Prior to the destruction 
of study records the I nvestigator or his representative shall contact the Sponsor to 
 
 ensure that they no longer need to be retained. In addition, Sponsor shall be contacted 
if the Investigator plans to leave the investigational site so that arrangements can be made for the handling or transfer of study records.  
13.3 Institutional Review Board and FDA Approval 
Regulatory approvals must be obtained prior to enrol lment of the first subject . The 
Sponsor is responsible for obtaining regulatory and local approvals for the study. The Sponsor or its designated representative will require a copy of any I RB and FDA 
correspondence as well as the final approval letter from the  IRB. 
An Investigator may not make CIP changes without prior approval by the Sponsor. All 
significant CIP changes that may affect the following must be submitted and approved 
by the IRB and FDA before initiating the change: 
• Validity of the data or information resulting from the completion of the approved CIP 
• Relationship of the likely subject risk to benefit relied upon to approve the CIP 
• Scientific soundness of the CIP  
• Rights, safety, or welfare of the human subjects involved in the investigation 
The Sponsor will notify the investiga tional site of such changes to ensure the study 
continues to be conducted consistent with the approved CIP. 
13.4 Procedure for Amending the CIP  
The process of amending the CIP and/or related documents is the responsibility of the Sponsor. The procedure for amending the CIP shall be as follows:  
• The Sponsor, Investigator, or other relevant party (e.g., IRB, FDA, CEC, D SMB ) 
may recommend modification of the CIP.  
• The Sponsor will then modify as necessary the CIP and any associated documents 
requiring amendment as a result of the modification(s).  
• The Sponsor or designated CRO will then submit the revised CIP and any other 
affected documents to the  IRB and FDA for approval. 
• Once all required approvals are obtained, the site will be trained to the latest approved version of the CIP and any other affected documents. 
13.5 Device Accountability  
The Sponsor will only ship investigational devices to the site once evidence of required regulatory approval has been provided to the Sponsor or designee. 
The Investigator must keep complete, current and accurate records of the receipt, use, 
or disposition of investigational devices (21 CFR 812.140 (a)(2)). 
 
 14. Biblio graphy 
 
1  Page RL . Newly Diagnosed Atrial Fibrillation . New England Journal of 
Medicine , 351(23):2408–16, 2004. 
2  Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between 
prothrombin a ctivation fragment F1.2 and international normalized r atio in 
patients with a trial fibrillation . Stroke Prevention in Atrial Fibrillation  
Investigators. Stroke.  1997;28(6):1101-1106. 
3  Fuster V, Rydén LE, Asinger, RW , et al . ACC/AHA/ESC guidelines for the 
management of patients with atrial fibrillation: executive summary. A report of 
the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. ACC. J Am Coll Cardiol . 2001;38(4):1231-1266. 
4  Go AS, Hylek EM, Phillips KA  et al. Prevalence of diagnosed atrial fibrillation in 
adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study . JAMA . 
2001;285(18):2370-2375. 
5  Miyasaka Y, Barnes ME, Gersh BJ, et al . Secular trends in incidence of atrial 
fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2) :119-125.  
6  Wolf PA, Abbott RD, Kannel WB . Atrial fibrillation as an independent risk factor 
for stroke: the Framingham Study. Stroke  1991;22(8):983-988. 
7  Le Heuzey JY, Paziaud O, Piot O, et al . Cost of care distribution in atrial 
fibrillation patients: the COCAF study . Am Heart J  2004;147:121- 126. 
8  Calkins H, Hindricks G, Cappato R, et al . HRS/EHRA/ECAS/APHRS/SOLAECE 
expert consensus statement on catheter and surgical ablation of atrial fibrillation . 
Heart Rhythm . 2017;14(10):e275-e444. 
9  Al-Sakere B, André F, Bernat C, et al . Tumor ablation with irreversible 
electroporation. PLoS One. 2007;2(11): e1135. 
10  Neumcke, B, Walz, D, Läuger, P. Nonlinear effects in lipid bilayer membranes . 
III. The dissociation field effect . Biophys  J. 1970;10(2):172-182. 
11  Benz R, Beckers F, Zimmermann U . Reversible electrical breakdown of lipid 
bilayer membranes: a charge-pulse relaxation study . J Membr Biol . 
1979;48(2):181-204. 
12  Chang, DC. Cell por ation and cell fusion using an oscillating electric field . 
Biophys J . 1989;56(4) :641-652. 
13  Chang DC, Reese TS. Changes in membrane structure induced by electroporation 
as revealed by rapid -freezing electron microscopy. Biophys J. 1990;58(1):1-12. 
14  Wendler JJ, Pech M, Blaschke S , et al . Angiography in the isolated perfused 
kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation . Cardiovasc Intervent Radiol . 
2012; 35(2):383-390. 
 
 
  
15  Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: 
characterization and consequences for drug and gene delivery. Biochim Biophys 
Acta. 2002;1569(1-3):51-58. 
16  Kingham TP, Karkar AM, D’Angelica MI et al . Ablation of perivascular hepatic 
malignant tumors with irreversible electroporation . J Am Coll Surg. 
2012;215(3):379-387. 
17  Olweny EO, Kapur P, Tan YK et al . Irreversible electroporation: evaluation of 
nonthermal and thermal ablative capabilities in the porcine kidney . Urology. 
2013;81(3):679-684. 
18  Maor E, Ivorra A, Leor J, et al. Irreversible electroporation attenuates neointimal 
formation after angioplasty . IEEE Trans Biomed Eng . 2008;55(9):2268- 2274. 
19  Thomson KR, Cheung W, Ellis SJ,  et al. Investigation of the safety of irreversible 
electroporation in humans. J Vasc Interv Radiol . 2011;22(5):611-21. 
20  Wittkampf FH1, van Driel VJ,  van Wessel H,  et al . Feasibility of electroporation 
for the creation of pulmonary vein ostial lesions . J Cardiovasc Electrophysiol. 
2011;22(3):302-309. 
21  van Driel VJ, Neven KG,  van Wessel H, et al.  Pulmonary vein stenosis after 
catheter ablation: electrop oration versus radiofrequency. Circ Arrhythm 
Electrophysiol . 2014;7(4):734-738. 
22  Neven K, van Driel V, van Wessel H, et al. Epicardial linear electroporation 
ablation and lesion size. Heart Rhythm . 2014;11(8):1465-1470. 
23  van Driel V, Neven K, van Wessel H, et al. Low vulnerability of the right phrenic 
nerve to electroporation ablation. Heart Rhythm . 2015;12(8):1838-1844. 
24  Op. cit. 25  Koruth JS, Kuroki K, Kawamura I, et al. Pulsed field ablation versus 
radiofrequency ablation: esophageal injury in a novel porcine model. Circ Arrhyt hm Electrophysiol. https://doi.org/10.1161/CIRCEP.119.008303. 
26  Sponsor preclinical study, on file. 27  Sponsor preclinical study, on file. 28  Final Clinical Study Report, Document Number CS1009, Rev A. The IMPULSE Study: A Safety and Feasibility Study of the FARAPULSE™ Endocardial Ablation System in the Treatment of Paroxysmal Atrial Fibrillation . July 27, 
2020. 
29  Interim Clinical Study Report, Document Number CS1010, Rev A. PEFCAT: A Safety and Feasibility Study of the FARAPULSE™ Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation . July 28, 2020 
30  Interim Clinical Study Report, Document Number CS1011, Rev A. PEFCAT II: Expanded Safety and Feasibility Study of the FARAPULSE™ Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation . July 28, 2020. 
31  Sponsor analysis of study data, on file. 32  Cochet H, Nakatani Y, Sridi-Cheniti S, Cheniti G, Ramirez D, Goujeau C, André 
C, Nakashima T, Eggert C, Schneider C, Viswanathan R, Derval N, Duchateau J, Pambrun T, Chauvel R, Reddy VY, Montaudon M, Laurent F, Sacher F, Hocini M, Haïssaguerre M, Jais P, Pulsed Field Ablation Selectively Spares the 
 
 
  
Esophagus After Pulmonary Vein Isolation For Atrial Fibrillation. In Review, 
Journal of the American College of Cardiology: Electrophysiology. 
33  Sponsor analysis of study data, on file. 34  Kuroki K, Whang W, Eggert C, et al.  Ostial dimensional changes after pulmonary 
vein isolation: pulsed field ablation vs radiofrequency ablation . Heart Rhythm . 
https://doi.org/10.1016/j.hrthm.2020.04.040. 
35  Dr. Hubert, Cochet, personal communication regarding analysis of PEFCAT and 
PEFCAT II subjects by brain MRI post- ablation . 
36  January CT, Wann LS, Calkins H, et al . 2019 AHA/ACC/HRS focused update of 
the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a  report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart  Rhythm 
Society. Circulation. 2019;139.
 
37  Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation 
for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235-2245. 
38  Broglio KR, Connor JT, Berry SM., “Not too big, not too small: a Goldilocks 
approach to sample size selection,” J Biopharm Stat . 2014;24(3):685-705.  
39  Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin 
Trials . 2004;25(2):143-156. 
40  James KE, Bloch DA, Lee KK, et al. An index for assessing blindness in a 
multi- centre clinical trial: disulfiram for alcohol cessation-- a VA cooperative 
study. Stat Med . 1996;15(13):1421-1434. 
41  Lakkireddy D, Chung, M, Gopinathannair R, et al. Guidance for c ardiac 
electrophysiology during the coronavirus (COVID-19) pandemic from the Heart 
Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American  College of Cardiology; and the Electrocardiography and Arrhythmias 
Committee of the Council on  Clinical Cardiology, American Heart Association, 
Heart Rhythm . https://doi.org/10.1016/j.hrthm.2020.03.028. 
42  FDA Guidance on conduct of clinical trials of medical products during 
COVID-19 public health emergency. Guidance for Industry, Investigators, and Institutional Review Boards., March 2020, updated on July 2, 2020, US Department of Health and Human Services, Food and Drug Administration. 
43  Statistical considerations for clinical trials during the COVID -19 public health 
emergency.  Guidance for Industry. June 2020, US Department of Health and 
Human Services, Food and Drug Administration. 